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1 Zusammenfassung 
Kardiovaskuläre Erkrankungen sind die häufigste Todesursache weltweit. In den meisten 
Fällen ist die Atherosklerose, eine progressive, chronische Entzündungskrankheit der 
Blutgefäße, die pathologische Ursache dieser kardiovaskulären Erkrankungen. Ein erhöhter 
Cholesterinspiegel im Blut gilt als wichtiger Risikofaktor für die Entstehung der 
Atherosklerose, und die medikamentöse Senkung von zirkulierendem LDL-Cholesterin ist 
derzeit eine der erfolgreichsten Behandlungsmethoden. Ablagerungen von kristallinem 
Cholesterin in den Gefäßwänden gelten als Merkmal fortgeschrittener atherosklerotischer 
Plaques. Darüberhinaus sind Cholesterinkristalle aber bereits in den frühen 
Entwicklungsstadien der Atherosklerose vorhanden. Makrophagen, die häufigsten und 
bedeutendsten Zellen in atherosklerotischen Plaques, erkennen Cholesterinkristalle mithilfe 
des NLRP3 Inflammasoms. Dieser Multiproteinkomplex des angeborenen Immunsystems 
verursacht die Ausschüttung der pro-inflammatorischen Zytokine Interleukin (IL)-1β und IL-
18, die entscheidend zur vaskulären Inflammation beitragen und damit für das 
Voranschreiten der Atherosklerose verantwortlich sind. Eine Reduktion der 
Cholesterinkristallmenge in atherosklerotischen Plaques könnte voraussichtlich die vaskuläre 
Inflammation und folglich das Voranschreiten der Atherosklerose verringern. 
In dieser Studie wurde im Mausmodell untersucht, ob 2-Hydroxypropyl-β-cyclodextrin (CD), 
welches Cholesterin in Lösung bringt und aus Zellen entfernen kann, auch die vaskuläre 
Ablagerung von Cholesterinkristallen reduziert oder diese aus den atherosklerotischen 
Plaques entfernen kann, und ob dadurch die Entwicklung und das Voranschreiten der 
murinen Atherosklerose verhindert wird. Tatsächlich beeinträchtigte die Behandlung mit CD 
die Entwicklung der Atherosklerose in Mäusen, was an einer Reduktion der Plaquegröße und 
der Cholesterinkristallmenge im Plaque erkennbar war. Zudem bewirkte die Behandlung mit 
CD sogar die Regression von bereits etablierten atherosklerotischen Plaques. Daraufhin 
wurden die molekularen Mechanismen des atheroprotektiven Effekts von CD in vitro in 
Makrophagen untersucht. Die Behandlung von Cholesterinkristall-beladenen Makrophagen 
mit CD führte zur Auflösung der intrazellulären Cholesterinkristalle und förderte die 
Esterifizierung und den Efflux des aus den Kristallen herausgelösten Cholesterins. Zudem 
wurde dieses Cholesterin vermehrt zu Oxysterinen, wie zum Beispiel 27-Hydroxycholesterin, 
metabolisiert. Einige Oxysterine fungieren als endogene Agonisten für LXR (liver X receptor) 
Transkriptionsfaktoren, die wiederum Gene aktivieren, welche den Cholesterinefflux und anti-
inflammatorische Prozesse regulieren. Tatsächlich induzierte die Behandlung mit CD eine 
LXR-basierte transkriptionelle Umprogrammierung der Makrophagen auf erhöhten 
Cholesterinefflux. Damit einhergehend förderte CD in Abhängigkeit von LXR den reversen 
Cholesterintransport und die Ausscheidung von ursprünglich kristallinem Cholesterin aus 
Cholesterinkristall-beladenen Makrophagen. Darüber hinaus war die Aktivierung von LXR 
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Transkriptionsfaktoren auch für die atheroprotektiven und anti-inflammatorischen Effekte von 
CD in vivo in muriner Atherosklerose erforderlich. 
Die vorliegende Studie zeigt eine atheroprotektive Wirkung von CD im Mausmodell, die mit 
der Auflösung und Beseitigung von Cholesterinkristallen aus atherosklerotischen Plaques 
einhergeht. Dabei spielt die erhöhte Produktion von Cholesterin-basierten endogenen LXR 
Agonisten, welche zur Aktivierung anti-atherogener Transkriptionsprozesse führen, eine 
entscheidende Rolle. Da eine Behandlung mit CD bereits von der FDA (U.S. food and drug 
administration) für die klinische Nutzung zugelassen ist, könnte CD unmittelbar in klinischen 
Studien zur Prävention und Behandlung von humaner Atherosklerose getestet werden. 
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1 Summary 
Atherosclerosis is the underlying pathology of cardiovascular diseases (CVDs), the leading 
cause of deaths worldwide. Elevated blood cholesterol levels have been linked to this slowly 
progressing inflammatory disease and lowering the amount of circulating low-density 
lipoprotein (LDL) cholesterol is one of the most successful treatment approaches. Crystalline 
cholesterol deposits in the vessel wall are a hallmark of advanced atherosclerotic plaques, 
but they actually already occur in early stages of atherosclerosis development. Cholesterol 
crystals (CCs) can activate the NLRP3 inflammasome, a cytosolic multimolecular signaling 
complex present in innate immune cells, such as macrophages, which are the most 
prominent cell type in the developing atherosclerotic plaque. NLRP3 inflammasome 
activation results in the release of the pro-inflammatory cytokines IL-1β and IL-18, which are 
key contributors to the vascular inflammation driving atherosclerosis progression. Therefore, 
presumably a reduction in the amount of CCs in atherosclerotic plaques could also decrease 
vascular inflammation and consequently atherosclerosis progression. 
In this study, whether 2-hydroxypropyl-β-cyclodextrin (CD), a compound that solubilizes 
cholesterol and removes cholesterol from cells, is effective in reducing vascular CC 
deposition or removing CCs from atherosclerotic plaques and thereby preventing 
atherosclerosis development was investigated in mice. CD treatment indeed impaired murine 
atherosclerosis development, which was indicated by a reduction of atherosclerotic plaque 
size and CC load. Moreover, CD treatment even mediated the regression of already 
established atherosclerotic plaques. The molecular mechanisms of CD-mediated 
atheroprotection were further examined in vitro in macrophages. CD treatment of CC-loaded 
macrophages mediated the dissolution of intracellular CCs and subsequently promoted 
crystal-derived cholesterol esterification, efflux and metabolism to oxysterols such as  
27-hydroxycholesterol. Some oxysterols function as endogenous agonists for liver X receptor 
(LXR) transcription factors, which in turn activate genes regulating cholesterol efflux and anti-
inflammatory processes. Indeed, CD treatment induced LXR-mediated transcriptional 
reprogramming of macrophages towards increased cholesterol efflux. Thereby, CD promoted 
the reverse cholesterol transport and excretion of crystal-derived cholesterol from CC-loaded 
macrophages in an LXR-dependent manner. Moreover, LXR transcription factor activation 
was required for the atheroprotective and anti-inflammatory effects of CD in vivo in murine 
atherosclerosis. 
This study shows that CD is atheroprotective in mice by dissolving and removing CCs from 
atherosclerotic plaques and by promoting the production of cholesterol-derived endogenous 
LXR agonists that activate anti-atherogenic transcriptional processes. Since CD treatment is 
already approved for clinical use by the U.S. food and drug administration (FDA), it could be 
directly tested in clinical trials for the prevention or treatment of human atherosclerosis. 
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2 Introduction 
2.1 The immune system 
The mammalian body is constantly exposed to potentially harmful microorganisms. 
Consequently, the body has developed several mechanisms to circumvent microbial 
invasion. Physical, chemical, and microbiological surface barriers, such as skin, epithelial 
surfaces, mucus, gastric acid, and commensal gut microbiota, provide a first line of host 
defense against invading microorganisms. When microbes overcome these protective 
barriers, they encounter the cellular and humoral defense mechanisms of the host immune 
system. 
The immune system is a highly complex system, which has evolved to efficiently protect the 
body against infection by pathogens. It can basically be subdivided into innate and adaptive 
immunity. Innate immunity is the evolutionarily ancient arm of the mammalian immune 
system. The innate immune response is generally non‐specific and its purpose is to 
physically eliminate pathogens before an infection is established. The innate immune system 
is also required for activating adaptive immunity. The adaptive immune system, in turn, 
eliminates pathogens in the later phase of an infection and mediates immunological memory, 
allowing for quicker, more effective immune responses upon re-infection. Adaptive immune 
responses are mediated by lymphocytes, which express receptors that are somatically 
recombined and clonally selected for a specific antigen, and cause a long‐lasting, pathogen‐
specific immune response. Efficient elimination of infectious pathogens usually requires both 
innate and adaptive immune responses. 
2.1.1 Innate immunity 
The innate immune system is composed of phagocytes (macrophages, dendritic cells (DCs), 
natural killer (NK) cells), granulocytes (neutrophils, eosinophils, basophils, mast cells), and 
humoral factors such as the complement system. It provides the initial host response to any 
pathogens that have breached surface barriers and invaded the host tissue. Tissue-resident 
innate immune cells, such as macrophages, DCs and mast cells, detect the presence of 
either pathogens themselves or tissue damage that indicates infection. These cells then 
secrete inflammatory mediators such as cytokines and chemokines, which recruit further 
innate immune cells such as monocytes and neutrophils from the circulation. Together, 
activated tissue-resident and recruited innate immune cells combat the pathogens by 
phagocytic destruction or secretion of toxic granules and antimicrobial peptides. In addition, 
the secreted pro-inflammatory cytokines interleukin (IL) 6, IL-1β and tumor necrosis factor 
(TNF) mediate a systemic acute-phase response by inducing the production of acute phase 
proteins in the liver. These humoral factors contribute to pathogen clearance by 
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opsonization-promoted phagocytosis and complement activation. Activation of innate 
immunity can therefore already result in pathogen clearance before adaptive immunity is 
even established. However, the initiation of pathogen-specific adaptive immune responses 
requires phagocytic innate immune cells such as DCs to process phagocytozed microbial 
antigens for surface presentation to lymphocytes1. After the infection has been cleared, the 
innate immune system, in particular tissue-resident macrophages, are also important in 
resolving the inflammation as well as mediating tissue repair and restoring tissue 
homeostasis2. 
2.1.2 Recognition principles of the innate immune system 
Innate immune cells express germ line-encoded pattern recognition receptors (PRRs), which 
allow for the detection of a wide variety of infectious microbes. They recognize pathogens by 
conserved microbial structures, termed pathogen-associated molecular patterns (PAMPs). 
PAMPs are often molecules, which are essential for microbial survival and are therefore 
highly conserved across microbial species and unlikely to mutate during evolution. As most 
of these microbial patterns are not present on host molecules, the concept that PRRs allow 
innate immune cells react to infection by discriminating between self and non-self structures 
was proposed3. However, this theory was altered when it became evident that PRRs also 
recognize endogenous molecules that indicate tissue injury or infection, such as molecules 
released from damaged or dying cells4. Analogously to PAMPs these endogenous PRR 
ligands were therefore termed damage-associated molecular patterns (DAMPs) (also known 
as danger-associated molecular patterns). 
PRRs are expressed in different cellular compartments of innate immune cells, for example 
on the cell surface, in the cytoplasm or in endosomes. PRRs are grouped into five different 
classes according to their molecular structure: the membrane-bound C-type lectin receptors 
(CLRs) and Toll-like receptors (TLRs), and the cytosolic absent in melanoma (AIM)-like 
receptors (ALRs), Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and nucleotide-
binding and oligomerization domain (NOD)-like receptors (NLRs)5. These receptors are all 
composed of a ligand binding domain and a signaling domain, and their activation is often 
regulated by dimerization, oligomerization or conformational changes induced upon ligand 
binding. Adaptor molecules are subsequently recruited to the receptor signaling domain, 
which activates intracellular signaling cascades culminating in inflammatory gene expression 
and the release of inflammatory mediators. PRRs of different classes can have synergistic or 
complementary effects, for example, when the same inflammatory pathways are induced 
upon recognition of different PAMPS derived from the same infectious organism. Similarly, 
sufficient activation of certain PRRs often requires the engagement of other PRR classes or 
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signaling pathways6. This cooperative signaling of different PRRs facilitates controlled but 
effective pathogen detection and elimination. 
2.1.2.1 TLRs 
The first PRRs identified were TLRs, which are as such the best-characterized class of 
PRRs. So far, 10 human (TLR 1-10) and 12 functional murine (TLR 1-9 and 11-13) TLRs 
have been described7. Most TLRs are expressed on the cell surface (TLR 1, 2, 4, 5, 6, and 
10), where they mainly detect microbial membrane components. However, the TLRs that are 
responsible for nucleic acid sensing (TLR 3, 7, 8, 9) are localized in intracellular endosomal 
compartments. Together, these TLRs can sense a wide variety of PAMPs from bacteria, 
viruses, fungi and protozoa as well as several endogenous DAMPs. To achieve recognition 
of such a broad spectrum of different ligands, TLRs cooperate with each other, such as 
TLR2, which forms heterodimers with TLR1 or TLR6 to sense triacylated lipopeptides from 
Gram-negative bacteria and diacylated lipopeptides from Gram-positive bacteria, 
respectively. Moreover, TLR4 is known to form a complex with myeloid differentiation factor 2 
(MD2) and cluster of differentiation 14 (CD14) to recognize lipopolysaccharide (LPS), a cell 
wall component of Gram-negative bacteria7, but it can also cooperate with TLR6 and the 
scavenger receptor cluster of differentiation 36 (CD36) to recognize DAMPs, such as 
endogenous oxidized low density lipoprotein (oxLDL)8. Therefore, cooperative interactions 
between TLRs and other signaling molecules and cell surface receptors can expand TLR 
ligand diversity. 
TLRs are type I integral membrane glycoproteins consisting of an extracellular ligand-binding 
domain containing leucine-rich repeat (LRR) motifs, a transmembrane domain and a 
cytoplasmic Toll/IL-1 receptor (TIR) domain. Upon ligand binding, TLRs form homo- or 
heterodimers, which initiates the recruitment of TIR domain-containing adaptor proteins, 
including myeloid differentiation factor 88 (MyD88), TIR domain-containing adaptor protein-
inducing IFN-β (TRIF), TRIF-related adaptor molecule (TRAM), TIR-associated protein 
(TIRAP, also known as MyD88 adaptor-like (MAL)) and sterile-α and HEAT-Armadillo motifs 
(SARM)9. MyD88 is utilized by all TLRs with the exception of TLR3 and mediates the 
activation of mitogen-activated protein (MAP) kinases and nuclear factor kappa B (NF-κB). In 
turn, the activated transcription factors regulate the expression of pro-inflammatory 
cytokines, such as IL-6, IL-12 and TNF, as well as other inflammatory genes. MyD88 
recruitment to TLR7 and TLR9 additionally results in the production of type I interferons 
(IFNs) via activation of IFN regulatory factor (IRF) 7 in plasmacytoid DCs, which represent a 
subset of immune cells that is specialized on the detection of viruses10. TRIF is used by 
TLR3 and TLR4 and, besides pro-inflammatory cytokine induction via NF-κB and MAP 
kinases, also initiates an alternative pathway leading to activation of IRF3, which 
subsequently induces the production of type I IFN. TLR4 is unusual as it can recruit both 
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TIRAP and TRAM as linking adaptors for MyD88 and TRIF, respectively. The TIRAP-MyD88 
adaptor complex drives an early induction of pro-inflammatory cytokines via MAP kinases 
and NF-κB, whereas the TRAM-TRIF adaptor complex induces type I IFN via IRF3 as well as 
late induction of pro-inflammatory cytokines via MAP kinases and NF-κB11. The fifth TIR 
domain-containing adaptor molecule SARM was described to act as an inhibitor of TRIF-
dependent signaling in humans12. 
2.1.2.2 NLRs 
NLRs represent a large family of cytoplasmic PRRs, which are composed of three functional 
domains: C-terminal LRRs that might contribute to ligand recognition, a central NOD domain 
that possesses ATPase activity and is responsible for receptor oligomerization, and an  
N-terminal protein-protein interaction domain that is required for downstream signal 
transduction. In the absence of a ligand the C-terminal LRRs conceal the N-terminal domain 
thereby preventing uncontrolled downstream NLR signaling13,14. 
Several NLR orthologues are found among the plant resistance (R) proteins, which are the 
PRRs of the plant immune system15. This evolutionary conservation across species and 
kingdoms (from plants to humans) indicates a vital role for these receptors in host defense. 
Interestingly, plant pathogen recognition by R proteins mainly relies on an indirect detection 
mechanism through interaction with host proteins that have been altered (e.g. by proteolytic 
cleavage or phosphorylation) in response to infection (described as the “guard 
hypothesis”)16. Indirect recognition of PAMPs or DAMPs might also play a role in sensing of 
infection or tissue damage by mammalian NLRs. 
In humans, 22 NLRs have been identified so far14, which are subdivided into several 
subfamilies according to their N-terminal domain NLRA (NOD, LRR and acidic 
transactivation domain containing), NLRB (NOD, LRR and baculovirus inhibitor of apoptosis 
protein repeat (BIR) domain containing), NLRC (NOD, LRR and caspase activation and 
recruitment domain (CARD) containing), NLRP (NOD, LRR and pyrin domain (PYD) 
containing) and NLRX (NOD, LRR and CARD-related X effector domain containing)17. 
The NLRC family members NOD1 and NOD2 recognize similar ligands as TLRs, such as 
bacterial peptidoglycan or viral ribonucleic acids (RNAs), thereby activating downstream 
signaling via NF-κB or IRFs, which results in similar pro-inflammatory responses. Therefore, 
it has been suggested that TLRs and NLRs might cooperate in synergistically activating pro-
inflammatory cytokine production10. 
Other members of the NLR family, mainly members of the NLRP subfamily, are the sensor 
proteins in cytosolic multimolecular signaling platforms termed inflammasomes. The heart of 
these multimeric protein complexes is the inflammasome adaptor molecule apoptosis 
associated speck-like protein containing a CARD (ASC), which links the inflammasome 
sensor to the inflammatory protease caspase-1. Upon activation of the inflammasome 
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sensor, the C-terminal LRRs undergo a conformational change, uncovering the N-terminal 
protein-protein interaction domain, which is typically the PYD domain14. This allows 
recruitment of ASC, which promotes the multimerization of the adaptor molecule causing the 
formation of a so-called ASC speck13. ASC recruits pro-caspase-1 via homotypic CARD 
interactions, which enables the self-cleavage of pro-caspase-1 molecules. Activated 
caspase-1 in turn proteolytically cleaves the pro-forms of the pro-inflammatory cytokines  
IL-1β and IL-18 into their active forms. Furthermore, upon inflammasome activation, cells 
undergo a rapid, inflammatory form of cell death, called pyroptosis13. 
The inflammasome sensors described so far include NLRs, such as NLRP1, NLRP3, 
NLRP6, NLRP12 and NLRC4 (also known as IL-1β-converting enzyme protease-activating 
factor (IPAF)). Furthermore, the ALR members AIM2 and IFNγ-inducible protein 16 (IFI16) as 
well as the RLR family member RIG-I can function as inflammasome sensors in response to 
microbial nucleic acids13. In contrast, most NLR-containing inflammasomes have mainly 
been implicated in the recognition of bacterial components, such as bacterial peptidoglycan, 
toxins, flagellin and components of type III and type IV secretion systems18. The NLRP3 
inflammasome is unique in terms of its activating ligands, as it is activated by a large number 
of structurally diverse endogenous, exogenous and pathogenic activators, and has been 
implicated in the pathogenesis of many diseases. 
2.1.3 NLRP3 inflammasome in infection and inflammatory diseases 
Immune responses are required for efficient elimination of potentially harmful 
microorganisms, but excessive activation of inflammatory responses and dysregulated 
inflammation can harm the host and result in detrimental chronic inflammatory diseases. 
Therefore, inflammatory responses are typically tightly regulated. NLRP3 inflammasome 
activation is a pertinent example of how the innate immune response can be both protective 
or pathogenic depending on context. While NLRP3 importantly contributes to the elimination 
of bacterial, viral, fungal and parasitic infections, it has also been implicated in the pathology 
of a large number of chronic inflammatory diseases14,18. 
2.1.3.1 NLRP3 inflammasome in chronic inflammatory diseases 
NLRP3 was originally discovered when mutations in this gene were identified in patients 
suffering from cryopyrin-associated periodic syndromes (CAPS) such as familial cold 
autoinflammatory syndrome and Muckle-Wells syndrome19. Due to its structural homology to 
NLRP1, the role of NLRP3 as an inflammasome-forming innate immune receptor was 
established, and the CAPS-related mutations were found to be gain-of-function mutations 
resulting in hyper-activation of the NLRP3 inflammasome and overproduction of IL-1β20. 
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These findings already indicated the detrimental effects of dysregulated NLRP3 
inflammasome function. 
Table 2-1: NLRP3 inflammasome in chronic inflammatory diseases. 
Various crystalline and aggregated endogenous and exogenous molecules, which are characteristic of 
chronic inflammatory diseases, activate NLRP3 inflammasome-mediated inflammatory responses, therefore 
linking the NLRP3 inflammasome to disease pathology. 
DAMP Origin of DAMP Disease Ref 
Monosodium urate 
(MSU) crystals 
Uric acid released during cell death precipitates in 
extracellular space 
Gout 
 
21 
Calcium 
pyrophosphate 
(CPPD) crystals 
Spontaneous crystallization of calcium 
pyrophosphate 
Pseudogout 21 
Fibrillar amyloid β  Spontaneous aggregation of Amyloid β Alzheimer’s 
disease 
22 
Islet amyloid 
polypeptide (IAPP) 
Increased insulin secretion promotes secretion and 
subsequent oligomerization and amyloid deposition 
of IAAP 
Type 2 diabetes 
mellitus (T2DM) 
23 
Cholesterol 
crystals 
Extracellular cholesterol crystal precipitation or 
intracellular cholesterol crystal formation upon uptake 
of modified low density lipoprotein (e.g. oxidized LDL)  
Atherosclerosis 24,25 
Silica crystals Inhalation of exogenous inorganic silica crystals Silicosis 26,27 
Asbestos Inhalation of exogenous inorganic asbestos fibers Asbestosis 27 
 
Since the discovery of NLRP3, plenty of molecules that trigger NLRP3 inflammasome 
activation have been identified. These NLRP3 inflammasome activators comprise a broad 
spectrum of endogenous as well as exogenous molecules of environmental or pathogenic 
origin, such as bacterial toxins and cell wall components or microbial nucleic acids. A well-
described DAMP among the NLRP3 activators is extracellular adenosine triphosphate (ATP), 
which is released by dying cells during tissue damage. Furthermore, many DAMPs sensed 
by the NLRP3 inflammasome are aggregated or crystalline endogenous or exogenous 
molecules, which are related to chronic inflammatory diseases (Table 2-1). For example, the 
NLRP3 inflammasome is activated by environmental stimuli like asbestos and silica crystals, 
the causative agents of asbestosis and silicosis; but it can also recognize aggregated or 
crystallized host molecules such as uric acid crystals, cholesterol crystals and amyloid β 
fibrils and as such the NLRP3 inflammasome is also involved in metabolic disorders like 
gout, atherosclerosis and Alzheimer’s disease. 
2.1.3.2 NLRP3 inflammasome activation 
Since NLRP3 inflammasome activation has been linked to several chronic inflammatory 
diseases, the mechanisms of NLRP3 inflammasome activation are the subject of intense 
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study. Given the multitude of endogenous and exogenous NLRP3 activators of various origin 
and diverse structures, it is unlikely that one PRR can directly sense all these structurally 
diverse molecules and indeed no direct interaction between NLRP3 and it’s activators has 
been observed so far. It has therefore been postulated that NLRP3 is activated indirectly, for 
example by sensing changes in the cellular environment28. This is in line with the suggestion 
that mammalian NLRs might, similar to their plant orthologues, indirectly detect infection or 
tissue damage15. 
Activation of the NLRP3 inflammasome is a two-step process. Firstly, a priming step induces 
adequate expression levels of the inflammasome sensor NLRP3 and the caspase-1 
substrate pro-IL-1β. Secondly, detection of NLRP3 activators results in conformational 
changes in NLRP3 that enable assembly and activation of the NLRP3 inflammasome. 
The priming signal (signal 1) is provided by the activation of the transcription factor NF-κB 
during TLR, NLR or cytokine receptor (e.g. IL-1 receptor (IL-1R)) signaling29. In vitro, the 
TLR4 ligand LPS is commonly used as a priming stimulus for NLRP3 inflammasome assays 
in macrophages. However, some NLRP3 inflammasome activators such as oxLDL24 or 
amyloid-β22 were shown to mediate both NLRP3 priming via activation of TLRs and 
subsequent NLRP3 activation. However, additional priming stimuli can considerably 
potentiate the response to these crystallizing and aggregating ligands indicating a regulatory 
role of the priming step in determining the extent of the subsequent NLRP3-mediated 
inflammatory response13. 
The signal activating the NLRP3 inflammasome (signal 2) is not entirely understood yet30. As 
mentioned above, direct ligand-receptor activations are implausible; instead the current 
consensus is that NLRP3 activators induce common pathways upstream of NLRP3. 
Intensive research into the molecular mechanisms of NLRP3 inflammasome activation has 
generated various hypotheses for potential upstream events that trigger NLRP3 activation. In 
brief, ion fluxes such as potassium efflux and calcium fluxes, production of mitochondrial 
reactive oxygen species (ROS), or sensing of mitochondrial dysfunction via cardiolipin or 
mitochondrial deoxyribonucleic acid (DNA) release and the subsequent cellular re-
localization of NLRP3 to mitochondria have all been implicated in mediating NLRP3 
inflammasome activation. Furthermore, post-translational modification of NLRP3 might also 
regulate inflammasome assembly; for instance deubiquitination was reported to be required 
for NLRP3 activation30. Another hypothesis is that phagocytozed protein aggregates or 
crystalline material induce lysosomal damage, resulting in the release of the lysosomal 
proteases such as cathepsins into the cytoplasm. NLRP3, similar to plant NLR orthologues, 
might then indirectly detect this unusual cytosolic protease activity, for example in the 
proteolytic cleavage of NLRP3 inhibitor proteins or sensing of proteolytically cleaved host 
molecules31. A further hypothesis based on the similarity between plant NLR orthologues and 
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Figure 2-1: NLRP3 inflammasome activation. 
NLRP3 inflammasome activation is controlled by a two-checkpoint mechanism. It requires a priming signal 
activating NF-κB-dependent transcription of NLRP3 and pro-IL-1β, and a subsequent activation signal that 
induces conformational changes in NLRP3 allowing for recruitment of ASC and caspase-1 to form the 
mulitmeric inflammasome complex. The activation signal is not entirely understood yet, but mechanisms like 
release of lysosomal proteins upon lysosome disruption, production of mitochondrial ROS and cellular 
potassium efflux are proposed to contribute to the activation signal mediating NLRP3 inflammasome 
assembly and subsequent cleavage and secretion of IL-1β. Figure from Horvath et al.28 with reprint 
permission (see appendix). 
NLRP3 is, that suppressor of G2 allele of S-phase kinase-associated protein 1 (SGT1) and 
heat shock protein (HSP) 90, which form complexes with R proteins to keep them inactive, 
also keeps NLRP3 in an inactive conformation. Indeed SGT1 and HSP90 were shown to 
directly interact with NLRP332. 
In summary, a variety of potential molecular mechanisms involved in NLRP3 inflammasome 
activation have been described within the last years (Fig. 2-1), but no distinct mechanism has 
been elucidated. Therefore, it is likely that NLRP3 inflammasome activation is controlled at 
several levels and requires more than one particular pathway to be activated. Nevertheless, 
despite a tightly controlled, two-checkpoint activation mechanism, the NLRP3 inflammasome 
is efficiently activated by several danger molecules, which are present during metabolic 
disorders and therefore contributes to the chronic inflammation underlying the pathology of 
these diseases. 
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2.2 Atherosclerosis 
Cardiovascular diseases (CVDs), which comprise all diseases affecting the cardiovascular 
system, are the most prevalent cause of mortality worldwide*. The major cause of CVD is 
atherosclerosis, which is a progressive chronic inflammatory disease characterized by the 
formation of lipid-rich plaques in the subendothelial space of the large arteries. 
Atherosclerosis develops as a result of an imbalanced lipid metabolism and the associated 
excessive cardiovascular inflammation. While atherosclerosis remains asymptomatic for 
many years, the continuous growth and increasing complexity of the atherosclerotic plaques 
raise the risk of acute clinical events such as myocardial infarction (heart attack) or cerebral 
infarction (stroke). 
2.2.1 Risk factors and clinical treatment 
Epidemiological, clinical and animal studies have revealed important environmental, 
behavioral and genetic risk factors for atherosclerosis, including hyperlipidemia, consumption 
of a high-fat diet, lack of exercise, cigarette smoking, hypertension, diabetes, gender (male) 
and aging. One of the major risk factors of atherosclerosis is an increase in blood cholesterol 
levels, which has been causally linked to the pathogenesis of atherosclerosis. In turn, 
lowering blood cholesterol levels, or more precisely low-density lipoprotein (LDL) cholesterol 
levels, by pharmacological inhibition of cholesterol synthesis with statins, is amongst the 
most successful therapeutic approaches for delaying atherosclerosis and decreasing the risk 
of cardiovascular events. Besides drug therapy, current clinical treatment mainly relies on 
surgical interventions including balloon angioplasty, endarterectomies and bypass grafting33. 
2.2.2 Atherosclerotic plaque formation 
The process of atherosclerotic plaque formation (atherogenesis) (Fig. 2-2) is initiated when 
apolipoprotein (Apo) B-containing lipoproteins such as LDL are retained in the arterial intima 
(the area between endothelial layer and the smooth muscle cells of the arterial media). This 
accumulation and oxidative or enzymatic modification of the cholesterol-rich lipoproteins 
activates endothelial cells to produce pro-inflammatory molecules such as adhesion 
molecules and chemotactic proteins. This inflammatory response results in the recruitment of 
monocytes to the intima, where they primarily differentiate into macrophages. These 
monocyte-derived macrophages then ingest the accumulated lipoproteins, and thereby 
develop into lipid-laden cells with cytoplasmic lipid droplets that are called foam cells. As a  
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	  World Health Organization (WHO) - Fact sheet N°317 on Cardiovascular diseases CVDs); 
http://www.who.int/mediacentre/factsheets/fs317/en/ - 14th March, 2016, 10:37 am (see appendix) 
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Figure 2-2: Atherosclerosis plaque development and progression. 
Atherosclerotic plaque formation starts with the formation of so-called fatty streak lesions in the arterial 
intima, which are characterized by accumulation of ApoB-containing lipoproteins (ApoB-LP) and resultant 
recruitment of macrophages and DCs. Due to continuous ApoB-LP retention, infiltration of lymphocytes and 
smooth muscle cells as well as the deposition of extracellular matrix components fatty streak lesions 
develop into more complex established atherosclerotic plaques that are covered by a fibrous cap. 
Accumulation of apoptotic cells as a result of defective efferocytosis causes the formation of a lipid-rich 
necrotic core, which is characteristic of advanced atherosclerotic plaques. Due to thinning of the fibrous cap 
advanced atherosclerotic plaques become instable and vulnerable to rupture resulting in subsequent 
thrombus formation. Figure from Moore and Tabas34 with reprint permission (see appendix). 
result of imbalanced macrophage lipid metabolism, these macrophage foam cells are 
retained in the subendothelial space where they contribute to atherosclerotic plaque 
progression by amplifying pro-inflammatory responses in the early fatty streak lesions35. The 
ongoing accumulation of lipids and immune cells, including monocytes and lymphocytes, as 
well as smooth muscle cell infiltration causes the expansion of the arterial intima towards the 
vessel lumen. A fibrous cap, consisting of smooth muscle cells and secreted extracellular 
matrix components, which forms underneath the endothelial cell layer, subsequently covers 
the accumulated lipoproteins and immune cells. At this stage of atherosclerosis a non-
resolving pro-inflammatory immune response causes further atherosclerotic plaque 
progression. In particular, increased apoptotic cell death within the plaque, combined with 
defective phagocytic clearance of apoptotic cells (efferocytosis) causes the build-up of 
extracellular lipids and the formation of a lipid-rich necrotic plaque core, which is a sign of 
advanced atherosclerotic plaques. Concurrently, the release of matrix degrading proteases 
results in the thinning of the fibrous cap. These events destabilize the atherosclerotic plaques 
and make them vulnerable to rupture. Plaque rupture exposes thrombogenic plaque content 
to the bloodstream resulting in platelet aggregation and the formation of a lumenal thrombus. 
Thrombotic occlusion of the already narrowed artery finally manifests clinically by myocardial 
or cerebral infarction due to insufficient oxygen supply to the heart or the brain. 
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2.2.3 Mouse models of atherosclerosis 
Animal models have greatly advanced our understanding of the key steps in the 
development and progression of atherosclerosis. Common animal models for studying diet-
induced atherosclerosis include rabbits, pigs and non-human primates, but the most 
preferred animal for these studies is the mouse. However, wild type (WT) mice are highly 
resistant to diet-induced atherosclerosis and only develop small fatty streak-like lesions even 
when fed a prolonged high-fat, high-cholesterol diet, which is an insufficient model for human 
atherosclerosis. To overcome this, various genetically modified mouse models have been 
generated within the last decades. In these models, the mice develop atherosclerotic plaques 
that more closely mirror human disease, due to dyslipidemia induced upon feeding of an 
atherogenic diet36. ApoE- or LDL receptor (LDLR)-deficient mice fed a high-fat diet are the 
most frequently used and best-characterized mouse models of atherosclerosis. ApoE is one 
of the major ligands of the LDLR, the cell surface receptor responsible for clearing ApoB- or 
ApoE-containing lipoproteins from the plasma. Hence, the absence of either the ligand 
(ApoE) or the receptor (LDLR) impairs LDL cholesterol clearance and thus causes high 
serum cholesterol levels in response to a cholesterol-rich diet37. While both mouse models 
develop atherosclerotic plaques that morphologically resemble human atherosclerotic 
plaques, diet-induced atherosclerosis progression is faster and more severe in ApoE 
knockout (ApoE-/-) mice, which even develop spontaneous atherosclerosis under chow diet38. 
In contrast, LDLR knockout (LDLR-/-) mice, which are a model of human familial 
hypercholesterolemia, require a cholesterol-rich diet for induction of hypercholesterolemia 
and atherosclerosis36. The major limitation of these murine atherosclerosis models is the lack 
of vulnerable plaque formation, which hampers proper studies on plaque rupture and 
subsequent thrombosis - the clinically important events in atherosclerosis37. Nevertheless, 
these models are very useful for investigating the mechanisms of atherosclerosis initiation, 
early atherosclerotic plaque development and atherosclerosis progression up to advanced 
atherosclerotic plaques. 
2.2.4 Chronic cardiovascular inflammation 
Inflammatory changes in the atherosclerotic vessel wall were already described in the 19th 
century. However, for a long time it was unclear whether this inflammation was a coincidental 
result of atherosclerotic alterations in the vessels, or whether the cellular inflammatory 
changes were of primary importance and actually the causal effectors of the disease39,40. 
Today it is well established that atherosclerosis is a chronic inflammatory disease and that 
cardiovascular inflammation plays a key role in atherogenesis. 
The overabundance of immune cells in atherosclerotic plaques is the first indication for an 
important role of inflammation in atherosclerosis development. These cells, in particular 
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macrophages and DCs, secrete pro-inflammatory cytokines and chemokines, such as IL-1β, 
IL-6, IL-12, TNF-α and monocyte chemotactic protein (MCP)-1, which have all been shown to 
promote atherosclerosis progression41. Local non-resolving inflammatory responses in the 
vessel wall result in further immune cell recruitment and lipid deposition in the intimal space. 
This, in turn, leads to a systemic increase of pro-inflammatory cytokines in the blood and 
subsequent activation of acute-phase reactants in the liver. Indeed, high serum levels of 
TNF-α, IL-6 and particularly high sensitivity C-reactive protein (hsCRP) have been 
associated with increased risk of future cardiovascular events and represent inflammatory 
biomarkers for prediction of CVD. Amongst those, hsCRP, which is clinically used as 
inflammatory biomarker, has been shown to be as predictive as total cholesterol or HDL-
cholesterol levels for determining CVD risk42, which supports the importance of systemic 
inflammation in atherosclerosis. Another link between systemic inflammation and 
atherosclerosis is derived from the finding that patients with chronic inflammatory diseases, 
such as rheumatoid arthritis and systemic lupus erythematosus, have an increased risk for 
cardiovascular events43,44. 
Since the major function of the immune system is to protect the body from invading 
pathogens, and the vasculature is an important interface for pathogen recognition, a popular 
hypothesis was that vascular inflammation deriving from microbial infections might contribute 
to the pathogenesis of atherosclerosis. Indeed, some bacterial and viral pathogens, such as 
C. pneumoniae, H. pylori, Influenza and HIV, were associated with human atherosclerosis 
development45. However, while it is likely that the systemic inflammation caused by chronic 
infection with these pathogens might increase the risk of developing atherosclerosis there is 
no evidence for a direct causative effect of microbial infection on atherogenesis45. Moreover, 
a study using germ-free mice provided evidence that atherogenesis occurs independently of 
microbial infections46, which indicates that endogenous danger signals rather than microbial 
molecules might elicit the inflammation responsible for atherosclerosis progression. Indeed, 
several DAMPs are present in atherosclerotic plaques and have been linked to 
cardiovascular inflammation and atherosclerosis development (Table 2-2). 
Therefore, atherosclerosis is no longer considered to develop from passive accumulation of 
cholesterol and lipoproteins in the vessel wall, but it is rather regarded as complex chronic 
inflammatory disease, in which sterile cardiovascular inflammation initially caused by 
imbalances in cholesterol metabolism is the main driver of disease progression. 
Consequently, a plethora of anti-inflammatory therapies for atherosclerosis, including generic 
anti-inflammatory agents such as colchicine and methotrexate, are currently being tested42. 
Currently, the most promising approach is the inhibition of the pro-inflammatory cytokine  
IL-1β, which is a potent pro-atherogenic cytokine with pleitropic effects, such as promoting 
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Table 2-2: Triggers of sterile inflammation in atherosclerosis. 
Several endogenous danger signals accumulate in atherosclerotic plaques and have been associated with 
cardiovascular inflammation, the main driver of atherogenesis45. 
Origin of DAMP DAMP 
Extracellular matrix Fibronectin, Hyaluron, Heparan sulfate 
Oxidation epitopes Oxidized LDL, Oxidized phospholipids, Minimally modified LDL 
Cell death Advanced glycation end-products (AGEs), Heat shock proteins, 
HMGB1, Fatty acids, Nucleic acids, ATP 
Metabolic products Cholesterol crystals, Uric acid crystals 
Microenvironment Acidosis, Hyperglycemia 
 
the proliferation and differentiation of monocyte-derived cells, augmenting local cytokine and 
growth factor production and increasing endothelial adhesion molecule and coagulation 
factor expression, thereby favoring thrombus formation. In human coronary arteries of 
atherosclerosis patients macrophage and endothelial cell-derived IL-1β levels correlate with 
atherosclerosis severity47. Furthermore, murine atherosclerosis progression is attenuated in 
mice lacking IL-1β, confirming that IL-1β has atherogenic activity24,48. Several animal models 
have suggested the protective role of IL-1β blockade in atherosclerosis48-51, and a clinical trial 
is currently testing the effectiveness and safety of canakinumab, a human monoclonal 
neutralizing IL-1β antibody, in patients with coronary artery disease (CANTOS trial)52. While 
targeting vascular inflammation appears to be a promising approach for the development of 
anti-atherogenic therapies, the inhibition or modulation of systemic inflammation always 
carries the caveat of disturbing immune homeostasis, which might therefore cause 
detrimental side effects for example during infection and therefore requires careful evaluation 
of risks and benefits. 
2.2.5 Cholesterol uptake, metabolism and elimination 
In vertebrates, cholesterol is an essential lipid that is either derived from endogenous de 
novo synthesis or taken up via the diet. Cholesterol is a fundamental component of cell 
membranes, where it is crucial for maintaining membrane structure, function and 
permeability and is also importantly involved in cellular signal transduction. Moreover, 
cholesterol metabolites such as oxysterols, vitamin D, bile acids and steroid hormones are 
also essential for several physiological processes. Despite these essential functions, 
excessive amounts of cholesterol in the body can be detrimental. Therefore, cellular 
cholesterol uptake, biosynthesis, metabolism and elimination need to be tightly regulated. 
Introduction 
 
 17 
2.2.5.1 The “good” and the “bad” cholesterol 
The hydrophobic nature of cholesterol requires that lipoprotein carriers in the blood transport 
it through the body. The major cholesterol-carrying lipoprotein in humans is LDL, which 
delivers cholesterol, including dietary cholesterol from the liver, to the peripheral tissues. In 
contrast, high-density lipoprotein (HDL) is responsible for removing excess cholesterol from 
peripheral tissues to the liver for bile acid synthesis and fecal excretion from the body in a 
process known as reverse cholesterol transport (RCT). 
Since high LDL cholesterol levels increase the risk of developing atherosclerosis, it has been 
commonly referred to as the “bad” cholesterol for a long time. Because LDL accumulates in 
the subendothelial space where it triggers inflammatory responses and initiates 
atherosclerosis plaque formation, it is still regarded as the major atherogenic lipoprotein53. In 
contrast, HDL cholesterol levels have been inversely correlated to CVD risk, and since HDL 
cholesterol levels were observed to be protective in epidemiological studies54, it was 
subsequently referred to as the “good” cholesterol. However, more recent studies have 
elucidated that HDL function, or more specifically, its capacity to efflux cholesterol from 
macrophages, is a more important predictor atherosclerosis risk than HDL cholesterol levels 
alone55. Besides its important role in RCT, HDL has anti-oxidative, anti-thrombotic, anti-
apoptotic and anti-inflammatory effects, and is therefore regarded as anti-atherogenic 
lipoprotein53,56. 
2.2.5.2 Cellular cholesterol uptake and storage 
Cells in peripheral tissues obtain cholesterol from the circulation by receptor-mediated 
endocytosis of LDL particles by the LDLR. Upon endocytic uptake, the LDLR is recycled 
back to the plasma membrane, whereas its cholesterol cargo is exported from late 
endosomal compartments by the proteins Niemann-Pick type C (NPC) 1 and NPC2. This 
LDL-derived cholesterol is then either directly integrated into cellular membranes or it is 
enzymatically converted to cholesterol esters by acyl-coenzyme A (CoA):cholesterol 
acyltransferase (ACAT) in the endoplasmic reticulum (ER). This esterification of cholesterol 
is of importance as the accumulation of free cholesterol is toxic for the cells57, while 
cholesterol esters are a nontoxic storage form of cholesterol, which can be stored in 
cytoplasmic lipid droplets. Cholesterol ester hydrolase (CEH) hydrolyzes esterified 
cholesterol from lipid droplets and thus makes the stored cholesterol available for cellular 
cholesterol metabolism58. 
2.2.5.3 Cellular cholesterol efflux and reverse cholesterol transport 
A key mechanism for maintaining cellular cholesterol homeostasis is the efflux of excess 
cholesterol from peripheral cells, such as cholesterol-rich macrophage foam cells in the 
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arterial walls. Cholesterol efflux is mainly mediated via the transmembrane ATP-binding 
cassette transporters A1 (ABCA1) and G1 (ABCG1), which initiate RCT by loading 
cholesterol into HDL (Fig. 2-3). ABCA1 transfers cholesterol to lipid-poor ApoA1 particles, 
thereby forming nascent HDL particles. Lecithin-cholesterol acyltransferase (LCAT) 
generates mature HDL particles esterifying the cholesterol present in these nascent HDL 
particles. In contrast to ABCA1-mediated cholesterol efflux, ABCG1 transfers cellular 
cholesterol to lipid-rich mature HDL particles. While some cholesterol can be transferred 
directly from mature HDL to VLDL and LDL particles by cholesterol ester transfer protein 
(CETP), HDL mainly delivers its incorporated cholesterol to the liver, where it is removed 
from the circulation via hepatic scavenger receptor B1 (SR-B1). In the liver, HDL-derived 
cholesterol esters are converted back to free cholesterol, which then serves as substrate for 
bile acid synthesis. Finally, cholesterol and bile acids are eliminated from the body via biliary 
excretion into the feces59. 
   
Figure 2-3: Cellular cholesterol efflux and reverse cholesterol transport. 
Reverse cholesterol transport describes the process by which excess cellular cholesterol effluxed to HDL 
particles and transported to the liver for excretion from the body. The cholesterol efflux transporters ABCA1 
and ABCG1 transfer cellular cholesterol to lipid-poor ApoA1 or lipid-rich HDL particles, respectively. 
Effluxed free cholesterol (FC) is converted into cholesterol esters (CE) by LCAT, thereby forming mature 
HDL particles. CEs in HDL particles are then either transferred by CETP to VLDL and LDL particles that 
also contain trigylcerides (TG) or directly taken up into the liver via SR-BI for subsequent bile acid synthesis 
and biliary cholesterol excretion. Figure adapted from Rader and Tall60 with reprint permission (see 
appendix). 
 
2.2.5.4 Regulation of cellular cholesterol homeostasis 
For maintaining cellular cholesterol homeostasis, cellular cholesterol synthesis, uptake, 
storage and efflux need to be tightly regulated. Transcriptional regulation of cellular 
cholesterol homeostasis primarily involves two families of transcription factors, whose activity 
is controlled by the binding of sterols and oxysterols, and therefore directly depends on the 
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sterol status of the cell. Cholesterol biosynthesis and uptake are regulated by genes under 
the control of sterol regulatory element-binding protein (SREBP) transcription factors, which 
are activated in response to low levels of cellular cholesterol. In contrast, genes involved in 
cholesterol efflux pathways are under the control of the liver X receptor (LXR) transcription 
factors, which are activated under conditions of excess cellular cholesterol (Fig. 2-4)61. 
SREBPs 
Transcription factors of the SREBP family control the expression of genes that regulate both 
the cholesterol and fatty acid biosynthesis pathways. While SREBP-1a regulates both 
pathways and SREBP-1c regulates fatty acid synthesis, SREBP-2 is the main regulator of 
cholesterol biosynthesis. SREBP precursor proteins reside in the ER as integral membrane 
proteins, which interact with SREBP cleavage activating protein (SCAP). When cellular 
cholesterol levels are low, SCAP mediates the transport of SREBP precursors to the Golgi 
where proteolytic processing produces the mature SREBP transcription factors. Upon 
translocation to the nucleus, SREBPs bind to sterol-response elements in their target genes 
thereby activating their transcription62. SREBP-2 target genes encode proteins involved in 
cholesterol uptake and biosynthesis, such as LDLR or HMG-CoA reductase, which is the 
rate-limiting enzyme for cholesterol synthesis. Therefore, activation of SREBPs results in an 
increase of cellular cholesterol levels. However, when cellular cholesterol levels are high, 
cholesterol and its precursor desmosterol cause SREBP/SCAP ER retention by directly 
binding to SCAP, which prevents SCAP-mediated SREBP trafficking to the Golgi, while 
oxysterols bind to the ER-retention proteins insulin-induced gene (INSIG) 1 or INSIG2, which 
promotes their binding to SCAP mediating ER-retention of SREBP61. With SREBPs inactive 
and sequestered in the ER, they are no longer able to activate their gene expression 
programs. 
LXRs 
Transcription factors of the LXR nuclear receptor family, namely LXRα and LXRβ, form 
heterodimers with retinoid X receptor (RXR) transcription factors to bind LXR response 
elements in their target genes. LXR/RXR heterodimers can both positively and negatively 
control the transcription of their target genes depending on the presence of endogenous LXR 
agonists. While SREBPs can be directly regulated by cholesterol, LXRs are solely activated 
by sterols and oxysterols that accumulate under conditions of high cellular cholesterol. These 
endogenous LXR agonists include the cholesterol precursor desmosterol and several 
oxysterols, such as 24(S)-hydroxycholesterol (HC), 25-HC and 27-HC. Therefore, when 
cellular cholesterol levels are low, no LXR ligand is present and LXR/RXR heterodimers 
interact with a co-repressor complex resulting in inhibition of target gene expression. But  
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Figure 2-4: Transcriptional regulation of cellular cholesterol homeostasis. 
Cellular cholesterol levels control transcriptional regulation of cholesterol homeostasis by SREBPs and 
LXRs. Low cellular cholesterol levels (top) cause SCAP-mediated transport of SREBP precursors to the 
Golgi, where proteolytic processing generates mature SREBP transcription factors. Nuclear translocation of 
SREBP induces the transcription of genes encoding proteins involved in cholesterol synthesis and uptake 
(e.g. HMG-CoA reductase or LDLR). At the same time LXR/RXR heterodimers repress the transcription of 
genes encoding proteins involved in cholesterol efflux (e.g. ABCA1 and ABCG1). This cooperative 
transcriptional regulation causes an increase in cellular cholesterol. High cellular cholesterol levels (bottom) 
cause the retention of SCAP/SREBP complexes in the ER, which is mediated by desmosterol, cholesterol 
and oxysterols, and prevents SREBP target gene expression. At the same time desmosterol and oxysterols 
bind to LXRs thereby activating the transcription of target genes (e.g. Abca1 and Abcg1). This activation of 
cellular cholesterol efflux pathways results in a decrease in cellular cholesterol. Figure from Spann and 
Glass61 with reprint permission (see appendix). 
when cellular cholesterol levels are high, endogenous LXR ligands bind LXRs and induce the 
recruitment of a co-activator complex resulting in activation of target gene expression. LXR 
target genes encode proteins important for cellular cholesterol efflux, such as ABCA1, 
ABCG1 and ApoE, but LXRs also activate genes involved in fatty acid biosynthesis, among 
them SREBP-1c61. SREBP-1c in turn activates stearoyl-CoA desaturase-1 (Scd-1), the 
enzyme producing oleoyl-CoA, which is the preferred substrate for ACAT, resulting in 
increased esterification of free cholesterol by ACAT63. Therefore, LXR activation restores 
cellular cholesterol homeostasis predominantly by regulating cholesterol efflux, but also by 
indirectly promoting cholesterol storage. Finally, in addition to regulating cholesterol 
homeostasis, activated LXR transcription factors can also function as transcriptional 
repressors of pro-inflammatory responses by transrepression of NF-κB64. 
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Oxysterols 
Oxysterol production under conditions of excess cellular cholesterol is of particular 
importance for regulating cellular cholesterol homeostasis, as cholesterol itself is not a ligand 
for LXR and therefore cannot regulate cholesterol efflux pathways. Instead, oxysterols 
function as indirect signals of cholesterol excess, which can simultaneously regulate 
cholesterol efflux pathways by LXR activation and cholesterol biosynthetic pathways by 
suppression of SREBP processing. Moreover, oxysterols can also promote INSIG1 binding 
to HMG-CoA reductase resulting in ubiquitination and proteasomal degradation of HMG-CoA 
reductase, which represents another mechanism of inhibiting cholesterol biosynthesis65. In 
the liver, oxysterols can be further metabolized to bile acids and therefore importantly 
contribute to cholesterol removal from the body by biliary cholesterol excretion66. Oxysterols 
are generated from cholesterol by specific enzymes. For instance cholesterol 24-hydroxylase 
(Cyp46a1), cholesterol 25-hydroxylase (Ch25h) and cholesterol 27-hydroxylase (Cyp27a1) 
catalyze the production of 24(S)-HC, 25-HC and 27-HC, respectively67. The hydroxylation at 
the side-chain of cholesterol makes the oxysterol more hydrophilic, which improves its 
movement in the aqueous cytoplasmic environment increasing its potential to function as 
signaling molecule66. Furthermore, oxysterols regulate intracellular cholesterol trafficking 
between internal compartments, such as the ER, where many cholesterol regulatory 
enzymes reside, and the plasma membrane65. This regulation of intracellular cholesterol 
trafficking is important for adequate cellular responses to changes in cellular cholesterol 
levels and maintaining of cellular cholesterol homeostasis. 
2.2.6 Cholesterol crystals in atherosclerosis 
The physical state of cholesterol is greatly influenced by its concentration, but also by several 
environmental factors such as the surrounding medium, pH, temperature and pressure. 
Since cholesterol is a hydrophobic molecule with low water solubility, high cholesterol 
concentrations in aqueous environments result in the crystallization of cholesterol. 
The deposition of crystalline cholesterol has long been regarded as a hallmark of advanced 
atherosclerotic plaques. However, the role of cholesterol crystals (CCs) in the development, 
progression and clinical outcome of atherosclerosis was underestimated for a long time. 
Initially, CC deposition was only observed in late stages of the disease, and moreover, CCs 
were only indirectly detected by the presence of so-called cholesterol crystal clefts, which 
occur when the organic solvents used for common histological sample preparation dissolve 
deposited crystalline cholesterol. While both extra- and intracellular cholesterol crystal clefts 
have been described, the origin of the crystalline material, especially inside the cells, was 
unclear68. Indeed, one hypothesis was that cholesterol crystallization might be a handling 
artifact arising during tissue preparation, but in the 1970s Small and colleagues confirmed 
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the presence of monohydrate CCs in intermediate and advanced atherosclerotic plaques69. 
They also already proposed that supersaturation of free cholesterol inside lysosomes 
induces intracellular cholesterol crystallization followed by lysosome disruption and 
subsequent cell death, thereby promoting the formation of the lipid-rich necrotic core of 
advanced atherosclerotic plaques69. This concept was proven by in vitro studies on 
macrophage foam cells that showed intracellular cholesterol monohydrate crystal formation 
upon free cholesterol accumulation in the lysosome70, which was accompanied by apoptotic 
and necrotic cell death71. The findings of the latter in vitro study, which used an ACAT 
inhibitor to increase free cholesterol in the cells, were confirmed in vivo, where ACAT 
deficiency in atherosclerosis mouse models resulted in extensive accumulation of 
extracellular CCs and a drastic decrease in macrophage plaque content, presumably due to 
increased cell death in response to excessive free cholesterol72. These studies provided 
evidence that intra- and extracellular phase transition of free cholesterol to its crystalline form 
is physically possible in vivo, and that this can be triggered by dysregulated cellular 
cholesterol homeostasis, resulting in high cholesterol concentrations. Therefore, in the 
atherosclerotic plaque, cholesterol crystallization may occur in response to accumulated 
cholesterol derived from lipoproteins or dying cells. While increased efferocytosis and 
phagocytic lipoprotein clearance might overwhelm regulatory mechanisms of cellular 
cholesterol homeostasis and drive intracellular CC formation, the accumulated cholesterol 
can also directly crystallize in the extracellular milieu of the atherosclerotic plaque. 
2.2.6.1 CCs as contributors to the clinical outcome of atherosclerosis 
CCs, which were long-known to be present in late stage atherosclerotic plaques, are also 
abundantly present at sites of plaque rupture in human atherosclerosis, suggesting an 
important role for CCs in the clinical manifestations of CVD73. In a series of studies, Abela 
and colleagues elucidated the contribution of CCs in advanced atherosclerotic plaques to 
plaque rupture and the clinical outcomes of atherosclerosis. First they observed in vitro that 
cholesterol phase transition to crystalline cholesterol results in the formation of large sharp-
edged CCs, which can penetrate and thereby damage biological membranes74. Therefore, 
they suggested the contribution of CCs to plaque vulnerability and rupture. Evidence for this 
was provided by scanning electron microscopical analysis of human coronary arteries of 
patients with severe atherosclerosis, who had either died from myocardial infarction or other 
causes. They found that CCs perforated the arterial intima and the fibrous cap of 
atherosclerotic plaques exclusively in patients who died from acute coronary syndrome, 
indicating a correlation between mechanical plaque disruption and disease outcome73. 
Furthermore, this vascular injury triggered by CC penetration of the endothelial cell layer 
might also cause a systemic inflammatory response by local production of IL-6 and 
subsequent hepatic production of the acute phase protein hsCRP, which is the primary 
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inflammatory biomarker for the prediction of future acute cardiovascular events75. Finally, 
statin treatment, which inhibits cholesterol biosynthesis, beneficially reduced cholesterol 
crystallization and promoted CC dissolution in human carotid plaque tissue, thereby 
promoting plaque stabilization, which might be another of the beneficial pleiotropic effects of 
statins in atherosclerosis76. Together these findings demonstrate that CCs present in 
advanced atherosclerotic plaques contribute to the clinical outcome of atherosclerosis by 
promoting plaque rupture and subsequent thrombus formation. 
2.2.6.2 CCs as contributors to atherosclerosis progression 
Although a pathogenic role for crystalline cholesterol was already suggested in the 1980s77, 
the potential contribution of CCs to atherosclerosis progression was largely ignored, most 
likely because CCs were only observed in late stages of atherosclerosis. However, the 
application of a novel imaging technique based on the reflective nature of crystalline 
cholesterol combined with solvent-free sample preparation finally allowed the direct 
visualization of CCs in atherosclerotic plaques. Indeed crystalline cholesterol was shown to 
be present in all stages of murine atherosclerosis, even in very early diet-induced 
atherosclerotic plaques. Moreover, the appearance of CCs in early atherosclerotic plaques 
coincided with the first appearance of innate immune cells in these plaques24, indicating that 
CCs might be inflammatory and directly contributing to atherosclerosis progression. 
As an essential molecule, cholesterol was long regarded as a non-immunogenic substance. 
However, evidence that crystalline cholesterol might have immunostimulatory potential has 
accumulated over the years. Firstly, CCs were found to activate both the alternative and 
classical pathways of the complement system, which itself was already suggested to play a 
role in the pathogenesis of atherosclerosis78,79. Furthermore, CCs were shown to induce the 
production of specific IgG antibodies80. In a model of chronic apical periodontitis, another 
disease characterized by CC accumulation, the recruitment of immune cells to CC implants 
was observed. While the recruited immune cells were not able to clear the CC implants, the 
induction of a robust, non-resolving inflammation was observed81. Beyond this, deposition of 
extracellular CCs in the ACAT deficient atherosclerosis mice was also accompanied by a 
substantial inflammatory response indicating a link between extracellular crystalline 
cholesterol deposition and cardiovascular inflammation72. Ten years later, two independent 
studies reported that extracellular CCs are abundantly phagocytozed by murine and human 
macrophages, which causes the damage of lysosomal compartments. In turn the NLRP3 
inflammasome becomes activated, which results in caspase-1 mediated processing and 
secretion of pro-inflammatory and pro-atherogenic cytokines of the IL-1β family: IL-1β and  
IL-1824,25. 
The finding that crystalline cholesterol, which is present in the vessel wall at all stages of 
atherosclerosis, activates the NLRP3 inflammasome in macrophages provided a possible 
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molecular mechanism for IL-1β production in atherosclerotic plaques. Moreover, 
atherosclerosis development was impaired in LDLR-/- mice transplanted with bone marrow 
from mice deficient in either NLRP3 or the central inflammasome adaptor molecule ASC, 
indicating that CC-induced myeloid NLRP3 inflammasome activation mediates the IL-1β-
dependent inflammatory response that promotes atherosclerosis progression24. While one 
conflicting study reported that a deficiency in NLRP3 inflammasome components had no 
influence on atherosclerosis progression in ApoE-/- mice82, which was most likely due to 
differences in experimental conditions (e.g. use of mouse model and much stronger 
atherogenic diet), several other studies supported the importance of NLRP3 inflammasome 
activation for atherosclerosis development and progression. For example, macrophage-
specific ATG5-null mice, a common mouse model for autophagy deficiency, when crossed to 
ApoE-/- mice developed enlarged atherosclerotic plaques upon high-fat diet feeding, which 
was attributed to increased CC-mediated inflammasome activation and subsequent IL-1β 
secretion in autophagy-deficient macrophages83. NLRP3 is also highly expressed in the 
aortas of patients with coronary atherosclerosis and NLRP3 expression levels correlate with 
disease severity as well as clinical risk factors for CVD, which is further indirect evidence for 
a role of NLRP3 inflammasome activation in atherosclerosis84. Furthermore, lentiviral gene 
silencing of NLRP3 in ApoE-/- mice reduced atherosclerotic plaque growth, macrophage and 
lipid plaque content and pro-inflammatory cytokine production, demonstrating impaired 
atherosclerosis progression in the absence of NLRP385. 
In vitro, activation of the NLRP3 inflammasome requires an initial priming signal, which 
induces NRLP3 and pro-IL-1β expression before stimulation with the activating ligands, such 
as CCs (see section 2.1.3.2). While it was shown that oxLDL particles, which are present in 
large quantities in early atherosclerotic plaques, can provide this obligatory priming signal for 
NLRP3 activation in macrophages in vitro24, other factors might mediate macrophage priming 
in the atherosclerotic plaque in vivo. For example, CC-mediated complement activation was 
shown to prime monocytes in human whole blood while simultaneously promoting CC 
phagocytosis therefore providing both signal 1 and 2 for NLRP3 activation in this system86. 
Moreover, a recent study demonstrated that CCs trigger the release of neutrophil 
extracellular traps (NETs), which can in turn prime human monocytes for CC-mediated 
inflammasome activation and subsequent pro-inflammatory cytokine release. Since NET-
deficient mice show impaired atherosclerosis development accompanied with decreased 
plasma levels of pro-inflammatory cytokines, NET formation might be an essential 
requirement for inflammasome priming in vivo87.  
In summary, these studies showed that cholesterol in its crystalline state is a potent 
immunogenic DAMP, which stimulates innate immune cells, such as macrophages, by 
activating the NLRP3 inflammasome. The NLRP3 inflammasome, in turn, was associated 
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with atherosclerosis progression. Since CCs are already present in early atherosclerotic 
plaques, they qualify as inducers of this NLRP3-dependent atherogenesis. Therefore, these 
findings collectively demonstrate that CCs contribute to the non-resolving cardiovascular 
inflammation that drives disease progression by activating the NLRP3 inflammasome to 
release pro-atherogenic IL-1β. 
2.3 Cyclodextrins 
Cyclodextrins are cyclic oligosaccharides of natural origin. They are generated from the 
enzymatic degradation of starch by cyclodextrin glycosyltransferases. These bacterial 
enzymes are closely related to α-amylases, but have the unique ability to catalyze the 
cyclization of six to eight α-(1,4)-linked D-glucopyranose units. This enzymatic reaction 
produces the three main cyclodextrins: α-, β- and γ-cyclodextrin, which contain six, seven or 
eight glucose units, respectively (Fig. 2-5A). The circular sugar molecules form cone-shaped 
3D-structures, with a central hydrophobic cavity, while the outer part is hydrophilic because 
of the large number of hydroxyl groups (Fig. 2-5B). Therefore, cyclodextrins are both water-
soluble and able to incorporate hydrophobic molecules or hydrophobic moieties of molecules 
into their central hydrophobic cavity. This reversible, non-covalent incorporation of “guest” 
 
 
Figure 2-5: Cyclodextrins and formation of cyclodextrin inclusion complexes. 
(A) Chemical structures of α-, β- and γ-cyclodextrin with six, seven and eight glucopyranoside units, 
respectively. (B) Chemical structure and schematic representation of the conical 3D structure of  
β-cyclodextrin (representative for all cyclodextrins). The cone-like structure is composed of the glucose 
residues, forming a hydrophobic central cavity, whereas the exterior is hydrophilic due to the presence of 
the hydroxyl groups. The primary hydroxyl groups (light grey arrow) of the cyclic oligosaccharides reside on 
the narrow side, while the secondary hydroxyl groups (dark grey arrow) reside on the wider side of the 
cone. The size of the central cavity varies between α-, β- and γ-cyclodextrins as it is determined by the 
number of glucopyranoside units. (C) Schematic illustration of the dynamic equilibrium between free 
cyclodextrins, free “guest” molecules and their formed 1:1 inclusion complex. Figure adapted from Davis 
and Brewster88 with reprint permission (see appendix). 
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molecules into cyclodextrin inclusion complexes is the most important feature of 
cyclodextrins, because it changes the physicochemical properties (such as solubility, stability 
and bioavailability) of the incorporated molecule. Cyclodextrins are therefore extensively 
utilized for various applications including agrochemicals, fragrances, cosmetics, foods and 
pharmaceuticals88,89. 
The formation of inclusion complexes between cyclodextrins and suitably sized hydrophobic 
“guest” molecules is a reversible process characterized by a dynamic equilibrium (Fig. 2-5C). 
The formation and dissociation of these inclusion complexes is determined by the affinity of 
the “guest” molecule for the cyclodextrin cavity. Although 1:1 inclusion complexes are most 
common, interactions with more than one cyclodextrin molecule are possible, depending on 
conformation and size of the “guest” molecule88,90. Since cyclodextrin inclusion complexes 
are in a dynamic equilibrium with the free cyclodextrin and “guest” molecules and no covalent 
bonds are formed between cyclodextrins and the incorporated molecules, the release from 
cyclodextrin is mediated by simple dilution and does not affect the nature of the released 
“guest” molecules. However, the equilibrium can be shifted in the presence of high-affinity 
acceptors of the incorporated molecules89. Furthermore, the release of the “guest” molecule 
from cyclodextrin might also be triggered by competitive displacement by other molecules 
with a higher binding affinity91. 
The parent cyclodextrins are water-soluble, but their solubility in aqueous solutions is limited, 
ranging from only 2% (w/w) in the case of β-cyclodextrin to 26% (w/w) for γ-cyclodextrin88. 
Therefore, several chemically modified cyclodextrin derivatives have been synthesized, 
where the hydroxyl groups are randomly substituted by other chemical moieties resulting in a 
drastic increase in water solubility. The most commonly used chemical modifications for 
increasing the water solubility of cyclodextrins are methylation, hydroxypropylation and 
sulfobutylation. Hydroxypropylated β-cyclodextrin, for instance, has a water solubility of  
60% (w/w). While these cyclodextrin derivatives can still incorporate molecules in their 
central cavity, the binding affinity will be different compared to the parent cyclodextrins89,90. 
2.3.1 Pharmaceutical use of cyclodextrins 
Cyclodextrins have emerged as useful tools for the formulation of (for example) poorly water-
soluble drugs. By forming reversible, non-covalent inclusion complexes, they increase both 
the drug’s solubility and its physical or chemical stability without affecting the drug molecule 
itself. Cyclodextrins can therefore potently improve the bioavailability of these drugs. While 
this is probably the most important pharmaceutical application of cyclodextrins, they can also 
have further beneficial effects, such as masking the bitter taste or the bad odor of some 
drugs. 
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2.3.1.1 Pharmacokinetics of cyclodextrins 
Cyclodextrins are mainly resistant to stomach acid, but can be degraded by α-amylases, 
which, in humans, are mainly present in pancreatic juice and saliva. However, their 
susceptibility to enzymatic degradation is reduced when cyclodextrins are complexed with 
other molecules, and the rate of their hydrolysis also depends on their ring size. While α- and 
β-cyclodextrins are mainly resistant to α-amylases in the gastrointestinal tract, γ-cyclodextrin 
is rapidly degraded in pancreatic juice and saliva. Therefore, orally administered  
γ-cyclodextrin is almost completely degraded in the gastrointestinal tract, while α- and  
β-cyclodextrin proceed to the colon. Here, they can be digested and metabolized by bacterial 
and fungal amylases, in which α-cyclodextrin is again less susceptible to enzymatic 
degradation than β-cyclodextrin89,91. 
The oral bioavailability of pharmaceutically interesting cyclodextrins is generally below 4%, 
which is mainly due to their high molecular weight and their hydrophilic character, which 
impedes their ability to cross biological membranes and accordingly their absorption from the 
gastrointestinal tract. However, once absorbed, any intact cyclodextrin subsequently 
distributes to various tissues including the kidney, adrenal gland, urinary bladder, liver, but 
most of it accumulates in the kidney. Cyclodextrins disappear from the tissues quite quickly 
after administration (within the first few hours) and the intact cyclodextrins are excreted via 
the urine. Similarly, intravenous administration of cyclodextrins results in rapid renal 
excretion of the unmetabolized cyclodextrin molecules with nearly 100% recovery in the 
urine. As such, cyclodextrin clearance from the circulation is dependent on the glomerular 
filtration rate and renal function89,91.  
2.3.1.2 Toxicity of cyclodextrins 
An important determinant for the pharmaceutical application of cyclodextrins is their 
biocompatibility. Cyclodextrins do not induce immune responses in mammals and show quite 
low toxicity in animals and humans, although the toxicity of cyclodextrins is highly dependent 
on the type of cyclodextrin and the route of administration88. 
In vitro studies revealed that cyclodextrins have a hemolytic activity on human erythrocytes, 
which correlates to their ability to solubilize cholesterol and to extract cholesterol from 
membranes89. Moreover, β-cyclodextrin and its methylated derivative, which have the highest 
affinity for cholesterol, were shown to induce caspase-dependent apoptotic cell death in 
human keratinocytes in response to membrane cholesterol depletion, which was not 
observed with other parent cyclodextrins or hydroxypropylated β-cyclodextrin92. However, 
this hemolytic activity has not been directly shown in vivo. 
Oral administration of cyclodextrins is mainly nontoxic, presumably because of their low 
absorption from the gastrointestinal tract. Only at high doses, the hypertonic nature of 
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cyclodextrins causes side effects like flatulency, soft stool and diarrhea, which are similar to 
side effects caused by other poorly digestible carbohydrates (e.g. lactose) and osmotically 
active nutrients or excipients. Therefore, most cyclodextrins are included in the U.S. food and 
drug administration’s (FDA) “generally recognized as safe” (GRAS) list of compounds and 
are generally accepted as food additives91. 
Parenteral administration of cyclodextrins generally shows more toxic effects. Intravenous, 
subcutaneous or intramuscular injections of cyclodextrins at high doses or over a long period 
of time resulted in histopathological changes in laboratory animals. These included 
vacuolation of the kidney and urinary bladder, as well as the appearance of foamy 
macrophages in liver, lung and lymph nodes91. However, due to the renal excretion of 
systemically absorbed cyclodextrins, the kidney is typically the most affected organ. While 
irreversible kidney damage and dysfunction has been reported upon administration of parent 
α- and β-cyclodextrins, parent γ-cyclodextrin as well as many cyclodextrin derivatives 
including hydroxypropylated β-cyclodextrin, only induced a reversible vacuolation of the 
proximal tubular epithelium of the kidney without any manifestation of cell injury, 
degeneration, or disruption of renal function89,91. Similarly, renal toxicity upon parenteral 
administration of β-cyclodextrin to rats was associated with the accumulation of intracellular 
needle-like CCs, which was not observed with hydroxypropylated β-cyclodextrin. While both 
β-cyclodextrin and hydroxypropylated β-cyclodextrin form inclusion complexes with 
endogenous cholesterol in blood, the water solubility of the two inclusion complexes is very 
different. Therefore, glomerular filtration of the β-cyclodextrin-cholesterol inclusion 
complexes most likely results in the dissociation of the complexes due to their limited 
aqueous solubility followed by cholesterol accumulation and crystallization in the proximal 
tubular cells of the kidney. In contrast, the considerably more hydrophilic inclusion complexes 
of hydroxypropylated β-cyclodextrin and cholesterol are less likely to dissociate, and 
therefore are able to be excreted without cholesterol accumulating and crystallizing in the 
kidneys, which might explain the lower nephrotoxicity of intravenously administered 
hydroxypropylated β-cyclodextrin93. 
In summary, while oral administration of most cyclodextrins is well tolerated, the parenteral 
administration of some cyclodextrins, in particular parent α- and β-cyclodextrins can cause 
problems like renal toxicity. However, some cyclodextrin derivatives, especially 
hydroxypropylated β-cyclodextrin, have less toxic side effects and are therefore safer for 
biomedical use than their parent cyclodextrins91. 
2.3.1.3 Pharmacokinetics and toxicology of 2-hydroxypropyl-β-cyclodextrin 
2-Hydroxypropyl-β-cyclodextrin (CD), a hydroxypropylated β-cyclodextrin with improved 
water solubility and good inclusion complexation, is one of the well-tolerated, non-
nephrotoxic cyclodextrin derivatives. Drug-CD complexes rapidly dissociate upon parenteral 
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administration and can drastically improve the oral bioavailability of poorly water-soluble 
drugs, while CD’s own bioavailability is limited. Together, these properties make CD a perfect 
oral drug carrier89,91,94. 
In humans, the oral bioavailability of CD ranges from only 0.5 to 3.3%. Approximately half of 
the orally administered dose is excreted as intact CD via the feces, while the remaining CD is 
metabolized in the colon by bacterial enzymes. When CD is intravenously administered to 
humans, it is rapidly excreted from the body as intact, non-metabolized CD molecules into 
the urine. CD has a small volume of distribution (i.e. the ratio of administered amount to 
plasma concentration), indicating that CD is not considerably distributed into the tissues. The 
biological half-life of CD is less than 2 hours and mainly depends on the glomerular filtration 
rate. Therefore, in individuals with normal kidney function, about 90% of the intravenously 
administered dose is excreted via the urine within 6 hours, and about 99% within 12 hours 
post administration (Fig. 2-6). Consequently, parenteral administration of CD will not result in 
considerable accumulation of CD in individuals with normal kidney function89. 
CD is listed in the FDA’s list of inactive pharmaceutical ingredients and is used as an 
excipient in several commercially available drugs95. Amongst these, the most prominent drug 
is the antifungal agent itraconazole, which is formulated with 40% (w/v) CD solutions for oral 
and intravenous administration. At this concentration CD increases the solubility of 
itraconazole by up to six orders of magnitude. During itraconazole treatment, patients receive 
an oral dose of 8 g CD per day or an intravenous dose of up to 16 g CD per day respectively 
(8 g twice a day, see Fig. 2-6 for resultant CD plasma concentrations)88,91. Therefore, the oral 
and intravenous administration of CD at these concentrations over approximately 2 weeks 
are known to be well tolerated with diarrhea being the main side effect of oral administration. 
Furthermore, even after parenteral administration of up to 24 g CD per day (12 g twice a day) 
over a period of 15 days no adverse effects were observed89. 
 
  
Figure 2-6: Plasma clearance of 2-Hydroxypropyl-β-cyclodextrin. 
Plasma concentrations of CD over time in humans, following repeated intravenous administration of 8 g CD 
twice a day. Figure from Lofftson and Brewster89 with reprint permission (see appendix). 
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2.3.2 Cyclodextrins and cellular cholesterol 
Cyclodextrins also interact with hydrophilic membrane components, such as phospholipids 
and cholesterol. While α-cyclodextrin predominantly forms inclusion complexes with 
phospholipids, β-cyclodextrin has the highest affinity for cholesterol. This feature of  
β-cyclodextrins prompted the development of several functionalized or conjugated  
β-cyclodextrins for selective cholesterol binding and detection96-98. More importantly, in vitro 
studies revealed that cyclodextrins extract lipid molecules from the cell membranes when 
forming inclusion complexes with these molecules, which was associated with their hemolytic 
activity in human erythrocytes89. This observation prompted the introduction of cyclodextrins 
as research tools to manipulate and study cellular membranes. In this regard β-cyclodextrins 
turned out to be powerful modulators of cellular cholesterol levels in living cells. While 
cyclodextrins can serve as cholesterol acceptors that remove cholesterol from cells, pre-
formed β-cyclodextrin-cholesterol inclusion complexes can also function as cholesterol 
donors that replenish or even enrich cellular cholesterol99. 
Furthermore, studies on the safety of the parenteral use of β-cyclodextrins and its derivatives 
in rats and rabbits showed a transient decrease in plasma cholesterol levels accompanied by 
redistribution of plasma cholesterol to the kidneys, resulting in the urinary excretion of  
 
 
Figure 2-7: 2-Hydroxypropyl-β-cyclodextrin in the shuttle/sink model for cellular cholesterol efflux. 
Cholesterol movement between cells and serum lipoproteins is a bidirectional process. Under normal 
conditions (1), cellular and lipoprotein cholesterol are at equilibrium with a constant exchange between the 
two cholesterol pools. When low concentrations of CD are present (2), CD functions as cholesterol shuttle 
which increases cholesterol turnover without affecting the equilibrium condition. When more cholesterol 
acceptors, such as serum lipoproteins, are present in addition to low concentrations of CD (3), the serum 
lipoproteins function as extracellular cholesterol sinks, which increases the cholesterol efflux rate and 
therefore shifts the equilibrium towards net efflux. At high concentrations of CD (4), CD molecules 
themselves function as extracellular cholesterol sinks mediating the net efflux of cellular cholesterol. Model 
adapted from Atger et al.100. 
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cholesterol in inclusion complexes with CD (2-Hydroxypropyl-β-cyclodextrin)93,101. These 
findings indicated that β-cyclodextrin derivatives, such as CD, catalyze the transport of lipids 
within the organism, and suggested a potential use for manipulating lipid transport and 
distribution in vivo. This idea was further supported by in vitro studies, which investigated the 
ability of CD to move cholesterol from cells to serum cholesterol acceptors, such as 
lipoproteins, thereby mimicking the first step of RCT in vivo. While CD itself depleted cellular 
cholesterol at high concentrations, low concentrations of CD only induced net cholesterol 
efflux from cells in the presence of cholesterol acceptors presumably by catalyzing the 
bidirectional exchange of cholesterol between cells and serum lipoproteins100. Based on 
these findings, a shuttle/sink model for the first step in RCT, which involves the net 
movement of cellular cholesterol to lipoproteins, was proposed100. Importantly, CD can 
function as both shuttles and sinks for causing net efflux of cellular cholesterol, depending on 
its concentration (Fig. 2-7). Moreover, CD was also effective in depleting free and esterified 
cholesterol from mouse and human foam cell macrophages, therefore presenting a potential 
pharmacological use of CD or CD-like cholesterol shuttles in the treatment of 
atherosclerosis100,102. 
2.3.3 Use of 2-hydroxypropyl-β-cyclodextrin in NPC disease 
While CD is currently extensively used as excipient for poorly water-soluble drugs, the 
potential of CD itself as an active drug molecule was disregarded for a long time. However, it 
is currently being tested in clinical trials as a pharmaceutical drug for the treatment of 
Niemann-Pick type C (NPC) disease. 
NPC disease is a rare inherited neurodegenerative disorder. Genetically, it is caused by a 
mutation in either the NPC1 gene or, in rare cases, the NPC2 gene. The mutations 
compromise the function of the proteins NPC1 and NPC2 respectively, which regulate 
intracellular trafficking of cholesterol and other lipids (see section 2.2.5.2). Without functional 
NPC1/2-mediated trafficking, free cholesterol and sphingolipids accumulate inside the cells 
of various organs, including the brain. The clinical manifestations of NPC disease are mainly 
neurological, such as swallowing problems, ataxia, seizures, and progressive impairment of 
motor and cognitive function. The first signs of disease can appear at different ages, ranging 
from infancy to adulthood, but they mainly occur in early childhood and patients mostly die in 
adolescence. So far, there is no adequate therapy available for NPC disease95. 
Cells from NPC patients are unable to release cholesterol from endolysosomal 
compartments resulting in the detrimental intracellular accumulation of free cholesterol. Since 
CD is known to mediate cellular cholesterol removal, whether CD treatment could improve 
cholesterol metabolism and efflux in NPC-/- cells and animal models was tested. Indeed, in 
NPC-/- cells in vitro, CD mobilized cholesterol transport from lysosomal compartments to the 
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ER and thereby enhanced cellular cholesterol metabolism, esterification and efflux103,104. 
Moreover, a plethora of NPC-/- animal studies have revealed that CD administration in vivo 
reverses defective lysosomal transport stimulating cholesterol metabolism, suppressing de 
novo cholesterol synthesis, improving liver dysfunction and neurodegeneration, and 
markedly prolonging the animal’s lifespan95. Interestingly, a single subcutaneous CD injection 
into NPC-/- mice was enough to mediate these effects105,106. Several routes of CD 
administration have been investigated in animals, including parenteral administration and 
direct injections into the brain (intracerebroventricularly or intrathecally). Injections of CD into 
the central nervous system (CNS) have proven particularly successful in the prevention of 
neurodegeneration95, most likely because of the low blood brain barrier permeability of CD107. 
Based on the evidence from the in vitro and in vivo studies, CD was considered a promising 
drug candidate for NPC patients. In 2009, the first Investigational New Drug (IND) application 
for intravenous CD administration was approved by the FDA, which was extended in 2010 to 
include intrathecal administration. IND approvals allow the application of a new drug to 
individual patients with serious life-threatening diseases if there is no alternative therapy and 
if the possible benefit justifies possible risks. Therefore, the use of CD on an individual basis 
already indicated the effectiveness and safety of CD administration in NPC patients95. 
However, well-controlled clinical trials with a larger number of NPC patients are needed to 
properly determine safety and efficacy of CD treatment in NPC disease. The first completed 
phase 1 clinical trial suggested that intrathecal CD administration in NPC patients is well-
tolerated and slows the progression of their neurologic disease, and a phase 2/ phase 3 
clinical trial for assessing ideal dosage and efficacy of intrathecal CD treatment in NPC 
patients is currently recruiting subjects (ClinicalTrials.gov Identifier: NCT02534844). 
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2.4 Objectives of this study 
Atherosclerosis is a progressive inflammatory disease that is linked to increased levels of 
cholesterol in the blood. Despite ongoing advances in surgical and pharmacological 
treatment of atherosclerosis, it still accounts for the majority of deaths worldwide. Identifying 
novel therapeutic targets will improve pharmacological treatment strategies and aid the 
development of new drugs for treating atherosclerosis. 
Several studies have highlighted the contribution of crystalline cholesterol to the 
development, progression and clinical outcomes of atherosclerosis. CCs play a role in late 
stages of the disease where they physically disrupt the fibrous cap promoting plaque rupture 
and thrombus formation, thereby initiating the acute clinical events. Moreover, CCs induce 
inflammatory responses by activating the NLRP3 inflammasome. This already happens in 
early atherosclerotic plaques and is likely to contribute to disease progression108. However, 
so far it has not been investigated whether decreasing the amount of CCs in the plaque 
represents a valuable strategy for pharmaceutical intervention in atherosclerosis. One 
possible agent for targeting CCs in atherosclerotic plaques is 2-hydroxypropyl-β-cyclodextrin 
(CD). CD is known to mediate the removal of cholesterol from cells and its potential 
pharmacological use in atherosclerosis as a shuttle for cholesterol mobilization from 
atherosclerotic plaque tissue to serum lipoproteins such as HDL for increased RCT was 
already proposed nearly 20 years ago100. However, the ability of CD to clear cholesterol from 
atherosclerotic plaque tissue in the walls of blood vessels has not yet been investigated. 
Therefore, the objective of this study was to investigate whether the cholesterol solubilizing 
substance CD has the potential to reduce the amount of CCs in atherosclerotic plaques and 
whether this reduction of crystalline cholesterol in turn impairs atherosclerosis development 
and progression. In detail, the specific aims of this study were: 
1. To evaluate whether CCs present a viable treatment target in atherosclerosis. 
2. To investigate whether CD has the potential to decrease CC plaque load in 
atherosclerosis mouse models. 
3. To determine if a reduction of crystalline cholesterol by CD in turn impairs murine 
atherosclerosis development and progression. 
4. To characterize the molecular mechanisms of CD’s potentially atheroprotective effects 
in vitro by assessing macrophage cholesterol efflux and metabolism. 
5. To determine the effect of CD on CC-induced macrophage inflammatory responses. 
6. To evaluate the relevance of the molecular mechanisms identified in vitro in 
atherosclerosis models using gene-specific knockout mice or bone marrow chimeras in 
vivo. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Consumables 
4-well microscopy dish (CELLview™ 
Cell Culture Dish, Glass bottom) 
Greiner Bio-One (Frickenhausen)                                 
. 
8-well microscopy dish (Nunc™          
Lab-Tek™ Chambered Coverglass)  
Thermo Fisher Scientific (Waltham, MA, USA)                                         
. 
96-well microscopy plate                     
(µclear-plate, black) 
Greiner Bio-One (Frickenhausen)                                 
. 
96-well V-bottom microplate, clear Greiner Bio-One (Frickenhausen)  
Cell scrapers Sarstedt (Nümbrecht) 
Cell Strainers, 70 µm (Falcon®) VWR International (Radnor, PA, USA) 
Centrifuge Tubes (15 ml/ 50 ml), 
(CELLSTAR® polypropylene, conical) 
Greiner Bio One (Kremsmünster, Austria)                          
. 
Cover glasses (22x50 cm),                  
thickness no. 1.5 
Marienfeld (Lauda Königshofen)                                      
. 
Dako pen (Delimiting pen) Dako Deutschland (Hamburg) 
ELISA plates (Nunc-Immuno™ 
MaxiSorp™ 96-Well plate) 
Nunc (Roskilde, Denmark)                                               
. 
Eppendorf safe-lock tubes                         
(1.5 ml/ 2 ml) 
Eppendorf (Hamburg)                                                
. 
FACS tubes Sarstedt (Nümbrecht) 
Glass vials (4 ml) with screw cap CS - Chromatographie Service (Langerwehe) 
MultiScreen-GV Filter Plate, 0.22 µm Merck (Darmstadt) 
Needles B. Braun (Melsungen) 
NuPAGE® Novex 4-12% Bis-Tris Gel 
1.5 mm, 10 Well 
Novex Life Technologies (Carlsbad, CA, USA)                               
. 
NuPAGE® Novex 4-12% Bis-Tris Gel 
1.5 mm, 15 Well 
Novex Life Technologies (Carlsbad, CA, USA)                               
. 
Opti-Seal Bioplastics (Landgraaf, Netherlands) 
PVDF membrane                         
(Immobilon-FL, 0.45 µm) 
Merck (Darmstadt)                                                     
. 
qPCR plate (MicroAmp® Optical          
384-Well Reaction Plate) 
Applied Biosystems Life Technologies      
(Carlsbad, CA, USA) 
Sterile filter tips Mettler Toledo (Greifensee, Switzerland) 
Superfrost™ Plus Microscope Slides  Thermo Fisher Scientific (Waltham, MA, USA) 
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Syringe filters, 0.2 µm            
(Whatman® Puradisc 30) 
Sigma-Aldrich (Taufkirchen)                                                   
. 
Syringes BD Biosciences (Heidelberg) 
Tali Cellular Analysis Slides Invitrogen Life Technologies (Carlsbad, CA, USA) 
Tissue culture flasks (25/ 75/ 175 cm2) Labomedic (Bonn) 
Tissue culture plates (6-well/ 12-well/     
24-well/ 96-well) 
Labomedic (Bonn)                                                      
. 
UHU plus schnellfest 2-K-
Epoxidharzkleber (5 min) 
UHU (Bühl)                                                                          
. 
Ultrafree-MC Centrifugal Filter, 0.22 µm Merck (Darmstadt) 
Whatman® cellulose chromatography 
paper 
Sigma-Aldrich (Taufkirchen)                                                    
. 
 
3.1.2 Chemicals and reagents 
[1,2-3H]-cholesterol Perkin Elmer (Waltham, MA, USA) 
1-Propanol p.a. AppliChem (Darmstadt) 
2 N H2SO4 Carl Roth (Karlsruhe) 
2-Mercaptoethanol  Sigma-Aldrich (Taufkirchen) 
Acridine orange Thermo Fisher Scientific (Waltham, MA, USA) 
Adenosine 5′-triphosphate disodium         
salt hydrate 
Sigma-Aldrich (Taufkirchen)                                                      
. 
Benzonase® Nuclease Sigma-Aldrich (Taufkirchen) 
Bovine Serum Albumin (BSA) Sigma-Aldrich (Taufkirchen) 
Cholera Toxin Subunit B, Alexa Fluor® 
488 Conjugate 
Molecular Probes Life Technologies                     
(Carlsbad, CA, USA)   
Cholera Toxin Subunit B, Alexa Fluor® 
647 Conjugate 
Molecular Probes Life Technologies                     
(Carlsbad, CA, USA)   
Cholesterol, suitable for cell culture Sigma-Aldrich (Taufkirchen) 
complete EDTA-free Protease Inhibitor 
Cocktail Tablets 
Roche (Mannheim)                                                                  
. 
CSL111 (reconstituted HDL)  CSL Behring (King of Prussia, PA, USA) 
D6-cholesterol               
([26,26,26,27,27,27-2H6]-cholesterol) 
CDN Isotopes (Pointe-Claire, Quebec, Canada)                            
. 
Dimethyl sulfoxide (DMSO),                     
cell culture grade 
AppliChem (Darmstadt)                                                                        
. 
dNTP Mix (10 mM each) Thermo Fisher Scientific (Waltham, MA, USA) 
Ethanol (EtOH) 99% absolute AppliChem (Darmstadt) 
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EtOH 99% denatured with 1% MEK 
AppliChem (Darmstadt)                                                                       
. 
Glycerol, anhydrous  Merck (Darmstadt) 
H-Leu-Leu-Ome (LeuLeu) Chem-Impex International (Wood Dale, IL, USA) 
Hoechst 34580                                             
. 
Molecular Probes Life Technologies                   
(Carlsbad, CA, USA)    
LD540                                                      
. 
produced and provided by Prof. Dr. Christoph 
Thiele (LIMES Institute, University of Bonn, Bonn) 
Methanol p.a. AppliChem (Darmstadt) 
MIN-U-SIL® 15 US Silica (Frederick, MD, USA) 
Monodosium urate (MSU) crystals                                              
. 
produced and provided by Anne Alfter (Institute of 
Innate Immunity, University Hospital Bonn, Bonn) 
Nigericin, free acid Invitrogen Life Technologies (Carlsbad, CA, USA) 
Oligo(dT)18 Primer  Thermo Fisher Scientific (Waltham, MA, USA) 
PageRuler™ Plus Prestained Protein 
Ladder, 10 to 250 kDa 
Thermo Fisher Scientific (Waltham, MA, USA)                       
. 
PMSF AppliChem (Darmstadt) 
RBITC-NH2-HPβCD  Cyclolab (Budapest, Hungary) 
Saponin from quillaja bark Sigma-Aldrich (Taufkirchen) 
Sodium chloride Merck (Darmstadt) 
Sodium deoxycholate Sigma-Aldrich (Taufkirchen) 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich (Taufkirchen) 
SuperScript® III Reverse 
Transcriptase 
Invitrogen Life Technologies (Carlsbad, CA, USA)       
. 
T0901317 (T09) Tocris R&D Systems (Minneapolis, MN, USA) 
Trappsol® Hydroxypropyl Beta 
Cyclodextrin, pharmaceutical grade 
CTD Holdings (Alachua, FL, USA)                            
. 
Triton X-100 Carl Roth (Karlsruhe) 
TRIzol® Reagent Ambion Life Technologies (Carlsbad, CA, USA) 
Tween-20 Sigma-Aldrich (Taufkirchen) 
Ultrapure LPS, E. coli 0111:B4 Invivogen (Toulouse, France) 
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3.1.3 Buffers and solutions 
3.1.3.1 ELISA 
ELISA blocking buffer 1x PBS; 1% (w/v) BSA, 0.2 µm filtered 
ELISA reagent diluent (mIL-1β)  
20 mM Tris-HCl pH7.4, 150 mM NaCl, 0.1% (w/v) 
BSA, 0.05% (v/v) Tween-20, 0.2 µm filtered 
ELISA reagent diluent (mTNF-α) 1x PBS; 1% (w/v) BSA, 0.2 µm filtered 
ELISA substrate (BD OptEIA™ TMB 
Substrate Reagent Set) 
BD Biosciences (Heidelberg)                                          
. 
3.1.3.2 Immunohistochemistry 
IHC blocking buffer                                
. 
1x PBS, 5% (v/v) FCS, 5% (w/v) BSA, 10% (v/v) 
goat serum, 0.1% (w/v) saponin  
IHC mounting medium dd H2O, 80% (v/v) glycerol 
IHC staining buffer 1x PBS, 10% (v/v) goat serum 
3.1.3.3 Western blot 
NuPAGE® LDS Sample Buffer, 4x Novex Life Technologies (Carlsbad, CA, USA) 
NuPAGE® MES SDS Running  
Buffer, 20x 
Novex Life Technologies (Carlsbad, CA, USA)                             
. 
NuPAGE® MOPS SDS Running 
Buffer, 20x 
Novex Life Technologies (Carlsbad, CA, USA)                             
. 
NuPAGE® Sample Reducing Agent, 
10x Novex Life Technologies (Carlsbad, CA, USA) 
Pierce™ 10X Tris-Glycine Buffer Thermo Fisher Scientific (Waltham, MA, USA) 
Pierce™ Tris-Glycine Buffer, 10x  Thermo Fisher Scientific (Waltham, MA, USA) 
RIPA buffer                                                            
. RIPA buffer                                                            
.  
20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% (v/v) Triton X-100, 10% (v/v) glycerol,                  
0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate 
Transfer buffer 1x Tris-Glycine buffer, 15% (v/v) methanol 
Tris Buffered Saline (TBS), 20x Santa Cruz Biotechnology (Heidelberg) 
TBS-T 1x TBS; 0.1% (v/v) Tween-20 
WB blocking buffer                                  
.  
1x TBS; 3% (w/v) BSA; 0.1% (w/v) Tween-20,            
0.2 µm filtered 
3.1.3.4 Tissue culture 
BMDM dissociation buffer 1x PBS, 2% (v/v) FCS, 2 mM EDTA  
Trypan blue solution (0.4%) Sigma-Aldrich (Taufkirchen) 
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Trypsin-EDTA (0.05%), phenol red Gibco Life Technologies (Carlsbad, CA, USA) 
3.1.3.5 Others 
16% (w/v) Formaldehyde solution, 
methanol-free 
Thermo Fisher Scientific (Waltham, MA, USA)                             
. 
Ampuwa (aqua ad iniectabilia) Fresenius Kabi (Bad Homburg) 
Goat serum Gibco Life Technologies (Carlsbad, CA, USA) 
Nuclease-free water Invitrogen Life Technologies (Carlsbad, CA, USA) 
Phosphate buffered saline (PBS), 10x  Santa Cruz Biotechnology (Heidelberg) 
Tris-HCl, pH7.4 (1M) AppliChem (Darmstadt) 
UltraPure™ 0.5M EDTA, pH 8.0 Invitrogen Life Technologies (Carlsbad, CA, USA) 
 
3.1.4 Cell culture media and supplements 
Dulbecco's Modified Eagle Medium 
(DMEM), high glucose 
Gibco Life Technologies (Carlsbad, CA, USA)                                            
. 
Dulbecco's PBS Gibco Life Technologies (Carlsbad, CA, USA) 
Fetal calf serum (FCS) Invitrogen Life Technologies (Carlsbad, CA, USA) 
L929 supernatant                                            
. 
Produced and provided by Gudrun Engels 
(Institute of innate immunity, University of Bonn) 
M-CSF R&D Systems (Minneapolis, MN, USA) 
Penicillin-Streptomycin (10,000 U/mL) Gibco Life Technologies (Carlsbad, CA, USA) 
 
3.1.5 Kits 
BD OptEIA™ TMB Substrate Reagent    
Set for ELISA 
BD Biosciences (Heidelberg)                                          
. 
CellTiter-Blue® Cell Viability Assay Promega (Mannheim) 
Maxima™ SYBR Green/ROX qPCR 
Master Mix 
Thermo Fisher Scientific (Waltham, MA, USA)       
. 
Mouse IL-1 beta/IL-1F2 DuoSet R&D Systems (Minneapolis, MN, USA) 
Mouse TNF-alpha DuoSet R&D Systems (Minneapolis, MN, USA) 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific (Waltham, MA, USA) 
RNase-Free DNase Set  Qiagen (Hilden) 
RNeasy Mini Kit Qiagen (Hilden) 
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3.1.6 Antibodies 
Antibodies used in this study are listed in Table 3-1 and Table 3-2 according to the indicated 
applications. 
 
Table 3-1: List of antibodies used for immunohistochemistry. 
Name Supplier Antigen Source Clone Conjugate Dilution 
Rat anti mouse CD68 AbD Serotec mouse 
CD68 
rat FA-11  -   1:500 
Goat anti-Rat IgG (H+L) 
Secondary Antibody, 
Alexa Fluor® 647 
conjugate 
Invitrogen Life 
Technologies  
rat 
IgG(H+L) 
goat polyclonal Alexa 
Fluor 647 
 1:500 
 
Table 3-2: List of antibodies used for western blot analysis. 
Name Supplier Antigen Source Clone Conjugate Dilution 
Anti-ABCA1 (MAB10005) Merck 
Millipore 
mouse 
ABCA1 
mouse AB.H10  -   1:250 
ASC Antikörper (N-15)-R Santa Cruz 
Biotechnology 
mouse 
ASC 
rabbit polyclonal  -   1:200 
β-Actin Rabbit 
Monoclonal Antibody 
LI-COR 
Biosciences 
mouse b-
actin 
rabbit monoclonal  -  1:1,000 
β-Tubulin (9F3) Rabbit 
mAb 
Cell Signaling mouse b-
tubulin 
rabbit 9F3  -  1:1,000 
Anti-NLRP3/NALP3 Adipogen mouse 
NLRP3 
mouse Cryo-2  -  1:5,000 
Mouse IL-1β Detection 
Antibody (from Mouse IL-
1 beta/IL-1F2 DuoSet Kit) 
R&D Systems mouse 
pro-IL-1b 
goat polyclonal biotin  1:1,000 
IRDye® 680RD Donkey 
anti-Rabbit IgG (H + L) 
LI-COR 
Biosciences 
rabbit 
IgG(H+L) 
donkey polyclonal IRDye 
680RD 
1:15,000 
IRDye® 800CW Donkey 
anti-Goat IgG (H + L) 
LI-COR 
Biosciences 
goat 
IgG(H+L) 
donkey polyclonal IRDye 
800CW 
1:15,000 
IRDye® 800CW Donkey 
anti-Mouse IgG (H + L) 
LI-COR 
Biosciences 
mouse 
IgG(H+L) 
donkey polyclonal IRDye 
800CW 
1:15,000 
 
3.1.7 Primers and probes for quantitative PCR 
Primers used for quantitative real-time PCR (qPCR) (Table 3-3) were designed for 
amplification of 100 to 150 base pairs of a specific target gene using Primer3 
(http://bioinfo.ut.ee/primer3-0.4.0/). Primers were placed across exon boundaries to avoid 
amplification of genomic DNA. Oligo7 (http://www.oligo.net) was used to select primer pairs 
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with minimal possible secondary structures (e.g. primer dimer or hairpin formation). Desalted 
primers were ordered from Metabion (Martinsried) and resuspended in nuclease-free water 
to a concentration of 100 µM. 
 
Table 3-3: List of qPCR primers used for amplification of mouse genes.  
Gene name, NCBI Reference Sequence (RefSeq) database accession (http://www.ncbi.nlm.nih.gov/refseq/) 
and primer sequence annotated from 5’ to 3’ end of the mouse gene of interest. 
Gene  RefSeq accession    Sequence 5’-3’ 
Abca1 NM_013454.3 fw GGAAGTTGGCAAGGTTGGTG 
  
rev TGGCTGTGGAGAGCTTTCGT 
Abcg1 NM_009593.2 fw ATCCCCGTCCTGCTCTTCTC 
  
rev GACCCCCTCAAAGCCGTATC 
Cyp27a1 NM_024264.4 fw TCATCGCACAAGGAGAGCAA 
  
rev CCAGCCGGGTGATAAAGTCA 
Hprt NM_013556.2 fw TGAAGTACTCATTATAGTCAAGGGCA 
  
rev CTGGTGAAAAGGACCTCTCG 
Insig1 NM_153526.5 fw ACCACGCCAGTGCCAAATTA 
  rev GCTTCGGGAACGATCAAATG 
Lss1 NM_146006.2 fw AGGCTGGGGAGAGGACTTTG 
  rev TGAGCAGTGATGTCGGGATG 
Nr1h3 NM_001177730.1 fw AGCACGCTATGTCTGCCACA 
  rev CAGCACACACTCCTCCCTCA 
 
Taqman® RT-qPCR assays were performed by Niklas Bode (Medical Clinic and Polyclinic II, 
University Hospital Bonn, Bonn) using commercially available Taqman probes (Table 3-4) 
purchased from Applied Biosystems (Life Technologies, Carlsbad, CA, USA). 
 
Table 3-4: List of Taqman probes used for quantitative amplification of mouse genes. 
Gene name, NCBI Reference Sequence (RefSeq) database accession (http://www.ncbi.nlm.nih.gov/refseq/) 
and Taqman probe ID of the mouse gene of interest. 
Gene RefSeq accession  Taqman probe ID 
Abca1 NM_013454.3 Mm00442646_m1 
Abcg1 NM_009593.2 Mm00437390_m1 
Rn18S NR_003278.3 Mm03928990_g1 
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3.1.8 Cells 
3.1.8.1 Immortalized macrophage cell lines 
Immortalized mouse macrophage (iMO) cell lines were previously generated from bone 
marrow-derived macrophages (BMDMs) of WT C57BL/6 and WT BALB/c mice by infection 
with a J2 recombinant retrovirus (carrying v-myc and v-raf(mil) oncogenes) as described by 
Hornung and colleagues26. 
3.1.8.2 Primary BMDMs 
Primary BMDMs were generated using either L929 supernatants or recombinant 
macrophage colony-stimulating factor (M-CSF) as described in section 3.2.5. Unless 
otherwise indicated, BMDMs were derived from WT C57BL/6 mice using L929 supernatants. 
Recombinant M-CSF was exclusively used for cell differentiation for microarray analysis. 
3.1.9 Mice 
WT C57BL/6 mice as well as ApoE-/- and LDLR-/- on C57BL/6J background were purchased 
from Charles River Laboratories (Wilmington, MA USA). LXRα-/-/LXRβ-/- mice on a mixed 
genetic background based on C57BL/6 and 129/Sv strains were obtained from Jan-Åke 
Gustaffson (University of Houston, Houston, TX, USA). LysmCreAbca1fl/flAbcg1fl/fl 
(MAC-ABCDKO) mice on C57BL/6J background were kindly provided by Alan R. Tall 
(Columbia University, New York, NY, USA). 
All animal studies described in this thesis were carried out by Dr. Sebastian Zimmer and 
colleagues (Medical Clinic and Polyclinic II, University Hospital Bonn, Bonn). Animal handling 
and all animal experiments were performed in accordance with institutional guidelines and 
the German animal protection law. 
3.2 Methods 
3.2.1 2-Hydroxypropyl-β-cyclodextrin 
2-Hydroxypropyl-β-cyclodextrin (Trappsol® Hydroxypropyl Beta Cyclodextrin, referred to as 
CD) was reconstituted in sterile pyrogen-free water (Ampuwa) to a concentration of 100 mM 
and filtered through a 0.2 µm syringe filter. For long-term storage 1.5 ml aliquots were frozen 
at -20°C. 
Rhodamine-labeled CD (RBITC-NH2-HPβCD) was reconstituted in sterile pyrogen-free water 
(Ampuwa) to a concentration of 25 mM under sterile conditions. 
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3.2.2 Cholesterol crystal preparation 
Cholesterol crystals (CCs) were prepared under sterile conditions from a sterile-filtered  
2 mg/ml cholesterol solution in 1-propanol. Crystallization was induced by addition of  
1.5 volumes of sterile pyrogen-free water (Ampuwa) and crystals were allowed to stabilize for 
at least 30 min. CCs were pelleted by centrifugation (3000 x g, 30 min) before as much liquid 
as possible was removed without disturbing the loose CC pellet. The remaining CC solution 
was then transferred into autoclaved 4 ml glass vials and dried in a drying cabinet at 75°C. 
Dried CCs were resuspended by water bath sonication in sterile PBS containing 0.1% FCS 
to obtain a stock solution of 20 mg/ml. 
3.2.3 Radioactive cholesterol crystal dissolution assay 
Radioactive tritium-labeled CCs (3H-CCs) were prepared from a 2 mg/ml cholesterol solution 
composed of 0.1 mCi [1,2-3H]-cholesterol in a 1:50 (w/w) ratio with unlabeled cholesterol. 
Crystallization was induced by addition of 1.5 volumes of sterile pyrogen-free water 
(Ampuwa) and crystals were allowed to stabilize for at least 30 min. The crystal solution was 
filtered through a 0.22 µm spin filter column to remove free [1,2-3H]-cholesterol. 3H-CCs were 
recovered from the filter membrane in a total volume of 5 ml PBS containing 0.1% FCS.  
A defined volume of 3H-CC (50 µl) was added to CD solutions (500 µl) ranging from 100 mM 
to 0.01 mM and the mixture was incubated overnight, shaking at 37°C in a heating block. 
 
Figure 3-1: Filtration-based CC dissolution assay using radioactive 3H-CCs. 
Radiolabeled 3H-CCs were incubated overnight in CD solutions of different concentrations prior to filtration 
through a 0.22 µm filter plate. The filter holds back the crystalline 3H-cholesterol, whereas solubilized  
3H-cholesterol passes the filter and can thus be detected in the filtrate. 3H-CCs on the filter membrane are 
dissolved by incubation in EtOH for 2 h and subsequent filtration allows the quantification of the previously 
crystalline 3H-cholesterol in the second filtrate.  
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The solutions were then transferred to 0.22 µm 96-well filter plates and vacuum filtration was 
used in order to determine the amount of solubilized [1,2-3H]-cholesterol in the first filtrate 
(solubilized fraction). For quantification of the amount of total crystalline [1,2-3H]-cholesterol, 
the retentate was washed with PBS containing 0.1% FCS, dissolved in ethanol for 2 h and 
subsequently filtered for measurement of radioactivity in the second filtrate (crystalline 
fraction). A summary of this method is provided in Fig. 3-1. Following filtration, the filtrates 
were transferred to scintillation tubes, 7 ml of liquid scintillation cocktail was added to each 
scintillation tube and radioactivity was determined by 3H-counting for 5 min using a liquid 
scintillation counter (Beckmann LS-6000 Scintillation Counter, Perkin Elmer, Waltham, MA, 
USA). 
3.2.4 Cell culture 
Cell culture work was always carried out in tissue culture hoods using sterile and pyrogen-
free consumables and reagents. Primary cells and cell lines were cultured at 37°C with  
5% CO2 in a humidified atmosphere. Cells were grown as monolayers in cell culture dishes 
or in cell culture flasks in DMEM supplemented with 10% (v/v) FCS and 1% (v/v) Penicillin-
Streptomycin (10,000 U/ml), referred to as complete DMEM. 
Immortalized mouse macrophages (iMOs) were detached by incubation with trypsin-EDTA 
for 5 min at 37°C. They were passaged every second or third day dependent on actual 
growth conditions. 
The cell number of a cell suspension was usually determined in a Neubauer cell counting 
chamber. The cell suspension was diluted in adequate amounts of trypan blue solution, 
which exclusively stains dead cells. Only unstained (living) cells inside the four large squares 
of the Neubauer counting chamber were counted under a light microscope. The total cell 
number was calculated using the following formula: 
 Cell number/ ml = No. of cells counted/ 4 * dilution factor * 104 
In some occasions cell numbers were determined using the “Quick Count” settings of the Tali 
Image Cytometer (Life Technologies, Carlsbad, CA, USA). 
3.2.5 Generation of primary BMDMs 
BMDMs were prepared from male, 6-10 week old WT C57BL/6 mice or from age and sex 
matched WT and LXRα-/-/LXRβ-/- mice. Bone marrow was collected under sterile conditions 
from femurs and tibiae. Any residual tissue was removed from intact bones by incubation in 
70% EtOH and subsequent cleaning. The bones were then flushed with complete DMEM 
using a 10 ml syringe with a 25G needle. After centrifugation (340 x g, 5 min) pelleted bone 
marrow cells from one mouse were resuspended in 40 ml of complete DMEM supplemented 
with 20% (v/v) L929 supernatant as the source of M-CSF or 40 ng/ml recombinant M-CSF. 
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The cell suspension was separated through a 70 µm nylon cell strainer and split up into two 
175 cm tissue-culture flasks. Adherent BMDMs were harvested on day 7 of differentiation by 
incubation in cold BMDM dissociation buffer for 10 min at 4°C and subsequent scraping. 
Cells were pelleted by centrifugation (340 x g, 5 min) and resuspended in complete DMEM 
for further experiments. 
3.2.6 CellTiter-Blue Cell Viability Assay  
WT BMDMs and BALB/c iMOs were seeded at 0.5x105 cells per well in 96-well plates and 
treated with different concentrations of CD for different time points. A 1:2 dose titration series 
starting with 50 mM CD was added in a reversed time course. Some cells were left untreated 
as positive control or were treated with 70% EtOH for 1 h prior to assessment of cell viability 
as a negative control (dead cells). Cell viability was determined by measuring the metabolic 
activity of the cells using the CellTiter-Blue (CTB) Viability Assay according to the 
manufacturer’s instructions. Fluorescence of the metabolized CTB reagent was read on the 
Spectramax i3 (Molecular Devices, Sunnyvale, CA, USA) using an excitation wavelength of 
530-570 nm and detecting emission at a wavelength of 580-620 nm. 
3.2.7 Mouse studies 
All mouse studies were performed in collaboration with Dr. Sebastian Zimmer (Medical Clinic 
and Polyclinic II, University Hospital Bonn, Bonn). Catharina Lahrmann, Niklas Bode and  
Dr. Sebastian Zimmer carried out all animal work described in this section, including animal 
care, handling, treatment and dissection. Mice were maintained in a 22°C room with a 12 h 
light/dark cycle and received food pellets and drinking water ad libitum. 
3.2.7.1 Atherosclerosis mouse models 
Atherosclerosis mouse models were carried out with age and sex matched 12-week old 
ApoE-/- mice on C57BL/6J background. To induce atherosclerosis development, the mice 
received an atherogenic high-fat, high-cholesterol (HFHC) diet containing 21% fat, 19.5% 
casein and 1.25% cholesterol (Ssniff, Soest) as indicated in the specific study protocols 
below. 
Body weight, arterial blood pressure and heart rate of the mice were controlled throughout 
the studies. Mice were fasted overnight and blood was collected from the inferior vena cava 
using a heparinized syringe directly after sacrifice. Animals were immediately dissected and 
various organs including liver, spleen and kidneys were snap-frozen and stored at -80°C for 
potential further analysis. Hearts with ascending aortas were directly embedded in  
Tissue Tek OCT embedding medium and snap-frozen. A cryostat (Leica, Mannheim) was 
used to cut 5 µm thick sections, starting at the aortic arch and progressing through the aortic 
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valve area into the heart. 3-5 tissue sections were placed on microscopy slides and stored 
at -80°C for further analyses. 
Plasma was obtained by centrifugation (3000 x g, 10 min) of the heparinized blood and 
plasma cholesterol concentrations were determined by gas chromatography-flame ionization 
detection using 5α-cholestane as internal standard. These measurements were performed 
by Prof. Dr. Dr. Dieter Lütjohann and colleagues (Institute of Clinical Chemistry and Clinical 
Pharmacology, University Hospital Bonn, Bonn). 
Atherosclerosis prevention study 
ApoE-/- mice received a HFHC diet for 8 weeks and were subcutaneously injected with  
2 g CD/ kg body weight or vehicle control twice a week. 
Atherosclerosis regression studies 
ApoE-/- mice received a HFHC diet for 8 weeks to establish advanced atherosclerosis.  
A control group of mice was sacrificed at this stage (pretreatment control). The remaining 
mice were either treated with CD or vehicle control as described above for another 4 weeks. 
During this treatment period the diet of some mice was switched to a normal chow diet 
(Regression A) or the mice were kept on the HFHC diet (Regression B). 
3.2.7.2 In vivo RCT model 
BMDMs were prepared from WT or LXRα-/-/LXRβ-/- mice and loaded with 100 µg D6-CCs 
(see section 3.2.14) per 1x106 cells for 3 h to allow for crystal intake. Following 3 washes 
with PBS containing 0.1% FCS to remove non-internalized D6-CCs, CC-loaded macrophages 
were harvested by incubation in cold BMDM dissociation buffer for 10 min at 4°C and 
subsequent scraping. Cells were pelleted by centrifugation (340 x g, 5 min), resuspended in 
sterile PBS and handed over to Dr. Sebastian Zimmer and colleagues (Medical Clinic and 
Polyclinic II, University Hospital Bonn, Bonn). 16-week old WT C57BL/6 mice were then 
intraperitoneally injected with 15x106 D6-CC-loaded BMDMs from either WT or 
LXRα-/-/LXRβ-/- mice. Subsequently mice were subjected to intraperitoneal treatment with 
either 2 g CD/ kg body weight or vehicle control. The first treatment injection was given 
approximately 30 min after application of the D6-CC-loaded BMDMs, and a second one was 
given 16 h later. Following the first treatment injection, feces and urine were collected every 
3-6 h over a 30 h period. The excrement was analyzed for presence of crystal-derived 
D6-cholesterol by gas chromatographic-mass spectrometric-selected ion monitoring 
(GC-MS-SIM) as described in section 3.2.15. Fecal D6-cholesterol was determined as the 
ratio area of D6-cholesterol to the endogenous cholesterol metabolite 5α-cholestane. 
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3.2.7.3 Bone marrow transplantation model 
Bone marrow of 14- to 18-week old WT, LXRα-/-/LXRβ-/- and MAC-ABCDKO 
(LysmCreAbca1fl/flAbcg1fl/fl) mice (see section 3.1.9) was collected under sterile conditions by 
flushing femurs and tibia with complete DMEM using a 23G needle. The cell suspension was 
filtered through a 70 µm nylon cell strainer, washed twice with Hank’s acid citrate dextrose 
solution and resuspended in PBS. For full engraftment of donor bone marrow, 8-week old 
recipient LDLR-/- mice were lethally irradiated with 6x6 Gy over 4 h from a Cs-137 source 
using an OB 29/4 (STS Steuerungstechnik & Strahlenschutz, Braunschweig). 4 h after 
irradiation recipient mice were reconstituted with 1x107 bone marrow cells from donor mice 
by intravenous injection into the tail vein. All mice received drinking water containing  
0.1 mg/ml Ciprofloxacin for 7 days to prevent systemic infection during neutropenia. The 
atherosclerosis study was initiated 4 weeks after irradiation following the protocol of the 
atherosclerosis prevention study described in section 3.2.7.1. 
3.2.8 Immunohistochemistry of aortic cryosections 
Fluorescent immunohistochemistry (IHC) was performed for microscopical characterization 
of atherosclerotic lesions. Aortic cryosections were encircled using the hydrophobic Dako 
Pen prior to fixation for 30 min with 4% (v/v) methanol-free formaldehyde. Tissue sections 
were then blocked and permeabilized for 60 min with IHC blocking buffer. For detection of 
macrophages, indirect fluorescent immunolabeling of cluster of differentiation 68 (CD68) was 
performed. First, the sections were incubated with primary rat anti-mouse CD68 antibody 
(MCA1957) diluted to 2 µg/ml in IHC staining buffer overnight at 4°C in a humidified 
chamber. Following three washes with IHC staining buffer, the sections were incubated with 
the secondary goat anti-rat IgG Alexa647 conjugate diluted to 4 µg/ml in IHC staining buffer 
for 60 min in the dark. The sections were again washed three times with IHC staining buffer 
before a final incubation with Hoechst 34580 (nuclear counterstain) diluted to 5 µg/ml in PBS 
for 2 min in the dark was performed. Subsequently the sections were washed twice with PBS 
and a final wash was done with double-distilled water (ddH2O). Coverslips were mounted 
using 80% glycerol in ddH2O as mounting medium and the edges were carefully sealed 
using a solvent-free two-component epoxy resin adhesive (UHU, Bühl). 
3.2.9 Confocal laser reflection and fluorescence microscopy 
Confocal microscopy was performed using a Leica TCS SP5 II AOBS confocal laser-
scanning microscope controlled by the Leica Application Suite Advanced Fluorescence  
(LAS AF) software. Fluorescence staining was detected using standard confocal imaging 
techniques. Laser reflection microscopy was used to visualize crystalline material, more 
precisely crystalline cholesterol, as previously described24,26. For detection of the reflected 
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laser light, the detector was set to cover the wavelength of the laser light (± 5-10 nm) and the 
acousto-optical beam splitter was set to enhanced transmittance allowing the laser light to be 
passed to the detector. A combination of fluorescence and laser reflection microscopy 
allowed the detection of fluorescence and laser reflection signals derived from the same 
confocal plane. 
3.2.10 Quantitative image analysis 
Volocity Quantitation (PerkinElmer, Waltham, MA, USA) was used for quantitative image 
analysis. Measurement protocols were designed for the specific analysis purposes. Between 
individual experiments measurement protocols were slightly adapted to the respective image 
properties, but within one experiment identical measurement protocols were applied to every 
image analyzed to ensure comparability of the quantification results. 
Microscopic images of aortic cryosections were examined for atherosclerotic plaque size, CC 
plaque load, plaque cellularity and plaque macrophage load. For this purpose, regions of 
interest (ROIs) were manually drawn to assess total vessel wall area (Fig. 3-2A) and 
 
Figure 3-2: Quantitative image analysis of aortic cryosections. 
ROIs for (A) total surface area and (B) plaque surface area were manually drawn and are represented by 
green translucent surfaces. (C) Images represent an overlay image and the separate channels of the 
enlarged area outlined by the dashed line in (B). The first image illustrates an overlay of fluorescence and 
reflection signals (CC = white, macrophages = red, nuclei = blue) as well as the plaque surface ROI (green 
translucent surface). The other three images show the separate channels with the detected objects inside 
the plaque surface ROI (illustrated by translucent surfaces and outlines in blue for CC, green for 
macrophages and red for nuclei). 
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Figure 3-3: Automated intracellular object quantification. 
(A) ROIs of cell surfaces were automatically generated from the CtxB signal (green). (B) The obtained cell 
surface mask was used for quantification of intracellular objects, such as nuclei (green outlines),  
CC (red outlines) or lipid droplets (blue outlines). 
atherosclerotic plaque area (Fig. 3-2B). Measurement protocols were designed to detect and 
quantify reflection and fluorescence signals as well as single nuclei objects obtained from the 
Hoechst staining within the ROI representing the atherosclerotic plaque (Fig. 3-2C). Image 
analysis of the aortic cryosections was performed blinded to the treatment of the respective 
animals. 
Intracellular reflection and fluorescence signals were quantified in fixed, cholera toxin subunit 
B (CtxB) stained cells (see sections 3.2.12 and 3.2.13). CtxB staining was used for creating a 
ROI of the cell surfaces (Fig. 3-3A). The area of reflection or fluorescence signals, as well as 
the number of single nuclei (as obtained with Hoechst staining) were then determined 
exclusively within this cell surface mask (Fig. 3-3B). 
3.2.11 CD binding and uptake assays 
Rhodamine-labeled CD (see section 3.2.1) was used to investigate CD binding to CCs and 
CD uptake into macrophages. Binding and uptake of rhodamine-labeled CD was measured 
by flow cytometry using a MACSQuant analyzer (Miltenyi Biotec, Bergisch Gladbach) where 
rhodamine fluorescence was detected in the Y2 channel. In addition confocal microscopy 
was used to visualize the localization of the fluorescent rhodamine signal. 
CD binding to CCs was assessed by incubation of 1 mg CCs in 0.5 mM rhodamine-labeled 
CD for 6 h shaking at 4°C. Crystals were washed 5 times with PBS prior to confocal 
microscopic or flow cytometric analyses. 
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CD uptake into macrophages was investigated in C57BL/6 iMOs and CC-loaded C57BL/6 
iMOs. For microscopic analysis 75,000 cells were seeded into a 4-well microscopy dish and 
20 µg CCs were added to one of the wells. Cells were left to adhere for 3 h before live cell 
imaging was started to capture rhodamine-labeled CD uptake. 1 mM rhodamine CD solution 
(1:10 mixture of rhodamine-labeled CD and unlabeled CD) was added to the wells and the 
cells were imaged for 6 h. Following 3 washes with PBS, the cells were fixed for 30 min with 
4% (v/v) methanol-free formaldehyde and stained for nuclei using Hoechst 34580 (diluted to 
5 µg/ml in PBS) and cell membranes using Alexa Fluor 488-conjugated CtxB (diluted to  
1 µg/ml in PBS) for 10 min. Cells were again washed 3 times with PBS and confocal 
microscopy was performed to estimate the localization of rhodamine-labeled CD. For flow 
cytometry 300,000 cells were seeded into a 24-well plate and 40 µg CCs were added to 
some of the wells. Cells were left to adhere for 3 h before addition of 1 mM rhodamine CD 
solution (1:10 mixture of rhodamine-labeled CD and unlabeled CD) or appropriate controls 
(unlabeled CD only or PBS). Following 3 washes in PBS, cells were trypsinized and 
transferred to FACS tubes for detection of rhodamine fluorescence on the MACSQuant 
analyzer. 
3.2.12 Intracellular CC dissolution 
Intracellular CC dissolution was determined by confocal laser reflection and fluorescence 
microscopy. For this, 1x105 WT BMDMs were seeded into 8-well microscopy dishes and 
loaded with 100 µg CC per 1x106 cells for 3 h to allow for crystal intake. Following 3 washes 
with PBS containing 0.1% FCS to remove non-internalized CCs, BMDMs were incubated 
with 10 mM CD or medium control for 24 h. Cells were fixed for 30 min with 4% (v/v) 
methanol-free formaldehyde and stained for nuclei using Hoechst 34580 (diluted to 5 µg/ml 
in PBS) and cell membranes using Alexa Fluor 647-conjugated CtxB (diluted to 1 µg/ml in 
PBS) for 10 min. Cells were washed 3 times with PBS and confocal reflection and 
fluorescence microscopy was performed. 10-15 random images were acquired per sample 
and analyzed for intracellular CC content as described in section 3.2.10. 
3.2.13 Lipid droplet staining 
Lipid droplets were stained using the lipid droplet dye LD540109 which was kindly provided by 
Prof. Dr. Christoph Thiele (Life & Medical Sciences Institute (LIMES), University of Bonn, 
Bonn). In detail, 0.5x105 C57BL/6 iMOs were seeded per well into a 96-well microscopy 
plate. The cells were loaded with 100 µg CCs per 1x106 cells for 3 h to allow for crystal 
intake. Following 3 washes with PBS containing 0.1% FCS to remove non-internalized CCs, 
cells were incubated with 10 mM CD or medium control for 24 h. Cells were fixed for 30 min 
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with 4% (v/v) methanol-free formaldehyde and stained with LD540 (diluted to 0.1 µg/ml in 
PBS) for 30 min at 37°C. Subsequently nuclei and cell membranes were stained using 
Hoechst 34580 (diluted to 5 µg/ml in PBS) and Alexa Fluor 647-conjugated CtxB (diluted to  
1 µg/ml in PBS) for 10 min. Cells were washed 3 times with PBS and confocal reflection and 
fluorescence microscopy was performed. Per sample 10 random images were acquired and 
cellular lipid droplet content was determined as described in section 3.2.10. 
3.2.14 Analysis of crystal-derived cholesterol in macrophages 
D6-cholesterol ([26.26.26.27.27.27-2H6]-cholesterol) was used to prepare deuterium-labeled 
CCs (D6-CCs) according to the protocol described in section 3.2.2. 
1.5x106 C57BL/6 iMOs were incubated with 200 µg D6-CCs per 1x106 cells for 3 h to allow 
for crystal intake. Cells were washed 3 times with PBS containing 0.1% FCS to remove non-
internalized D6-CCs and a control sample was harvested to assess D6-cholesterol distribution 
prior to further treatment (0h control). The remaining cells were treated with 10 mM CD for  
24 h and 48 h. Where indicated 0.25 mg/ml reconstituted HDL (rHDL) (CSL111) was added 
together with CD. Supernatants were collected and the cells were harvested by scraping in 
1M ethanolic NaOH or PBS depending on downstream analysis. The samples were then 
transferred to the laboratory of Prof. Dr. Dr. Dieter Lütjohann (Institute of Clinical Chemistry 
and Clinical Pharmacology, University Hospital Bonn, Bonn) for analysis of crystal-derived 
sterols and oxysterols by gas chromatographic-mass spectrometric-selected ion monitoring 
(GC-MS-SIM). 
3.2.15 GC-MS-SIM  
GC-MS-SIM analyses including GC-MS-SIM-specific sample preparation was entirely 
performed by the laboratory of Prof. Dr. Dr. Dieter Lütjohann (Institute of Clinical Chemistry 
and Clinical Pharmacology, University Hospital Bonn, Bonn). 
A certain set of sterols was measured in all samples. This set includes cholesterol precursors 
such as lanosterol, lathosterol and desmosterol, which can be used as surrogate markers of 
cholesterol synthesis. Epicoprostanol was used as internal standard for detection of these 
sterols110,111. 
Crystal-derived D6-cholesterol was analyzed for degree of esterification and oxidation 
products. Degree of esterification was calculated from the difference of the cholesterol levels 
with (total D6-cholesterol) and without (free D6-cholesterol only) alkaline hydrolysis. 
D6-cholesterol was extracted and derivatized to its trimethyl silylether prior to GC-MS-SIM on 
m/z 464 [M+] using epicoprostanol as internal standard on m/z 370 [M+]112. The oxidized 
metabolite [26,26,26,27,27-2H5]-27-hydroxycholesterol (D5-27-hydroxycholesterol) was 
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Figure 3-4: Sample preparation for analysis of crystal-derived cholesterol. 
Macrophages were loaded with D6-CCs and a 0 h control was harvested to assess the distribution of 
D6-cholesterol right upon crystal loading of the cells. Following incubation with medium or 10 mM CD for  
24 h or 48 h, cells and supernatants were harvested for analysis of crystal-derived D6-cholesterol by  
GC-MS-SIM. GC-MS-SIM analysis was performed by Prof. Dr. Dr. Dieter Lütjohann and colleagues. 
determined by GC-MS-SIM on m/z 461 [M+-90]. The corresponding normal cellular 
cholesterol and its oxidation product 27-hydroxycholesterol were measured on m/z 458 [M+] 
and m/z 456 [M+-90], respectively113. 
3.2.16 Western blot analysis  
Protein expression was determined by western blot (WB) analysis using protein specific 
antibodies. 
Cholesterol efflux transporter expression was determined in macrophages incubated with 
200 µg CCs per 1x106 C57BL/6 iMOs (0.5x106 cells per sample) or 100 µg CCs per  
1x106 BMDMs (1.5x106 cells per sample) for 3 h to allow for crystal intake. Cells were 
washed 3 times with PBS containing 0.1% FCS to remove non-internalized CCs and cells 
were treated for 24 h with 10 mM CD, medium control or 10 µM LXR agonist T0901317 as 
positive control for LXR activation. 
For analysis of NLRP3 inflammasome priming, 1x106 C57BL/6 iMOs or 1.5x106 BMDMs 
were incubated for 16 h with 10 mM CD, medium control or 10 µM LXR agonist T0901317 as 
positive control for LXR activation. Subsequently the medium was replaced with complete 
DMEM containing 200 ng/ml LPS and samples were harvested after 3 h incubation. 
3.2.16.1 Preparation of cell lysates 
RIPA lysis buffer was made up from a 2x stock solution right before use and supplemented 
with 0.1 µM PMSF and cOmplete EDTA-free protease inhibitor cocktail. Preparation of cell 
lysates was performed entirely on ice. Supernatants were removed and cells were washed 
once with ice-cold PBS before addition of 150 µl RIPA lysis buffer per well. Cells were 
scraped off and transferred into 1.5 ml centrifuge tubes. Following 30 min incubation on ice, 
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the cell lysates were cleared by centrifugation at 13,000 x g for 10 min at 4°C and 
supernatants were collected into new 1.5 ml centrifuge tubes.  
3.2.16.2 Determination of protein concentration by BCA assay 
Protein concentrations were determined using the BCA protein assay kit according to the 
manufacturer’s instructions. Absorbance at 562 nm was read on the Spectramax i3 
(Molecular Devices, Sunnyvale, CA, USA) and protein concentrations were calculated from 
the blank-corrected BSA standard curve.  
3.2.16.3 Sample preparation for SDS-page gel electrophoresis 
Cell lysates were diluted to equal protein concentrations in RIPA lysis buffer and mixed with 
4x LDS sample buffer and 10x sample reducing agent. For denaturing gel electrophoresis 
the samples were heated for 10 min at 80°C. 
3.2.16.4 SDS-page gel electrophoresis 
Equal amounts of protein were leaded on pre-cast 4-12% Bis-Tris gels. PageRuler Plus 
Prestained protein ladder was used as a size standard ranging from 10 to 250 kDa. Proteins 
were separated by gel electrophoresis in either MES or MOPS running buffer at 150-200 V 
for approximately 45 min. 
3.2.16.5 Western blotting 
Following SDS-page gel electrophoresis proteins were transferred to a methanol-activated 
PVDF membrane using a semi-wet transfer unit (XCell II Blot Module, Novex Life 
Technologies, Carlsbad, CA, USA). Protein transfer was performed at 32 V for 1.5 h. For 
detection of multiple proteins of distinct sizes the membrane was cut with a scalpel using the 
prestained protein ladder as orientation. Membranes were blocked for 1h in WB blocking 
buffer prior to overnight incubation at 4°C with the specific primary antibodies (see section 
3.1.6, Table 3-2) diluted as indicated in 1% BSA in TBS-T. Following three washes in TBS-T 
the membranes were incubated with the respective IRDye secondary antibodies (see section 
3.1.6, Table 3-2) diluted 1:10,000 1% BSA in TBS-T for 45 min in the dark. Following two 
washes in TBS-T and 1 final wash in TBS the infrared fluorescent signals on the membranes 
were visualized using the Odyssey Imager (LI-COR, Lincoln, NE, USA). Quantification of 
western blot images was performed using Image Studio 3.1.4 (LI-COR, Lincoln, NE, USA). 
3.2.17 Reverse transcription quantitative real-time PCR 
Reverse transcription quantitative real-time PCR (RT-qPCR) was used to quantify the 
abundance of messenger RNA (mRNA) transcripts in a sample. For analysis of gene 
expression changes upon CD treatment, 2x106 BMDMs were incubated with 100 µg CCs per 
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1x106 cells overnight. Cells were washed 3 times with PBS containing 0.1% FCS to remove 
non-internalized CCs and where indicated a 0 h control sample was harvested to assess 
cellular gene expression right after crystal loading of the cells. The remaining cells were 
incubated for the indicated times (usually 4 h, 8 h or 24 h) in medium or 10 mM CD. Where 
indicated BMDMs were incubated with 10 µM LXR agonist T0901317 for 24 h as positive 
control for LXR activation. 
3.2.17.1 RNA preparation 
Plates were placed on ice, cells were washed once with PBS and 350 µl Buffer RLT (RNeasy 
mini kit) supplemented with 1% (v/v) β-mercaptoethanol was added per well. Cells were 
scraped off and the lysates were transferred into 1.5 ml centrifuge tubes, where they were 
homogenized using a 20G needle fitted to an RNase-free syringe. Total RNA was isolated 
using the RNeasy mini kit with on-column DNase digestion according to the manufacturer’s 
instructions. RNA concentration and purity were determined by measuring the absorbance at 
260 nm, 280 nm (indicating protein contamination) and 230 nm (indicating contamination with 
organic compounds). Absorbance readings were performed using the SpectraDrop  
Micro-Volume Microplate on the Spectramax i3 (Molecular Devices, Sunnyvale, CA, USA). 
3.2.17.2 cDNA synthesis 
Approximately 1 µg of isolated total RNA was used as starting material for complementary 
DNA (cDNA) synthesis by reverse transcription PCR (RT-PCR). Oligo(dT)18 primers, which 
hybridize to the poly(A) tail of mRNAs, were used for specific amplification of mRNA. The 
RT-PCR reaction was set up in a final volume of 20 µl containing RNA (approx. 1 µg),  
5 µM Oligo(dT)18 primer, 0.1 µl (20 U) SuperScript III reverse transcriptase with associated 
first-strand buffer, 5 mM DTT and 0.5 mM dNTPs. A control reaction without reverse 
transcriptase was included to control for genomic DNA contamination. In detail, the 
appropriate volume of RNA was diluted in nuclease-free water, mixed with Oligo(dT)18 primer 
and heated to 65 °C for 5 min. Upon incubation on ice for at least 1 min, SuperScript III 
reverse transcriptase, first-strand buffer, DTT and dNTPs were added. RT-PCR was 
performed for 50 min at 50°C and the reaction was inactivated by heating to 85°C for 5 min. 
The cDNA was finally diluted 1:20 in nuclease-free water and stored at -20°C. 
3.2.17.3 SYBR green based quantitative real-time PCR 
Quantitative real-time PCR was performed using SYBR Green, a fluorescent DNA 
intercalating dye, which allows for double-stranded DNA detection and quantification. To 
determine the amount of specific mRNA transcripts, cDNA was mixed with 0.4 µM gene-
specific primers (see section 3.1.7, Table 3-3) and 10x Maxima SYBR Green/ROX qPCR 
master mix containing SYBR Green, ROX as a passive reference dye as well as Maxima Hot 
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Start Taq DNA Polymerase and dNTPs in an optimized PCR buffer. A control without any 
template was included to control for DNA contaminations in the qPCR reaction mix. The 
qPCR reaction was performed in 384-well plates in a total reaction volume of 10 µl on the 
QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems Life Technologies, 
Carlsbad, CA, USA) using the following program: 95oC 10 min; 40x [95oC, 15 sec; 60oC,  
1 min]. Subsequent melt curve analysis was performed to control for primer specificity 
(indicative) and presence of primer-dimers. The ΔΔCT method (Applied Biosystems) was 
used to calculate relative mRNA expression to the reference gene hypoxanthine-guanine 
phosphoribosyltransferase (Hprt). 
3.2.18 NLRP3 inflammasome activation 
BALB/c iMOs or BMDMs were plated at 0.1x106 cells per well into a 96-well tissue culture 
plate. Macrophages were pretreated for 16 h with 10 mM CD, medium control or 10 µM LXR 
agonist T0901317 as positive control for LXR activation. Cells were primed with  
100 µl complete DMEM containing 200 ng/ml LPS for 3 h prior to addition of 25 µl 5-fold 
concentrated NLRP3 stimuli. Ultimately cells were stimulated with 5 mM ATP or 10 µM 
nigericin for 1 h, with 1 mM H-Leu-Leu-Ome (LeuLeu) for 4 h, 0.5 mg/ml silica crystals or  
1.5 mg/ml CCs for 6 h. Upon centrifugation (340 x g, 5 min) cell-free culture supernatants 
were collected and cytokine production was measured by enzyme-linked immunosorbent 
assay (ELISA). 
3.2.19 ELISA 
Cytokine secretion was quantified using commercial ELISA kits for the detection of murine  
IL-1β and murine TNF-α (see section 3.1.5). ELISAs were performed according to the 
manufacturer’s instructions, but all volumes were halved. In brief, 96-well ELISA plates were 
coated overnight with the respective coating antibody diluted in PBS. The wells were blocked 
for 2 h with ELISA blocking buffer before samples and standards were added to the plates. 
Cell culture supernatants were used undiluted for detection of mIL-1β or diluted 1:4 in ELISA 
reagent diluent (TNF-α) for mTNF-α detection. Samples and standards were incubated for  
2 h, plates were washed 3 times using ELISA wash buffer and the respective biotinylated 
detection antibody diluted in the respective ELISA reagent diluent was added for 2 h. 
Following 3 washes with ELISA wash buffer, streptavidin-conjugated horseradish-peroxidase 
was diluted in the respective ELISA reagent diluent and incubated for 20 min. The TMB 
substrate solution was prepared according to the manufacturer’s instructions and ELISAs 
were developed in the dark for approximately 15-20 min. The reaction was stopped with  
2 N Sulfuric Acid (H2SO4) and the absorbance at 450 nm and 570 nm was read on the 
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Spectramax i3 (Molecular Devices, Sunnyvale, CA, USA). Cytokine concentrations were 
calculated from the blank-corrected standard curves. 
3.2.20 Lysosomal damage and crystal uptake assay 
Lysosomal integrity can be measured by flow cytometry using acridine orange. Acridine 
orange is a cationic nucleic acid binding fluorescent dye that emits green light in its 
monomeric state when it is bound to nucleic acids and red light upon dimerization when it 
accumulates in acidic compartments, such as lysosomes26. As the amount of red 
fluorescence of acridine orange stained cells directly correlates to the amount of acidic 
lysosomes, lysosomal damage can be measured by a loss of red acridine orange 
fluorescence. 
BALB/c iMOs or BMDMs were plated at 0.1x106 cells per well in a 96-well tissue culture 
plate. Macrophages were pretreated for 16 h with 10 mM CD or medium control prior to 
staining with 5 µg/ml acridine orange for 15 min at 37°C. Following 3 washes with PBS, the 
cells were incubated for 6 h with 1 mM H-Leu-Leu-Ome (LeuLeu), 0.5 mg/ml silica crystals, 
1.5 mg/ml CCs or medium control. The cells were subsequently washed once with PBS 
containing 0.1% FCS, incubated with trypsin for 5 min at 37°C and detached from the plate  
 
 
Figure 3-5: Gating strategy for measuring lysosomal damage and crystal uptake. 
(A) The cell population gate was set according to the forward scatter (FSC) and side scatter (SSC) 
properties of a sample containing cells only (Cells) and crystal-loaded cells (Cells + CC). In addition, a 
control with 0.1 mg/ml CC only (CC) was used to ensure exclusion of free crystals present in the samples 
with crystal-loaded cells from the cell population. Subsequently doublet discrimination was performed on the 
cell population. (B) Histograms of the acridine orange fluorescence detected in the B2 channel. Gating for 
loss of acridine orange fluorescence on the single cell populations as measure of lysosomal damage.  
(C) SSC histograms of the single cell populations. The SSC median was analyzed as measure of cellular 
crystal uptake. 
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by pipetting up and down several times. Complete DMEM was added to the wells and the 
cell suspension was transferred into v-shape bottom 96-well plates. Upon centrifugation  
(340 x g, 5 min) cells were resuspended in 50 µl PBS and applied to the MACS Quant 
Analyzer (Miltenyi Biotec, Bergisch Gladbach). For quantification of lysosomal damage the 
red acridine orange fluorescence was detected in the B2 channel (Fig 3-5B). At the same 
time crystal uptake was analyzed using the side scatter signal (Fig 3-5C). 
3.2.21 Genome-wide transcriptome analysis by microarray 
For genome-wide transcriptome analysis by microarray, BMDMs of WT and 
LXRα-/-/LXRβ-/- mice were generated as described in section 3.2.5 using recombinant M-CSF 
for macrophage differentiation. 3x106 cells per well were plated into a 6-well dish and left to 
adhere overnight. Some wells were incubated with 100 µg CCs per 1x106 cells for 3 h to 
allow for crystal intake. 3 wash steps with PBS containing 0.1% FCS were performed to 
remove non-internalized CCs. Cells were then incubated for 6 h with 10 mM CD or medium 
control. Plates were placed on ice, cells were washed once with PBS, and scraped off in 1 ml 
Trizol per well. Samples were then handed over to Prof. Dr. Joachim Schultze and 
colleagues (Life & Medical Sciences Institute (LIMES), University of Bonn, Bonn) for further 
processing for array-based gene expression profiling. In brief, total RNA was purified using 
the MinElute Reaction Cleanup Kit (Qiagen, Hilden). Prior to further RNA processing for 
microarray analysis, sample quality was controlled by Taqman RT-qPCR performed by 
Niklas Bode (Medical Clinic and Polyclinic II, University Hospital Bonn, Bonn). For this, about 
300 ng RNA was reverse transcribed to cDNA using the Omniscript RT Kit (Qiagen, Hilden) 
according to the manufactures protocol and expression of cholesterol efflux transporters was 
determined using commercially available Taqman probes (see section 3.1.7, Table 3-4). 
Abca1 and Abcg1 mRNA expression was normalized to the abundance of 18S RNA. For 
subsequent microarray analysis biotin-labeled cRNA was produced using the TargetAmp 
Nano-g Biotin-cRNA Labeling Kit for the Illumina System (Epicentre, Madison, WI, USA). The 
biotin-labeled cRNA (1.5 µg) was subsequently hybridized to Illumina MouseWG-6 v2.0 
Beadchips and scanned on an Illumina iScan or HiScanSQ system (Illumina, San Diego, CA, 
USA). Raw intensity data were processed and exported with Genome Studio V2011.1 
(Illumina, San Diego, CA, USA). 
3.2.22 Bioinformatic analysis of microarray data 
Bioinformatic analyses were performed by or with the help of Dr. Thomas Ulas  
(Life & Medical Sciences Institute (LIMES), University of Bonn, Bonn). Array data was 
imported into Partek Genomics Suite 6.6 (Partek, St. Louis, MO, USA). Quality control 
analyses including principle component analyses and box-whisker plots to visualize 
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expression distribution were applied to the data set. Non-normalized data (log2) were 
quantile normalized and transcripts with variable expression within the dataset as well as 
differentially expressed (DE) genes between the different conditions were calculated using 
two-way analysis of variance (ANOVA) models including batch correction for sentrix bar code 
and gender where applicable. 
For analyses of the microarray data on in vitro treated BMDMs derived from WT or  
LXRα-/-/LXRβ-/- mice, DE genes were defined by a fold change (FC) greater 2 and  
p-value < 0.05. Gene set enrichment analysis (GSEA) was used to determine whether 
induction of a defined set of genes was statistically significant between two different states.  
A set of genes was statistically significant enriched when the p-value was ≤ 0.05 and the 
false discovery rate (FDR) was ≤ 0.25 comparing two different states. GSEA was performed 
with 1000 permutations against a list of LXR target genes generated from the LXR target 
genes identified by Heinz and colleagues114. FCs of genes involved in the steroid 
biosynthesis pathway (KEGG pathway mmu00100, http://www.genome.jp/kegg/pathway.html) 
were visualized in a heat map. 
For analyses of the microarray data on descending aortas of mice from the bone-marrow 
transplantation model, DE genes were defined by a FC greater 1.5 and p-value < 0.05.  
Gene expression of genes relevant for the NLRP3 inflammasome was visualized using 
Partek Pathway (KEGG pathway mmu04621: NOD-like receptor signaling pathway, 
http://www.genome.jp/kegg/pathway.html). 
3.2.23 Data processing and statistical analysis 
Unless otherwise indicated at least three individual experiments with duplicates were 
performed and data is presented as mean ± standard error of the mean (SEM). Statistical 
differences were assessed by Student’s t-test and one-way ANOVA with appropriate post 
test for multiple comparisons (as indicated) where applicable. Values of p < 0.05 were 
considered significant. All statistical hypothesis testing was performed using GraphPad Prism 
6 (GraphPad Software, San Diego, CA, USA). For graphical representation significance 
levels were grouped by p-value: *** = p<0.001, ** = p<0.01, * = p<0.05, ns = not significant. 
Basic data processing was performed with Microsoft Excel (Microsoft Corporation, Redmond, 
WA, USA). Unless otherwise indicated data visualization was performed using GraphPad 
Prism 6 (GraphPad Software, San Diego, CA, USA). Heat maps of sterol measurements 
were plotted in R version 3.1.0 (RStudio, Boston, MA, USA) using the package “pheatmap” 
version 1.0.2. Volocity Quantitation (PerkinElmer, Waltham, MA, USA) was used for 
quantitative microscopy image analysis, WB images were quantified using Image  
Studio 3.1.4 (LI-COR, Lincoln, NE, USA) and flow cytometry data was processed with 
FlowJo vX.0.7 (Tree Star. Ashland, OR, USA). Gene expression data was analyzed with 
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Partek Genomics Suite 6.6 (Partek, St. Louis, MO, USA) using ANOVA models and GSEA 
results were plotted by Dr. Thomas Ulas (Life & Medical Sciences Institute (LIMES), 
University of Bonn, Bonn) using Sigmaplot 12.2 (Systat Software, San Jose, CA, USA). 
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4 Results 
4.1 Targeting cholesterol crystal deposition in atherosclerosis 
mouse models 
Cholesterol crystals (CCs) potently stimulate innate immune cells, such as macrophages, by 
activating the NLRP3 inflammasome24,25. In atherosclerosis mouse models, CCs were found 
in early atherosclerotic plaques and their presence coincided with the first appearance of 
innate immune cells in these plaques24. Therefore, CC-induced inflammatory responses 
might contribute to the underlying inflammation that promotes atherosclerosis development 
and progression. Based on this assumption, it was hypothesized that reducing crystalline 
cholesterol deposition in atherosclerotic plaques might impede atherogenesis by lowering 
inflammation. 
4.1.1 Genetic deletion of oxLDL uptake receptor CD36 
Atherosclerotic plaque formation starts with the accumulation of lipids and lipoproteins in the 
vessel wall, which causes the infiltration of immune cells such as monocytes. Due to 
continuous lipid uptake these cells develop into cholesterol-laden macrophage foam cells115. 
CC formation in macrophage foam cells was observed upon accumulation of intracellular free 
cholesterol in vitro71,116. However, until recently, the origin of free cholesterol that crystallizes 
in plaque macrophage foam cells was unknown. 
The scavenger receptor CD36 mediates the uptake of oxLDL into macrophages117. 
Furthermore, recognition of oxLDL by CD36 induces the assembly of a TLR heterodimer 
consisting of TLR4 and TLR6 which subsequently induces an NFκB-mediated inflammatory 
response8. Hence, as CD36 promotes intracellular lipid accumulation and regulates an 
inflammatory response to modified endogenous ligands, it was linked to the pathogenesis of 
atherosclerosis. A recent study performed in collaboration with Dr. Frederick Sheedy and Dr. 
Kathryn J. Moore (New York University School of Medicine, New York, NY, USA) 
demonstrated that excess cholesterol crystallized in macrophage lysosomes following  
CD36-mediated uptake of oxLDL118. The relevance of this finding for atherosclerosis 
development was assessed in an atherosclerosis mouse model. ApoE-/- mice and 
ApoE-/- mice lacking CD36 (ApoE-/-/CD36-/-) or one of its signaling partners TLR4 
(ApoE-/-/TLR4-/-) or TLR6 (ApoE-/-/TLR6-/-) were fed a modified Western diet for 12 weeks to 
induce atherosclerosis. I received aortic root cryosections from these mice for analysis of 
atherosclerotic plaque size and plaque CC deposition by confocal laser reflection and 
fluorescence microscopy (Fig. 4-1A). Although the mice had similar serum cholesterol 
levels118, ApoE-/-/CD36-/-, but also ApoE-/-/TLR4-/-and ApoE-/-/TLR6-/- mice had significantly  
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Figure 4-1: Genetic deletion of CD36 reduces plaque CC deposition and impairs murine 
atherosclerosis development. 
ApoE-/- (n=10), ApoE-/-/Cd36-/- (n=8), ApoE-/-/Tlr4-/- (n=10) and ApoE-/-/Tlr6-/- (n=5) mice received a modified 
Western diet (containing 3 g cholesterol per kg chow; DYET#100244; Dyets) for 12 weeks. All animal work 
was performed in the laboratory of Dr. Kathryn J. Moore (New York University School of Medicine,  
New York, NY, USA). Serial aortic root sections were analyzed by confocal laser reflection and 
fluorescence microscopy. (A) Representative images of each study group with enlarged plaque area in 
bottom panels; Hoechst 34580 staining for nuclei (blue) and laser reflection signal for CCs (green). Scale 
bars indicate 200 µm. (B) Quantification of atherosclerotic plaque size depicted as plaque area as 
percentage of total vessel wall area. (C) Quantification of CC plaque load depicted as reflection area as 
percentage of plaque area. Data in (B) and (C) are shown as mean ± SEM of two to three individual 
sections per mouse. Significance was determined by one-way ANOVA comparing each group against the 
ApoE-/- control group applying Sidak’s post test for multiple comparisons (** = p<0.01, * = p<0.05). 
smaller atherosclerotic plaques than the ApoE-/- control mice (Fig. 4-1B). Furthermore, these 
mice had reduced aortic pro-inflammatory cytokine expression as well as reduced pro-
inflammatory cytokine levels in the serum118. However, a significant reduction of CC 
deposition was exclusively observed in the plaques of ApoE-/-/CD36-/- mice (Fig. 4-1C), which 
also showed the greatest reduction in atherosclerotic plaque size. 
In summary, these data showed that the genetic deletion of CD36, the receptor mediating 
intracellular cholesterol crystallization, causes a reduction in crystalline cholesterol deposition 
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in atherosclerotic plaques while limiting inflammation and atherosclerosis development. 
Hence, these findings supported the working hypothesis of this thesis that CCs represent a 
valuable therapeutic treatment target in atherosclerosis. 
4.1.2 Effects of CD treatment on atherosclerosis development 
Since 2-Hydroxypropyl-β-cyclodextrin (CD) has been described to mediate cholesterol 
depletion from cells, and especially from macrophage foam cells100,102, the therapeutic 
potential of CD in murine atherosclerosis was investigated with a particular focus on whether 
CD affected the amount of CCs present in atherosclerotic plaques. First, the effect of CD 
treatment on the development and progression of atherosclerosis was assessed in an 
ApoE-/- mouse model in collaboration with Dr. Sebastian Zimmer and colleagues (see section 
3.2.7). ApoE-/- mice were put on a HFHC diet for eight weeks while one group of mice was 
treated subcutaneously with 2 g CD per kg bodyweight twice a week, whereas the other 
group was injected with a vehicle control (Fig. 4-2A). For each mouse, parameters like body 
weight, arterial blood pressure and heart rate were controlled throughout the study period. 
No differences in these parameters were observed between the two treatment groups (data 
not shown, personal communication with Dr. Sebastian Zimmer). Serum cholesterol levels of 
the mice determined at the end of the study revealed a minimal decrease of serum 
cholesterol in CD-treated mice compared to vehicle-treated mice (Fig. 4-2B). 
For assessment of atherosclerosis development, cryosections of the aortic roots of the mice 
were examined by confocal laser reflection and fluorescence microscopy. Fig. 4-2C shows 
representative images of aortic roots of three vehicle-treated (left) and three CD-treated 
(right) mice. Both atherosclerotic plaque size, which is a measure of disease progression, 
and the abundance of laser reflection signal (green) representing CCs were visually reduced 
upon CD treatment. Quantitative analysis for atherosclerotic plaque size, CC plaque load, 
plaque cellularity and plaque macrophage load was performed on three to four sections per 
mouse. As indicated by the images in Fig. 4-2C, atherosclerotic plaque size (Fig. 4-2D) as 
well as the amount of CCs inside the plaques (Fig. 4-2E) were significantly reduced upon CD 
treatment. Although overall plaque cellularity (total number of all cells as determined by 
nuclear stain) was not changed by CD treatment (Fig. 4-2G), the amount of plaque 
macrophages was clearly reduced (Fig. 4-2F). 
These results indicated that CD treatment effectively impaired atherosclerosis development 
and progression in mice. Notably, crystalline cholesterol and CD68-positive macrophages 
were reduced upon CD treatment, suggesting a less inflammatory state of the arterial tissue. 
In line with this assumption, pro-inflammatory serum cytokines, such as IL-6, TNF-α and IL-
1β were also decreased in CD-treated mice (data not shown, Zimmer and Grebe et al., in 
press). 
Results 
 
 62 
 
Results 
 
 63 
Figure 4-2: CD treatment impairs atherosclerosis development and progression in mice. 
(A) Schematic of study protocol for the atherosclerosis prevention model. ApoE-/- mice received a HFHC 
diet for eight weeks accompanied by subcutaneous injections with CD (n=6) or vehicle control (n=7) twice a 
week. All animal work was performed by Dr. Sebastian Zimmer and colleagues. (B) Serum cholesterol 
levels after eight weeks of atherogenic diet determined by gas chromatography-flame ionization detection 
(performed by Prof. Dr. Dr. Dieter Lütjohann and colleagues). Data is shown as mean ± SD. (C-G) Serial 
aortic root sections were analyzed by confocal laser reflection and fluorescence microscopy.  
(C) Representative images of both study groups; Hoechst 34580 staining for nuclei (blue), CD68 staining for 
macrophages (red) and laser reflection signal for CCs (green). Scale bars indicate 200 µm.  
(D) Quantification of atherosclerotic plaque size depicted as plaque area as percentage of total vessel wall 
area. (E) Quantification of CC plaque load depicted as reflection area as percentage of plaque area.  
(F) Quantification of macrophage plaque load depicted as CD68 positive area as percentage of plaque 
area. (G) Quantification of plaque cellularity depicted as nuclei counts as percentage of plaque area. Data 
in (D-G) are shown as mean ± SEM of three to four individual sections per mouse. Significance was 
determined by unpaired two-tailed Student’s t-tests with Welch’s correction (* = p<0.05). 
4.1.3 Effects of CD treatment on atherosclerosis regression 
In the atherosclerosis prevention model it was observed that CD treatment impairs murine 
atherosclerosis development and progression. However, atherosclerosis in humans is 
usually only diagnosed and treated in the advanced stages of the disease. Hence a clinically 
relevant therapeutic treatment should be efficient in regressing already established 
atherosclerosis. To investigate whether CD treatment also possesses this important potential 
of mediating plaque reversion, two mouse models of atherosclerosis regression were 
performed in collaboration with Dr. Sebastian Zimmer and colleagues (see section 3.2.7). 
The study protocols of these atherosclerosis regression models are illustrated in Fig 4-3A. In 
an eight-week pretreatment phase all mice received a HFHC diet to induce advanced 
atherosclerosis. A pretreatment control group (Ctrl) was sacrificed at this stage to control for 
the development of advanced atherosclerotic plaques. In the subsequent four-week 
treatment phase the remaining mice were subcutaneously treated with 2 g CD per kg 
bodyweight or vehicle control twice a week. During this treatment period, the diet was either 
switched to a chow diet (Regression A), because patients with diagnosed atherosclerosis are 
typically advised to reduce their cholesterol intake as well, or the atherogenic HFHC diet was 
continued (Regression B). 
Again, for each mouse, parameters like body weight, arterial blood pressure and heart rate 
were controlled throughout the study period. Within one regression study group  
(Regression A or Regression B) no differences in these parameters were observed between 
CD-treated or vehicle-treated animals (data not shown, personal communication with  
Dr. Sebastian Zimmer). Serum cholesterol levels of the mice were measured in serum 
collected from a final blood draw right before sacrifice (Fig. 4-3B). In Regression A (upper 
panel) a highly significant drop in serum cholesterol levels was observed when comparing 
the pretreatment control mice (Ctrl) with the two treatment groups (Vehicle and CD). This 
reduction was caused by the change of diet during the treatment phase. However, within the 
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two treatment groups, only a minimal decrease of serum cholesterol in CD-treated mice 
compared to vehicle-treated mice was observed. In Regression B (lower panel) serum 
cholesterol levels remained unchanged besides the previously observed insignificant 
decrease of serum cholesterol in CD-treated animals. 
Atherosclerosis parameters were assessed by confocal laser reflection and fluorescence 
microscopy of three to four aortic root cryosections. Representative images are displayed in 
Fig. 4-3C, demonstrating the induction of advanced atherosclerotic plaques upon 8 weeks of 
HFHC diet in sections obtained from the pretreatment control group (Ctrl). Furthermore, for 
both regression models (Regression A and Regression B), a prominent reduction in 
atherosclerotic plaque size was visually apparent upon CD treatment. This was confirmed by 
quantitative image analysis where atherosclerotic plaque size was significantly decreased 
upon CD treatment when compared to the vehicle treatment and the pretreatment control 
(Ctrl) groups in both regression models (Fig. 4-3D). Analysis of CC plaque load (Fig. 4-3E) 
revealed that the switch of diets in Regression A already resulted in significantly lower 
amounts of CCs within the plaques when comparing pretreatment control (Ctrl) and vehicle 
treatment groups. This change in CC plaque load was not observed under continued HFHC 
diet (Regression B). However, when comparing CC plaque loads of CD-treated animals to 
vehicle-treated animals, a significant reduction upon CD treatment was found in both 
regression models, even in Regression A despite the already decreased basal level of CC 
plaque content. The data on plaque macrophage load (Fig. 4-3F) looked similar to the data 
on CC plaque load although this reduction was not statistically significant. In detail, in 
Regression A, a decrease in the amount of CD68-positive macrophages in the plaques was 
observed between pretreatment control (Ctrl) and both treatment groups, and thus coincided  
 
Figure 4-3: CD treatment mediates atherosclerosis regression in mice. 
(A) Schematic of study protocol for atherosclerosis regression models. ApoE-/- mice received a HFHC diet 
for eight weeks to induce advanced atherosclerosis. A pretreatment control group (Ctrl; n=8) was sacrificed 
at this stage; the remaining mice were subcutaneously treated for another four weeks with CD or vehicle 
control twice a week. During this treatment period, the diet was either switched to a chow diet (Regression 
A; Vehicle n=7, CD n=7) or the HFHC diet was continued (Regression B; Vehicle n=8, CD n=7). All animal 
work was performed by Dr. Sebastian Zimmer and colleagues.(B) Serum cholesterol levels determined by 
gas chromatography-flame ionization detection (performed by Prof. Dr. Dr. Dieter Lütjohann and 
colleagues). Data is shown as mean ± SD. (C-G) Serial aortic root sections were analyzed by confocal laser 
reflection and fluorescence microscopy. (C) Representative images of pretreatment control as well as CD 
and vehicle treatment of both regression models; Hoechst 34580 staining for nuclei (blue), CD68 staining 
for macrophages (red) and laser reflection signal for CCs (green). Scale bars indicate 200 µm.  
(D) Quantification of atherosclerotic plaque size depicted as plaque area as percentage of total vessel wall 
area. (E) Quantification of CC plaque load depicted as reflection area as percentage of plaque area.  
(F) Quantification of macrophage plaque load depicted as CD68 positive area as percentage of plaque 
area. (G) Quantification of plaque cellularity depicted as nuclei counts as percentage of plaque area. Data 
in (D-G) are shown as mean ± SEM of three to four individual sections per mouse. Significance was 
determined by one-way ANOVA with Tukey's post test for multiple comparisons (*** = p<0.001, ** = p<0.01, 
* = p<0.05, ns = not significant). 
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with the change of diet. Here, CD treatment did not reduce but rather slightly increased 
macrophage plaque load compared to vehicle treatment. In Regression B, where the HFHC 
diet was continued throughout the treatment phase, the amount of plaque macrophages was 
not altered in the vehicle treatment group compared to the pretreatment control (Ctrl) group. 
However, CD treatment reduced the amount of macrophages inside the plaque. Although 
overall plaque cellularity increased during the 4-week treatment phase, this was not further 
affected by CD treatment (Fig. 4-3G). 
These results confirmed	   that advanced atherosclerosis was established upon eight weeks of 
HFHC diet feeding. Beyond that, CD treatment was found to be efficient in mediating the 
regression of atherosclerotic plaques in mice even under continued administration of the 
atherogenic diet. 
4.2 2-Hydroxypropyl-β-cyclodextrin and cholesterol crystals 
The atherosclerosis mouse models showed that CD has beneficial effects on atherosclerosis 
development and is even efficient in mediating the regression of atherosclerotic plaques. 
However, the underlying molecular mechanisms of CD-mediated atheroprotection remained 
unclear. The finding that decreased murine atherosclerosis was accompanied with a 
reduction in crystalline cholesterol in the plaques supported the hypothesis that CD’s 
cholesterol solubilizing capacities might contribute to its anti-atherogenic properties. 
Moreover, the fact that CD treatment did not affect serum cholesterol levels, but decreased 
the amount of CCs in plaques indicated that CD might have more direct effects on plaque 
CCs than just lowering CC deposition through reduced serum cholesterol levels. While it is 
well described in the literature that CD molecules can interact with and solubilize cholesterol 
molecules99, it was unknown whether CD can also interact with cholesterol in a crystalline 
state. Therefore, the potential of CD to interact with and potentially mediate the dissolution of 
crystalline cholesterol was investigated. 
4.2.1 Interaction of CD with cholesterol crystals 
To test whether CD can interact with cholesterol in a crystalline state, CCs were incubated 
for 6 hours in fluorescent rhodamine-labeled CD. Incubation was performed at 4°C to allow 
for binding of rhodamine-labeled CD to crystalline cholesterol while reducing the chance of 
potential crystal dissolution. The crystals were vigorously washed to remove any unbound 
rhodamine-labeled CD prior to detection of rhodamine fluorescence by confocal laser 
reflection and fluorescence microscopy (Fig. 4-4A) as well as flow cytometry (Fig. 4-4B). 
Both methods confirmed the binding of fluorescent CD molecules to CCs as seen by a strong 
fluorescence increase in the rhodamine signal (Fig. 4-4B) as well as a clear encapsulation of 
the crystals by rhodamine-labeled CD (Fig. 4-4A). 
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Figure 4-4: CD binds to extracellular CCs and dose-dependently mediates their dissolution. 
(A,B) 1 mg CCs were incubated for 6 h shaking at 4°C in 0.5 mM rhodamine-labeled CD, unlabeled CD or 
PBS as control. (A) Representative images of CCs incubated in rhodamine-labeled CD obtained by 
confocal laser reflection and fluorescence microscopy. (n=2) (B) Flow cytometric analysis of CCs. 
Histogram of rhodamine fluorescence is representative of 2 independent experiments. (C) Radioactive 
3H-CC were incubated overnight shaking at 37°C in CD solutions of indicated concentrations. The solutions 
were filtered through 0.22 µm filter plates and 3H-cholesterol was measured in filtrate (solubilized 
3H-cholesterol) and retentate (crystalline 3H-cholesterol). Data are shown as mean + SEM of four 
independent experiments with duplicates. Significance was determined by one-way ANOVA of the 
crystalline cholesterol fraction comparing each sample with the 0 mM CD control applying Dunnett's post 
test for multiple comparisons (*** = p<0.001, ns = not significant). 
To further investigate whether CD can also mediate the dissolution of crystalline cholesterol, 
a filtration-based dissolution assay with radioactively labeled 3H-CCs was established (see 
section 3.2.3, Fig. 3-1). First, 3H-CCs were incubated overnight shaking in CD solutions of 
different concentrations ranging from 0.01 mM to 100 mM. Then the samples were filtered 
through a 0.22 µm filter to separate the crystalline cholesterol, which is unable to pass 
through the filter, from the solubilized cholesterol. Hence, subsequent detection of crystal-
derived 3H-cholesterol in the filtrate (soluble fraction) as well as in the retentate (crystalline 
fraction) allowed quantification of CC dissolution. The results revealed that CD dose-
dependently dissolved CCs where significant CC dissolution was observed with CD 
concentrations of 0.1 mM or higher (Fig. 4-4C). In addition, dissolution of extracellular CCs 
by CD could also be observed by general cell counting methods (Neubauer cell counting 
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chamber, Tali Image Cytometer), where the crystals simply disappeared upon incubation in 
concentrated CD solutions (data not shown). 
These results demonstrated CD binding to crystalline cholesterol as well as dissolution of 
extracellular CCs incubated in CD. However, beyond extracellular CCs, atherosclerotic 
plaques also contain intracellular CCs, mainly inside macrophages24,119. Therefore, the 
capacity of CD to dissolve intracellular CCs was investigated next. Beforehand, the 
cytotoxicity of CD on murine macrophages in in vitro experiments was tested in a time- and 
dose-dependent manner. Both normocholesterolemic immortalized macrophages (iMOs) 
(Fig. 4-5A) and CC-loaded hypercholesterolemic iMOs (Fig. 4-5B) were incubated for up to 
48 hours with increasing CD concentrations up to 50 mM CD. CD incubation showed dose- 
and time-dependent effects on macrophage viability under both conditions. Cell viability was 
drastically decreased upon incubation with CD concentrations higher than 10 mM (dashed 
lines), especially in normocholesterolemic macrophages. Similar results were obtained when 
cell viability was determined in normo- or hypercholesterolemic bone marrow-derived 
macrophages (BMDMs) (data not shown). Here, even a slight improvement of cell viability 
was observed with low CD concentrations between1.5 and 10 mM. Since macrophage 
viability was not considerably impaired upon incubation with 10 mM CD for up to 48 hours in 
both macrophage cell types, this concentration (10 mM) was used for all further in vitro 
experiments in macrophages. 
Next, the uptake of CD into macrophages as a prerequisite for intracellular CC dissolution by 
CD was investigated. CC-loaded macrophages were incubated with fluorescent rhodamine-  
 
 
Figure 4-5: Dose- and time-dependent effects of CD incubation on macrophage viability. 
(A) Normocholesterolemic BALB/c iMOs or (B) BALB/c iMOs loaded with 200 µg CCs per 1x106 cells 
overnight were treated for indicated times with different concentrations of CD ranging from 50 mM to  
1.5625 mM. Cell viability was determined by CTB Viability Assay. Untreated cells served as positive control 
and 70% EtOH-treated cells were used as negative control. Dashed line indicates commonly used CD 
concentration (10 mM). Data are shown as mean ± SEM of three independent experiments with duplicates. 
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Figure 4-6: CD is internalized by macrophages and mediates intracellular CC dissolution.  
(A-C) Untreated or CC-loaded C57BL/6 iMOs were incubated for 6 h in a 1 mM CD solution containing  
one-tenth rhodamine-labeled CD. (A) Representative images of rhodamine-labeled CD accumulation in  
CC-loaded macrophages over time obtained by confocal live cell imaging. (n=2) (B) Representative Z-stack 
image (maximum intensity projection) of CC-loaded macrophages obtained by confocal laser reflection and 
fluorescence microscopy following 6h rhodamine-labeled CD incubation; rhodamine-labeled CD (red), 
Hoechst 34580 staining for nuclei (blue), CtxB A488 staining for cell membranes (green) and laser reflection 
signal for CCs (white). (n=2) (C) Flow cytometric analysis of macrophages treated with rhodamine-labeled 
CD, unlabeled CD or medium control. (n=1) (D-F) WT BMDMs were loaded with 100 µg CC per 1x106 cells 
for 3 h prior to 24 h incubation with 10 mM CD or medium control. (D) Representative images obtained by 
confocal laser reflection and fluorescence microscopy; Hoechst 34580 staining for nuclei (blue), CtxB A647 
staining for cell membranes (green) and laser reflection signal for CCs (red). (E) Quantification of 
intracellular crystal reflection area per cell. (F) Number of analyzed cells indicated by number of counted 
nuclei. Data presented in (E) and (F) are shown as mean + SEM of four independent experiments where 
10-15 individual fields of view were analyzed. Significance was determined using (E) a ratio paired  
one-tailed t-test or (F) a ratio paired two-tailed t-test (* = p<0.05). 
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labeled CD and confocal live cell imaging was performed to track CD uptake (Fig. 4-6A). The 
brightfield image acquired right before addition of rhodamine-labeled CD was used as a 
reference for macrophage localization. Thus, upon addition of rhodamine-labeled CD (0 h) a 
negative representation of the cells (black areas within red background stain) can be 
observed. The cells accumulated rhodamine-labeled CD over time as seen by an increase of 
rhodamine fluorescence in the previously black areas. The fluorescent signal shows a 
cytoplasmic, dotted pattern leaving a black spot representing the nucleus, which indicated 
uptake of rhodamine-labeled CD into cytoplasmic cellular compartments. Following live cell 
imaging the cells were washed and stained with CtxB for visualization of the cell membranes 
as well as Hoechst for visualization of the nuclei. Examination of maximum intensity 
projections of Z-stack images obtained by confocal laser reflection and fluorescence 
microscopy confirmed the uptake and the previously observed cellular distribution of 
rhodamine-labeled CD (Fig. 4-6B). Some overlap with the intracellular CC reflection signal 
was observed, particularly in 3D reconstructions of the Z-stack images (data not shown), but 
image resolution was not good enough to unequivocally prove interaction between CD and 
intracellular crystalline cholesterol. Flow cytometric analysis of CC-loaded macrophages or 
resting macrophages revealed a strong fluorescence increase in the rhodamine signal upon 
incubation with rhodamine-labeled CD (Fig. 4-6C) verifying that CD was efficiently taken up 
into macrophages. 
Intracellular CC dissolution by CD in macrophages was finally investigated by confocal laser 
reflection and fluorescence microscopy of CC-loaded BMDMs following 24 hours of CD or 
control treatment. A reduction in the crystal reflection signal (CC) upon CD treatment was 
clearly visible (Fig. 4-6D), already indicating the dissolution of intracellular CCs by CD. To 
quantify this, the amount of intracellular reflection signal representing crystalline cholesterol 
was determined by quantitative image analysis from 10-15 randomly acquired fields of view 
(see section 3.2.10, Fig. 3-3). CD treatment significantly decreased the amount of 
intracellular CCs (Fig. 4-6E) while the amount of analyzed cells was not considerably 
different (Fig. 4-6F). Similar results were observed in a single experiment using C57BL/6 
iMOs, although intracellular CC dissolution by CD was slightly more efficient in BMDMs (data 
not shown). In summary, these results indicated that CD has the capacity to mediate the 
dissolution of intracellular CCs in macrophages. 
4.2.2 Fate of crystal-derived cholesterol in macrophages 
In the previous section it was demonstrated that CD mediates intracellular CC dissolution. 
However, CC uptake and subsequent dissolution by CD presumably cause excessive 
accumulation of free cholesterol inside the macrophages. Intracellular accumulation of free 
cholesterol is known to be cytotoxic57, but no cytotoxic effects were observed in CC-loaded 
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macrophages upon treatment with 10 mM CD for 24 hours (see Fig. 4-5B). This suggested 
that the cholesterol derived from the crystals must either be converted into cholesterol esters, 
the nontoxic storage form of cholesterol that is deposited in lipid droplets, or it must be 
eliminated from the cells58. Therefore, the fate of the crystal-derived cholesterol inside the 
macrophages upon CD treatment was investigated. 
Firstly, the potential of CD to promote esterification and storage of crystal-derived cholesterol 
was examined. The formation of lipid droplets in CC-loaded macrophages following 24 hours 
of CD incubation was microscopically assessed using the lipid droplet dye LD540109. The 
representative microscopy images in Fig. 4-7A demonstrate that upon CD treatment the  
 
 
Figure 4-7: CD increases lipid droplet formation in CC-loaded macrophages and promotes 
esterification of crystal-derived cholesterol. 
(A-C) C57BL/6 iMOs were loaded with 100 µg CC per 1x106 cells for 3 h prior to 24 h incubation with  
10 mM CD or medium control. (A) Representative images obtained by confocal laser reflection and 
fluorescence microscopy; Hoechst 34580 staining for nuclei (blue), CtxB A647 staining for cell membranes 
(green), laser reflection signal for CCs (white) and LD540 staining for lipid droplets (red). (B) Quantification 
of lipid droplets depicted as LD540 positive area per cell. (C) Number of analyzed cells indicated by number 
of counted nuclei. Data presented in (B) and (C) are shown as mean + SEM of three independent 
experiments where 10 individual fields of view were analyzed. P-values were calculated using a ratio paired 
two-tailed t-test. (D) C57BL/6 iMOs were loaded with 200 µg D6-CC per 1x106 cells for 3 h prior to 24 h or 
48 h incubation with 10 mM CD or medium control. Before addition of CD a 0 h control sample was 
harvested. Degree of esterification of D6-cholesterol was determined by GC-MS-SIM (performed by  
Prof. Dr. Dr. Dieter Lütjohann and colleagues) and used to calculate the amount of esterified D6-cholesterol. 
Data are shown as mean + SEM of four independent experiments with duplicates. Significance was 
determined by one-way ANOVA comparing no CD versus CD with Sidak’s post test for multiple 
comparisons (* = p<0.05, ns = not significant). 
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square-edged intracellular structures in the brightfield representing CCs (see laser reflection 
signal) disappear, whereas the spherical structures in the brightfield, representing lipid 
droplets as confirmed by LD540 staining, accumulate inside the cells. Quantitative image 
analysis of the intracellular LD540 stain showed an increase in lipid droplet area per cell 
following CD treatment (Fig. 4-7B), while the number of cells analyzed was not considerably 
different (Fig. 4-7C). 
However, although this experiment showed that CD treatment increased lipid droplet 
formation, the origin of esterified cholesterol inside the lipid droplets was not clear. Therefore, 
to monitor the esterification of crystal-derived cholesterol in particular, macrophages were 
loaded with stable isotope-labeled D6-CCs. This allows the discrimination of crystal-derived 
D6-cholesterol from unlabeled endogenous cholesterol by GC-MS-SIM. Thus, D6-CC-loaded 
macrophages were treated for 24 hours or 48 hours with CD or medium as control and the 
amount and degree of esterification of crystal-derived D6-cholesterol were determined by 
GC-MS-SIM (see section 3.2.15), which was then used to back calculate the amount of 
esterified D6-cholesterol per sample. CD treatment of D6-CC-loaded macrophages for  
48 hours significantly increased the esterification of D6-cholesterol compared to non-CD 
treated cells (Fig. 4-7D). Taken together, these data indicated that CD treatment of  
CC-loaded macrophages promotes the intracellular esterification and storage of crystal-
derived cholesterol. 
Next, it was investigated whether crystal-derived cholesterol is eliminated from the 
macrophages upon CD treatment. For this, macrophages loaded with D6-CCs were 
incubated with CD or medium control for 24 hours or 48 hours and the distribution of crystal- 
derived D6-cholesterol was determined in the cells and the cell culture supernatants  
(Fig. 4-8A). The 0 hour control bars show the distribution of D6-cholesterol right after loading 
the cells with D6-CCs. Comparing the medium control samples to the 0 hour control sample, 
a decrease of D6-cholesterol was observed in the cells and consequently D6-cholesterol 
increased in the supernatants over time. This indicated that macrophages alone are able to 
dissolve CCs to a low extent and to export the crystal-derived cholesterol out of the cells. 
This basal efflux of crystal-derived cholesterol was significantly increased at 24 hours when 
macrophages were treated with CD. However, longer CD treatment did not further increase 
D6-cholesterol efflux from the macrophages suggesting that the maximum CD-mediated 
cholesterol efflux capacity is reached at 24 hours. 
Unexpectedly, analysis of unlabeled cholesterol in the same samples showed no effect of CD 
treatment on unlabeled, cellular cholesterol levels (Fig. 4-8B). A non-significant reduction of 
cellular cholesterol was observed upon incubation with CD for 24 hours, but no change was 
visible upon 48 hours. This suggested that CD specifically depletes crystal-derived 
cholesterol, but in contrast to D6-cholesterol, which can only be derived from D6-CCs, the 
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origin of the unlabeled cholesterol measured by GC-MS-SIM is unknown. Thus, the lack of 
CD-mediated depletion of unlabeled, cellular cholesterol might be due to cellular cholesterol 
being replenished by de novo synthesis or by uptake of excess cholesterol from the FCS-
containing cell culture medium. 
Export of free cholesterol from macrophages is primarily mediated by the cholesterol efflux 
transporters ABCA1 and ABCG1, which transfer the cholesterol to ApoA-1 or HDL particles, 
respectively58. To determine whether the addition of HDL as cholesterol acceptor can  
 
 
Figure 4-8: CD mediates efflux of crystal-derived cholesterol from macrophages, which is 
augmented by addition of rHDL. 
C57BL/6 iMOs were loaded with 200 µg D6-CC per 1x106 cells for 3 h prior to incubation with 10 mM CD or 
medium control for indicated times. Cells and supernatants were harvested and analyzed for the presence 
of crystal-derived D6-cholesterol and unlabeled cholesterol determined by GC-MS-SIM (performed by  
Prof. Dr. Dr. Dieter Lütjohann and colleagues). Before addition of CD a 0 h control sample was harvested to 
assess the distribution of D6-cholesterol right after D6-CC loading of the cells. (A) D6-cholesterol and  
(B) cholesterol distribution following CD or control treatment. Data are shown as mean + SEM of four 
independent experiments with duplicates. (C) D6-cholesterol and (D) cholesterol distribution upon 24 h CD 
or control treatment along with 0.25 mg/ml rHDL. Data are shown as mean + SEM of two independent 
experiments with duplicates. Significance was determined by one-way ANOVA with Tukey's post test for 
multiple comparisons (*** = p<0.001, ** = p<0.01, * = p<0.05, ns = not significant). 
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enhance the CD-mediated efflux of crystal-derived cholesterol, reconstituted HDL (rHDL) 
with low cholesterol content was added together with CD to D6-CC-loaded macrophages. 
While rHDL incubation for 24 hours did not mediate the efflux of D6-cholesterol by itself, it 
significantly reduced cellular D6-cholesterol when added in combination with CD (Fig. 4-8C). 
These results confirmed that the addition of rHDL as cholesterol acceptor could boost CD-
mediated efflux of crystal-derived cholesterol. However, while on initial observation this data 
conflicts with the current literature, where HDL is described to deplete cellular 
cholesterol120,121, when analyzing unlabeled, cellular cholesterol in these cells, rHDL 
treatment alone and in combination with CD did indeed significantly reduce total cellular 
cholesterol levels (Fig. 4-8D). This indicated that CD is required for mobilizing the crystalline 
D6-cholesterol for HDL-mediated efflux out of the macrophages. 
The previous results demonstrated that CD mediates the dissolution of intracellular CCs and 
subsequently promotes esterification for intracellular storage as well as efflux of crystal-
derived cholesterol. Free cholesterol can be further metabolized to other bioactive 
derivatives, such as oxysterols including 27-hydroxcholesterol (HC),	  24(S)-HC and 25-HC. To 
assess whether CD treatment affects oxysterol production, crystal-derived and cellular  
24(S)-HC and 27-HC were also analyzed by GC-MS-SIM. While both oxysterols were 
similarly regulated by CD treatment (data not shown), only the production of 27-HC, which 
was more efficiently produced in macrophages, was significantly affected by CD treatment. 
Therefore, the effects of CD treatment on crystal-derived and cellular 27-HC production were 
further investigated. 
For detection of D6-CC-derived 27-HC by GC-MS-SIM it needs to be considered that 
hydroxylation at the 27-position of the D6-cholesterol molecule removes one deuterium atom, 
resulting in D5-27-HC. When measuring this crystal-derived metabolite in D6-CC-loaded 
macrophages (Fig. 4-9A), no crystal-derived D5-27-HC was detectable right after 
macrophage loading with D6-CC (0 h Ctrl), but the production of small amounts of D5-27-HC 
was observed over time in control-treated cells (no CD). This again indicated that 
macrophages themselves are able to dissolve some crystalline cholesterol to a low extent, 
subsequently allowing the enzymatic conversion of crystal-derived cholesterol to oxysterols. 
However, when D6-CC-loaded macrophages were incubated with CD for 24 hours or  
48 hours, D5-27-HC production was significantly increased compared to the respective 
control-treated (no CD) samples. The majority of D5-27-HC was found in the supernatants of 
the cells, but as cholesterol 27-hydroxylase, the enzyme responsible for the conversion of 
cholesterol to 27-HC, is a mitochondrial enzyme122, 27-hydroxylation must happen inside the 
cells followed by efflux of the resultant oxysterols. 
The conversion of unlabeled, cellular cholesterol to 27-HC was also analyzed in the same 
samples (Fig. 4-9B). CD treatment also promoted 27-HC production from unlabeled, cellular 
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cholesterol in D6-CC-loaded macrophages. Taken together, these data suggested that CD 
treatment promotes 27-hydroxylation of cholesterol in general, rather than just increasing the 
total pool of cellular cholesterol available for enzymatic conversion into 27-HC by dissolution 
of intracellular CCs. To assess whether these observations could be explained by a general 
induction of cholesterol 27-hydroxylase (encoded by the gene Cyp27a1) by CD treatment, 
expression of this enzyme was analyzed in CC-loaded macrophages at the transcriptional  
 
 
Figure 4-9: CD induces the production of 27-HC independent of Cyp27a1 expression levels. 
(A,B) C57BL/6 iMOs were loaded with 200 µg D6-CC per 1x106 cells for 3 h prior to 24 h or 48 h incubation 
with 10 mM CD or medium control. Cells and supernatants were harvested and analyzed for the presence 
of (A) crystal-derived D5-27-HC and (B) cellular 27-HC by GC-MS-SIM (performed by Prof. Dr. Dr. Dieter 
Lütjohann and colleagues). Before addition of CD a 0 h control sample was harvested. Data are shown as  
mean + SEM of three independent experiments with duplicates. Significance was determined by one-way 
ANOVA with Tukey's post test for multiple comparisons (*** = p<0.001, ** = p<0.01, * = p<0.05,  
ns = not significant). (C-E) WT BMDMs were loaded with 100 µg CC per 1x106 cells overnight prior to 
incubation with 10 mM CD or medium control for 4 h, 8 h or 24 h. (C) Cyp27a1 mRNA levels relative to the 
reference gene Hprt assessed by RT-qPCR and presented as fold induction of the 0 h control. Data are 
shown as mean + SEM of three independent experiments with technical duplicates. (D,E) Cells and 
supernatants were harvested and analyzed for the presence of (D) crystal-derived D5-27-HC and  
(E) cellular 27-HC by GC-MS-SIM (performed by Prof. Dr. Dr. Dieter Lütjohann and colleagues). Before 
addition of CD a 0 h control sample was harvested. Data are shown as mean + SD of one experiment with 
triplicates.  
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level (Fig. 4-9C). However, no changes in Cyp27a1 mRNA abundance were observed upon 
CD treatment compared to the respective untreated cells (Fig. 4-9C). As the expression of 
cholesterol 27-hydroxylase was analyzed in CC-loaded BMDMs, whereas the  
27-hydroxylation product was determined in D6-CC-loaded iMOs, a single experiment was 
performed to confirm that CD also promotes 27-hydroxylation of crystal-derived and cellular 
cholesterol in BMDMs. A slight time-dependent increase in D5-27-HC (Fig. 4-9D) and 27-HC 
(Fig. 4-9E) was observed in control cells. However, CD treatment again strongly increased 
the production of both, crystal-derived D5-27-HC and unlabeled, cellular 27-HC, thus 
confirming the observations in iMOs in primary BMDMs. Protein expression of cholesterol  
27-hydroxylase was also assessed in one experiment using CC-loaded iMOs, but no 
changes were observed following CD treatment (data not shown) matching the findings on 
Cyp27a1 mRNA expression in BMDMs. These results indicated that CD promotes  
27-hydroxylation of crystal-derived and cellular cholesterol independent of cholesterol  
27-hydroxylase expression levels, which was confirmed in both iMOs and primary BMDMs.  
In summary, the data presented in this section showed that CD treatment of CC-loaded 
macrophages mediates the dissolution of intracellular CCs and subsequently promotes the 
esterification, metabolism to oxysterols such as 27-HC and efflux of crystal-derived 
cholesterol. CD-mediated efflux of crystal-derived cholesterol could also be further enhanced 
by addition of rHDL indicating active export of crystal-derived cholesterol via the cholesterol 
efflux transporters ABCA1 and ABCG1. 
4.3 Induction of LXR gene expression by 2-hydroxypropyl-β-
cyclodextrin 
The observation that CD mediated extra- and intracellular CC dissolution and subsequently 
promoted cellular efflux of crystal-derived cholesterol strongly supported the working 
hypothesis that lowering plaque CC loads, presumably through CC dissolution and 
cholesterol elimination from the tissue, might contribute to CD’s anti-atherogenic properties. 
Moreover, the finding that CD promoted the production of 27-HC in CC-loaded, 
hypercholesterolemic macrophages provided further insight into the potential molecular 
mechanisms of the beneficial effects of CD treatment on murine atherosclerosis. 
27-HC is one of the oxysterols known to activate LXR transcription factors123. LXR 
transcription factors in turn activate gene expression programs controlling cholesterol efflux 
and negatively regulating inflammatory responses64. Both, cholesterol efflux and 
inflammation play a critical role in atherosclerosis and activation of LXR transcription factors 
by synthetic LXR agonists was shown to be protective against atherosclerosis 
development116,124. Therefore, it was hypothesized that the increased production of the 
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endogenous LXR ligand 27-HC in response to CD treatment might contribute to the observed 
anti-atherogenic effects of CD in mice. 
4.3.1 Regulation of cholesterol efflux transporters by CD 
Macrophages mainly export free cholesterol via the cholesterol efflux transporters ABCA1 
and ABCG158. As these transporters were previously described as LXR target genes125-127 
and CD was found to promote the production of the endogenous LXR agonist 27-HC, the 
expression of ABCA1 and ABCG1 was investigated as an indication of CD-mediated LXR 
transcription factor activation. 
First, changes in the abundance of Abca1 and Abcg1 mRNA transcripts were determined by 
RT-qPCR in BMDMs treated with CD or medium control for 8 hours (Fig. 4-10A). Treatment 
with the synthetic LXR agonist T09 confirmed the LXR-induced upregulation of both 
cholesterol efflux transporter genes. CD treatment of normocholesterolemic BMDMs did not 
affect Abca1 and Abcg1 gene expression, while CC-loading of the macrophages already 
resulted in increased Abca1 and Abcg1 expression levels, presumably as normal cellular 
response to cholesterol overload128,129. However, CD treatment of CC-loaded macrophages 
clearly resulted in a further upregulation of Abca1 and Abcg1 gene expression. Furthermore,  
 
 
Figure 4-10: CD induces expression of cholesterol efflux transporters in macrophages. 
(A) WT BMDMs were partially loaded with 100 µg CC per 1x106 cells overnight prior to 8 h incubation with 
10 mM CD or medium control. Incubation with 10 µM T0901317 (T09) for 24 h was used as positive control. 
Abca1 and Abcg1 mRNA levels relative to the reference gene Hprt assessed by RT-qPCR and presented 
as fold induction of the untreated cells. (B, C) ABCA1 protein expression was analyzed by western blot in 
(B) WT BMDMs partially loaded with 100 µg CC per 1x106 cells and (C) C57BL/6 iMOs partially loaded with 
200 µg CC per 1x106 cells for 3h prior to 24 h incubation with 10 mM CD, 10 µM T0901317 (T09) or 
medium control. β-actin expression was used as loading control. Data are presented as representative blot 
and densitometry analysis of (A) two and (B) four independent experiments (mean + SD). Data are shown 
as mean + SEM of four independent experiments with technical duplicates. Significance was determined by 
one-way ANOVA with Tukey's post test for multiple comparisons (** = p<0.01, * = p<0.05, ns = not 
significant). 
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ABCA1 protein expression was analyzed upon 24h CD treatment in normocholesterolemic or 
CC-loaded, hypercholesterolemic BMDMs (Fig. 4-10B). Again, CC-loading already enhanced 
ABCA1 protein expression, which was significantly enhanced upon CD treatment of  
CC-loaded BMDMs. ABCA1 protein levels in CD-treated, CC-loaded macrophages were 
comparable to ABCA1 induction by the synthetic LXR agonist T09. As most of the  
GC-MS-SIM analyses were performed in samples derived from iMOs, CD-mediated effects 
on ABCA1 protein expression were also confirmed in these cells (Fig. 4-10C). In summary, 
CD treatment of CC-loaded macrophages, similar to LXR agonist treatment, resulted in 
increased expression of the cholesterol efflux transporters ABCA1 and ABCG1. 
4.3.2 Genome-wide analysis of LXR target gene expression in 
macrophages following CD treatment  
To further confirm whether CD promotes LXR activation, global LXR target gene expression 
in macrophages following CD treatment was investigated using genome-wide gene 
expression analysis, which was performed in collaboration with Prof. Dr. Joachim Schultze 
and colleagues (see sections 3.2.21 and 3.2.22). For this, BMDMs prepared from bone 
marrow of WT and LXRα-/-/LXRβ-/- mice were either loaded with CCs or left untreated before 
incubation in CD or medium alone for six hours. 
 
 
Figure 4-11: CD-mediated upregulation of cholesterol efflux transporters is LXR-dependent. 
BMDMs generated from WT and LXRα-/-/LXRβ-/- mice were partially loaded with 100 µg CC per 1x106 cells 
overnight prior to (A) 6 h or (B) 24 h incubation with 10 mM CD or medium control. Incubation with 10 µM 
T0901317 (T09) for 24 h was used as positive control. (A) Abca1 and Abcg1 mRNA levels relative to the 
reference gene Rn18S assessed by Taqman RT-qPCR and presented as fold induction of untreated cells of 
the respective genotype. Taqman RT-qPCR was run by Niklas Bode. Data are shown as mean + SEM of 
one experiment with two individual mice per genotype and technical duplicates. (B) ABCA1 protein 
expression analyzed by western blot. β-actin expression was used as loading control. Data are presented 
as representative blot and densitometry analysis of one experiment with three individual mice per genotype 
(mean + SD). 
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Prior to microarray analysis, quality controls of the cells and isolated RNAs were performed. 
The RNA isolated for microarray analysis was examined for Abca1 and Abcg1 gene 
expression (Fig. 4-11A), and in parallel to microarray sample preparation, some WT and 
LXRα-/-/LXRβ-/- BMDMs were also analyzed for ABCA1 protein expression following 24 hours 
of CD treatment (Fig. 4-11B). The results of both these quality control analyses confirmed the 
previously observed induction of cholesterol efflux transporter expression at both the mRNA 
and protein level following CD treatment of WT BMDMs. Furthermore, despite basally higher 
levels of ABCA1 and ABCG1 expression (due to normalization to respective untreated 
control only visible in ABCA1 WB in Fig. 4-11B), no changes in cholesterol efflux transporter 
expression were observed in LXRα-/-/LXRβ-/- BMDMs, either upon CD or upon T09 
incubation. The lack of ABCA1 and ABCG1 induction with the synthetic LXR agonist T09 
validated that LXRα-/-/LXRβ-/- BMDMs were indeed knockout cells. Furthermore, the finding 
that CC-loading and CD treatment also failed to induce cholesterol efflux transporter 
expression, confirmed that the regulation of ABCA1 and ABCG1 by cholesterol overloading 
as well as by CD treatment was dependent on LXR transcription factors. 
To assess whether CD treatment of macrophages particularly changed LXR target gene 
expression, gene set enrichment analysis (GSEA) was performed for a set of 533 previously 
described LXR target genes114 that were contained in the microarray. GSEA reveals whether 
the induction of a defined set of genes is statistically different between two different states. In 
LXRα-/-/LXRβ-/- BMDMs none of the treatments resulted in a significant enrichment of LXR 
target gene sets (Fig 4-12). In contrast, LXR target gene sets were significantly enriched  
 
 
Figure 4-12: GSEA for LXR target genes in CD-treated WT and LXRα-/-/LXRβ-/- macrophages. 
M-CSF-derived BMDMs generated from WT mice (n=3) and LXRα-/-/LXRβ-/- mice (n=4) were partially 
loaded with 100 µg CC per 1x106 cells overnight prior to incubation with 10 mM CD or medium control for  
6 h. Array-based gene expression profiling of these samples was performed by Prof. Dr. Joachim Schultze 
and colleagues. GSEA for LXR target genes was performed for both genotypes comparing all conditions 
against the untreated cells (Control) and CC-loaded and CD-treated samples against CC-loaded cells 
(CC+CD vs. Control). Results are presented in volcano plots showing the normalized enrichment score 
(NES) and the enrichment p-value. Dr. Thomas Ulas performed the GSEA and graphed the resultant data. 
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upon loading of WT BMDMs with CCs, which was in line with the observations on ABCA1 
and ABCG1 expression following CC-loading (see Fig. 4-10 and Fig. 4-11) and is 
presumably caused by cholesterol overloading of the macrophages. Furthermore, CD 
treatment of CC-loaded WT BMDMs resulted in a highly significant enrichment of LXR target 
gene sets when compared to normocholesterolemic WT BMDMs, and furthermore significant 
enrichment was even observed when compared to CC-loaded hypercholesterolemic WT 
BMDMs (Fig 4-12). This result reflected the ABCA1 and ABCG1 expression patterns 
observed in Fig. 4-10 and Fig. 4-11, and supported the concept that CD-mediated production 
of 27-HC in CC-loaded macrophages (see Fig. 4-9) results in the induction of LXR gene 
expression programs. However, a significant enrichment of LXR target gene sets was also 
observed in CD-treated normocholesterolemic WT BMDMs (Fig 4-12). This finding was 
counterintuitive considering that LXR-meditated gene expression is involved in regulation of 
cholesterol homeostasis, mainly by regulating cellular cholesterol efflux mechanisms130, while 
CD is known to deplete normocholesterolemic cells from cholesterol131. Therefore, the effects 
of CD treatment on normocholesterolemic macrophages were examined more closely. 
4.3.3 Oxysterol production and LXR gene expression in CD-treated 
normocholesterolemic macrophages 
In collaboration with Prof. Dr. Dr. Dieter Lütjohann GC-MS-SIM was performed on 
normocholesterolemic iMOs treated with CD or medium control for 24 hours and 48 hours. 
The results confirmed the removal of cholesterol from normocholesterolemic macrophages  
 
Figure 4-13: CD removes cholesterol and induces cholesterol biosynthesis in normocholesterolemic 
macrophages, but still mediates oxysterols production and LXRα upregulation. 
(A,B) C57BL/6 iMOs were incubated with 10 mM CD or medium control for indicated times. A 0 h control 
sample was harvested before addition of CD. Samples were analyzed by GC-MS-SIM (performed by  
Prof. Dr. Dr. Dieter Lütjohann and colleagues). (A) Cholesterol distribution in cells and supernatants Data 
are shown as mean + SEM of three independent experiments with duplicates. (B) 27-HC and cholesterol 
synthesis markers. Data combined from three individual experiments with duplicates are presented in a 
heatmap showing the fold induction of the 0 h control. (C,D) M-CSF derived BMDMs generated from WT 
and LXRα-/-/LXRβ-/- mice were partially loaded with 100 µg CC per 1x106 cells overnight prior to incubation 
with 10 mM CD or medium control for 6h. Array-based gene expression profiling was performed by  
Prof. Dr. Joachim Schultze and colleagues. (C) Graphical representation of the slightly adapted KEGG 
steroid biosynthesis reference pathway (KEGG mmu00100). Genes in grey boxes were not included in 
microarray analysis; green circles indicate cholesterol and the cholesterol synthesis markers measured by  
GC-MS-SIM. (D) Heatmap shows fold changes of genes included in the steroid biosynthesis pathway 
(KEGG mmu00100) ordered as they appear in the pathway in (C). (E) WT BMDMs were incubated with  
10 mM CD or medium control for 8 h. 27-HC and cholesterol synthesis markers determined by GC-MS-SIM 
(performed by Prof. Dr. Dr. Dieter Lütjohann and colleagues). Results of one experiment with triplicates are 
presented in a heatmap showing the fold induction of the 0 h control. (F-H) WT BMDMs were partially 
loaded with 100 µg CC per 1x106 cells overnight prior to incubation with 10 mM CD or medium control for  
8 h. (F) Lss1, (G) Insig1, and (H) Nr1h3 mRNA levels relative to the reference gene Hprt assessed by  
RT-qPCR and presented as fold induction of the untreated cells. Data are shown as mean + SEM of three 
independent experiments with technical duplicates. 
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upon CD treatment (Fig. 4-13A). In addition, CD-mediated cholesterol depletion from these 
cells was accompanied by the induction of cholesterol biosynthesis markers lanosterol, 
lathosterol and desmosterol (Fig. 4-13B). 
To confirm that CD also resulted in cholesterol depletion and subsequent induction of 
cholesterol biosynthesis in the samples analyzed by microarray, gene expression changes of 
genes contained in the steroid biosynthesis pathway (KEGG pathway mmu00100) were 
evaluated. Fig. 4-13C shows a slightly adapted graphical representation of this pathway, 
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indicating the position of the cholesterol precursors that were analyzed as cholesterol 
synthesis markers by GC-MS-SIM (green circles). All genes in white boxes were contained in 
the microarray analysis and their expression levels are represented as fold changes in  
Fig. 4-13D. Indeed, CD treatment of BMDMs for 6 hours upregulated genes involved in 
cholesterol biosynthesis regardless of the genotype, indicating that cholesterol depletion from 
normocholesterolemic macrophages and transcriptional regulation of the cholesterol 
biosynthesis pathway is independent of LXR activation. Furthermore, while macrophage 
loading with CCs resulted in the downregulation of cholesterol biosynthesis genes, additional 
treatment with CD partially reversed these effects, presumably by facilitating CC dissolution 
and efflux of crystal-derived cholesterol. However, of importance, the GC-MS-SIM data of 
iMOs treated with CD for 24 and 48 hours not only revealed the induction of cholesterol 
biosynthesis markers, but also production of 27-HC in response to CD treatment  
(Fig. 4-13B). 
To gain better insight into the status of the cells used for microarray analysis, production of 
27-HC and induction of cholesterol precursors were also analyzed in BMDMs treated with 
CD for 8 hours. This analysis confirmed that CD increased the levels of cholesterol 
biosynthesis markers, but at the same time mediated the production of 27-HC (Fig 4-13E). In 
addition, gene expression analysis of normocholesterolemic or CC-loaded BMDMs treated 
with CD for 8 hours confirmed the induction of genes involved in SREBP-mediated regulation 
of cholesterol biosynthesis, namely lanosterol synthase (Lss1) (Fig. 4-13F) and Insig1  
(Fig. 4-13G), but also revealed the simultaneous induction of the LXR target gene Nr1h3, 
which encodes for the LXRα receptor (Fig. 4-13H). Although the induction of Nr1h3 was 
higher in CC-loaded BMDMs, presumably due to greater amounts of the LXR ligand 27-HC 
(about 5 ng in normocholesterolemic BMDMs opposed to 8.8 ng crystal-derived plus 7.3 ng 
cellular 27-HC in CC-loaded BMDMs (Fig. 4-9D and Fig. 4-9E), the finding that Nr1h3 
expression was also induced in normocholesterolemic WT BMDMs confirmed the results of 
the GSEA (Fig. 4-12). 
In summary these results indicated that CD mediates the activation of LXR gene expression 
via the production of endogenous LXR ligands such as 27-HC in CC-loaded 
hypercholesterolemic, but also normocholesterolemic macrophages. 
4.3.4 CD-mediated reverse cholesterol transport of crystal-derived 
cholesterol 
It was observed that CD treatment results in LXR-dependent upregulation of macrophage 
cholesterol efflux transporters and facilitates the export of crystal-derived cholesterol from 
macrophages in vitro. To determine whether this could also occur in vivo, RCT and excretion 
of crystal-derived cholesterol was monitored in mice (see section 3.2.7.2). Therefore, 
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BMDMs generated from WT and LXRα-/-/LXRβ-/- mice were loaded with D6-CCs. These  
D6-CC-loaded macrophages were then injected into the peritoneum of WT mice. 30 minutes 
after injection of the D6‑CC-loaded BMDMs the mice were treated intraperitoneally with CD 
or vehicle control, which was repeated 16 hours later because of the fast clearance of CD 
upon parenteral administration (see section 2.3.1.3). Feces and urine were collected in three 
to six hour intervals over a 30 hours period and analyzed for presence of crystal-derived 
D6‑cholesterol using GC-MS-SIM. A schematic of the experimental workflow is provided in 
Fig. 4-14A. 
Almost no D6-cholesterol was detected in the feces of vehicle-treated mice (Fig. 4-14B and 
Fig. 4-14C). In contrast, large amounts of crystal-derived D6-cholesterol were excreted via 
the feces six hours after the first CD treatment of mice injected with D6‑CC-loaded WT 
BMDMs. This CD-mediated fecal excretion of crystal-derived D6-cholesterol, appeared to be 
LXR-dependent as only comparatively small amounts of D6-cholesterol were measured in the 
feces of CD-treated mice injected with D6‑CC-loaded LXRα-/-/LXRβ-/- BMDMs, and even this 
was only apparent 24 hours after the first CD treatment. 
Besides fecal cholesterol excretion, which is the conventional route of cholesterol excretion 
from the body132, urinary excretion of crystal-derived D6-cholesterol was also examined. This 
was done as CD is mainly secreted from the body via the urine91, and it was shown that 
cholesterol can exit the body in complex with CD molecules via the urine101. Indeed, the 
analysis of crystal-derived D6-cholesterol revealed the excretion via the urine upon CD 
treatment (Fig. 4-14D and Fig. 4-14E). Urinary excretion of crystal-derived D6-cholesterol 
from CD-treated mice injected with D6‑CC-loaded WT BMDMs peaked at approximately nine 
hours after the first CD injection and again at approximately 18 hours after the first CD 
injection (two hours after the second CD injection). Smaller amounts of crystal-derived  
D6-cholesterol were found in the urine of CD-treated mice injected with D6‑CC-loaded 
LXRα-/-/LXRβ-/- BMDMs. Here, D6-cholesterol was only excreted approximately 24 hours after 
the first CD injection (about six hours after the second CD injection). Similarly, very little  
D6-cholesterol was also detected in the urine of vehicle-treated mice injected with D6‑CC-
loaded LXRα-/-/LXRβ-/- BMDMs. For vehicle-treated animals injected with D6‑CC-loaded WT 
BMDMs almost no urinary excretion of crystal-derived D6-cholesterol was observed. 
In summary, this experiment showed that CD mediates the RCT of crystal-derived 
cholesterol from WT macrophages as well as subsequent excretion via both urine and feces. 
Some crystal-derived cholesterol was also removed from LXRα-/-/LXRβ-/- BMDMs upon CD 
treatment. However, RCT from these cells and subsequent excretion was considerably 
impaired, as less crystal-derived cholesterol was excreted and excretion was delayed. These 
findings indicated that CD-mediated RCT and excretion of crystal-derived cholesterol is at 
least partially dependent on LXR activation. 
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Figure 4-14: CD mediates RCT of crystal-derived cholesterol in vivo in a partially LXR-dependent 
manner. 
(A) Schematic of experimental setup for assessing RCT and excretion of crystal-derived cholesterol in vivo. 
BMDMs generated from WT and LXRα-/-/LXRβ-/- mice were loaded for 3 h with 100 µg D6-CC per 1x106 
cells. WT mice were intraperitoneally injected with 15x106 D6-CC-loaded BMDMs and subsequently treated 
with CD or vehicle control twice. The first treatment injection was given 30 min after application of the 
D6‑CC-loaded BMDMs, the second one was given 16 h later. Feces and urine were collected every 3-6 h 
over a 30 h period and analyzed for presence of crystal-derived D6‑cholesterol by GC-MS-SIM (performed 
by Prof. Dr. Dr. Dieter Lütjohann and colleagues). All animal work was carried out by Dr. Sebastian Zimmer 
and colleagues. Excretion kinetics of D6‑cholesterol in (B) feces presented as area under the curve (AUC) 
of D6‑cholesterol per mg feces and (D) urine presented as µg D6‑cholesterol per dl urine. Data are 
presented as individual replicates with lines connecting the means; WT = solid lines with circles, 
LXRα-/-/LXRβ-/- = dotted lines with squares, Vehicle = black, CD = grey. Dashed vertical line illustrates time 
of second treatment injection. Total D6‑cholesterol excreted via (C) feces and (E) urine. Data are shown as 
mean + SD of two replicates. 
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4.4 Role of cholesterol efflux transporters and LXR 
transcription factor activation in 2-hydroxypropyl-β-
cyclodextrin-mediated atherosclerosis protection 
The findings presented in the previous chapters led to the hypothesis that CD might exert its 
beneficial effects on murine atherosclerosis by dissolving plaque CCs and promoting the 
production of the endogenous LXR agonist 27-HC. Subsequent activation of LXR 
transcription factors would induce the expression of cholesterol efflux transporters and thus 
facilitate removal of cholesterol from the tissue and ultimately the whole body. The first 
evidence supporting this hypothesis was provided by Taqman RT-qPCR analysis of Abca1 
and Abcg1 gene expression in the descending aortas of the mice from the atherosclerosis 
prevention model, which was performed by Sebastian Zimmer and colleagues. This analysis 
revealed that Abca1 and Abcg1 expression was significantly increased in the aortic tissue of 
CD-treated animals compared to vehicle-treated animals (data not shown, Zimmer and 
Grebe et al., in press). 
To further test this hypothesis, it was investigated, whether LXR activation and subsequent 
induction of ABCA1 and ABCG1 expression contribute to the anti-atherogenic effects of CD 
treatment in murine atherosclerosis. Therefore, a bone marrow transplantation 
atherosclerosis model was performed in collaboration with Sebastian Zimmer and colleagues 
(see section 3.2.7). LDLR-/- mice were transplanted with WT, MAC-ABCDKO or 
LXRα-/-/LXRβ-/- bone marrow. Four weeks after transplantation the atherosclerosis study was 
initiated according to the protocol of the atherosclerosis prevention study presented in  
Fig. 4-2A. The mice received a HFHC diet for eight weeks accompanied by subcutaneous 
injections with CD or vehicle control twice a week (Fig. 4-15A). Atherosclerosis parameters 
were analyzed by confocal laser reflection and fluorescence microscopy of three to five aortic 
root cryosections. Two representative images of vehicle-treated (left) and CD-treated (right) 
mice per transplantation group are displayed in Fig. 4-15B. First, it was observed that the 
plaques of LDLR-/- mice fed a HFHC diet for eight weeks were not as pronounced and 
advanced as the plaques of equally treated ApoE-/- mice in the previous atherosclerosis 
studies (Fig. 4-2 and Fig. 4-3). However, this difference between these two mouse models of 
atherosclerosis is well described in the literature38. Nevertheless, the representative images 
demonstrate that atherosclerotic plaque size was visibly reduced upon CD treatment of mice 
transplanted with WT and MAC-ABCDKO, but not LXRα-/-/LXRβ-/- bone marrow. Quantitative 
image analysis confirmed this visual observation, as CD treatment resulted in significantly 
smaller atherosclerotic plaques in mice transplanted with WT and MAC-ABCDKO bone 
marrow, whereas plaque size of LXRα-/-/LXRβ-/- bone marrow-transplanted mice was 
unchanged by CD treatment (Fig. 4-15C). Analysis of CC plaque load did not reveal  
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Figure 4-15: The anti-atherogenic effects of CD are dependent on the presence of LXRs but not 
cholesterol efflux transporters. 
(A) Schematic of study protocol for bone marrow transplantation atherosclerosis model. LDLR-/- mice were 
transplanted with WT, MAC-ABCDKO or LXRα-/-/LXRβ-/- bone marrow. They received a HFHC diet for eight 
weeks accompanied by subcutaneous injections with CD or vehicle control twice a week (n numbers 
indicated for each group). All animal work was performed by Dr. Sebastian Zimmer and colleagues.  
(B-F) Serial aortic root sections were analyzed by confocal laser reflection and fluorescence microscopy. 
(B) Representative images of all study groups; Hoechst 34580 staining for nuclei (blue), CD68 staining for 
macrophages (red) and laser reflection signal for CCs (green). Scale bars indicate 250 µm.  
(C) Quantification of atherosclerotic plaque size depicted as plaque area as percentage of total vessel wall 
area. (D) Quantification of CC plaque load depicted as reflection area as percentage of plaque area.  
(E) Quantification of macrophage plaque load depicted as CD68 positive area as percentage of plaque 
area. (F) Quantification of plaque cellularity depicted as nuclei counts as percentage of plaque area. Data in 
(C-F) are shown as mean ± SEM of three to five individual sections per mouse. Significance was 
determined by unpaired two-tailed Student’s t-tests with Welch’s correction comparing Vehicle and CD per 
genotype (*** = p<0.001, ** = p<0.01, ns = not significant). 
significant changes between vehicle-treated and CD-treated mice (Fig. 4-15D). Nevertheless, 
a clear trend towards reduced amounts of CCs inside the plaques was observed in  
CD-treated mice transplanted with WT and MAC-ABCDKO bone marrow, whereas in 
LXRα-/-/LXRβ-/- bone marrow-transplanted mice CC plaque load rather increased upon CD 
treatment. In contrast to the observations from the ApoE-/- atherosclerosis models  
(Fig. 4-2 and Fig. 4-3), the amount of CD68-positive macrophages in the plaques  
(Fig. 4-15E) as well as overall plaque cellularity  (Fig. 4-15F) was almost unaffected by CD 
treatment in this LDLR-/- bone marrow transplantation atherosclerosis model. 
In summary, the results of the bone marrow transplantation atherosclerosis study indicated 
that CD treatment still impairs atherosclerosis development and progression in mice lacking 
macrophage ABCA1 and ABCG1, whereas this atheroprotective function is lost in the 
absence of LXR transcription factors in hematopoietic-derived cells. 
As for the other atherosclerosis mouse models, serum cholesterol levels of the mice were 
determined at the end of the study using gas chromatography-flame ionization detection. 
This analysis revealed that serum cholesterol levels differed between the individual 
transplant groups, but no changes were induced by CD treatment (Fig. 4-16A). Besides 
serum cholesterol levels, serum 27-HC levels were also measured. No significant changes 
were observed in WT bone marrow-transplanted LDLR-/- mice (Fig. 4-16B). However, serum 
27-HC was significantly increased upon CD treatment in MAC-ABCDKO-transplanted LDLR-/- 
mice, and an almost significant increase was also observed in LXRα-/-/LXRβ-/- bone marrow-
transplanted LDLR-/- mice. To determine whether CD treatment changed the distribution of 
cholesterol across the various lipoproteins, serum was fractionated by size exclusion 
chromatography followed by enzymatic cholesterol quantification (performed by the 
laboratory of Dr. Michael L. Fitzgerald (Center for Computational and Integrative Biology, 
Boston, MA, USA)). No significant changes in the lipoprotein profiles were observed in WT  
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Figure 4-16: CD treatment does not change serum cholesterol distribution on lipoproteins, but 
increases serum 27-HC levels in bone marrow transplantation atherosclerosis model. 
LDLR-/- mice transplanted with WT, MAC-ABCDKO or LXRα-/-/LXRβ-/- bone marrow received a HFHC diet for 
eight weeks accompanied by subcutaneous injections with CD or vehicle control twice a week. Serum  
(A) cholesterol and (B) 27-HC levels after eight weeks of atherogenic diet. Measurements were done using 
gas chromatography-flame ionization detection by Prof. Dr. Dr. Dieter Lütjohann and colleagues. Data are 
shown as mean ± SD. Significance was determined by unpaired two-tailed Student’s t-tests with Welch’s 
correction comparing Vehicle and CD per genotype (** = p<0.01, * = p<0.05, ns = not significant). (C) 
Serum was fractionated by size exclusion chromatography and cholesterol concentration of the fractions 
was quantified using an enzymatic assay (performed by Michael L. Fitzgerald and colleagues (Harvard 
Medical School, Boston MA, USA)). Results are presented as lipoprotein profiles (upper panels) and 
resultant cholesterol distribution on lipoproteins calculated from the lipoprotein profiles (lower panels). Data 
are shown as mean ± SEM of technical duplicates. Significance was determined by unpaired two-tailed 
Student’s t-tests with Welch’s correction comparing Vehicle and CD (* = p<0.05). 
and LXRα-/-/LXRβ-/- bone marrow-transplanted LDLR-/- mice comparing serum of CD- and 
vehicle-treated animals, while HDL cholesterol was significantly reduced following CD 
treatment of MAC-ABCDKO bone marrow-transplanted LDLR-/- mice (Fig. 4-16C). Together, 
these data confirmed the previous finding that CD treatment did not alter serum cholesterol 
levels and further suggested that lipoprotein profiles in the LDLR-/- atherosclerosis mouse 
model are also mostly unaffected by CD treatment. 
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Figure 4-17: NLRP3 inflammasome genes are negatively regulated by CD treatment in 
atherosclerotic aortic tissue in an LXR dependent manner.  
LDLR-/- mice transplanted with WT, MAC-ABCDKO or LXRα-/-/LXRβ-/- bone marrow received a HFHC diet for 
eight weeks accompanied by subcutaneous injections with CD or vehicle control twice a week. Array-based 
gene expression profiling of the descending aortas was performed by Prof. Dr. Joachim Schultze and 
colleagues. (n=6 per treatment group) (A) Enrichment score and significance level for NOD-like receptor 
signaling pathway (KEGG mmu04621) obtained from pathway enrichment analysis comparing CD vs. 
vehicle treatment. (B) Graphical representation of genes involved in NLRP3 inflammasome activation 
(extract of KEGG NOD-like receptor signaling reference pathway (KEGG mmu04621)). Colors indicate fold 
changes in gene expression in aortas of CD-treated versus vehicle-treated mice. 
Based on the in vitro observation that CD increased the production of the endogenous LXR 
agonist 27-HC, the potential effects of LXR transcription factor activation in atherosclerotic 
plaque tissue were investigated. For this, gene expression in descending aortas of the mice 
was analyzed by microarray (see sections 3.2.21 and 3.2.22). Pathway enrichment analysis 
of the differentially expressed genes in the aortas of CD-treated mice compared to aortas of 
vehicle-treated mice revealed a significant enrichment of genes in the NOD-like receptor 
signaling pathway (KEGG pathway mmu04621) (Fig. 4-17A). However, this enrichment was 
only observed in WT and MAC-ABCDKO bone marrow-transplanted LDLR-/- mice, but not in 
mice transplanted with LXRα-/-/LXRβ-/- bone marrow. A closer analysis of the individual genes 
in the NOD-like receptor-signaling pathway showed that genes involved in NLRP3 
inflammasome activation were negatively regulated by CD treatment in aortas of mice 
transplanted with WT and MAC-ABCDKO bone marrow (Fig. 4-17B). In particular, the genes 
encoding for NLRP3 inflammasome components NLRP3, ASC and caspase-1 as well as the 
pro-inflammatory inflammasome effector cytokines IL-1β and IL-18 were downregulated 
upon CD treatment. At the same time CD treatment induced the expression of SGT1 and 
HSP90, which are described to inhibit NLRP3 inflammasome function by retaining NLRP3 in 
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an inactive state32. All these genes were either much less or inversely regulated in aortas of 
LDLR-/- mice transplanted with LXRα-/-/LXRβ-/- bone marrow. This suggested that the 
activation of LXR transcription factors in hematopoietic-derived cells is required for the 
observed CD-mediated inhibitory gene expression changes of genes involved in NLRP3 
inflammasome activation. 
4.5 Effects of 2-hydroxypropyl-β-cyclodextrin treatment on 
cholesterol crystal-induced NLRP3 inflammasome 
activation 
The NLRP3 inflammasome was shown to play a critical role in murine atherosclerosis by 
contributing to the inflammatory response that drives disease progression24,85. LXR 
transcription factor activation is known to repress macrophage pro-inflammatory gene 
expression programs in general133,134, and interestingly, NLRP3 was found to be a primary 
LXR target gene in ChIP-sequencing analysis of human macrophages treated with a 
synthetic LXR agonist135. Therefore, based on the above observations that CD treatment 
downregulated NLRP3 inflammasome component expression in aortic plaque tissues in an 
LXR-dependent manner, the potentially LXR-dependent effects of CD on NLRP3 
inflammasome activation were investigated in vitro. 
All experiments assessing the effects of CD on the NLRP3 inflammasome were performed in 
immortalized WT BALB/c macrophages, as they respond much better to crystalline NLRP3 
stimuli than immortalized WT C57BL/6 macrophages. However, as all the previously 
performed in vitro experiments were done in immortalized or bone marrow-derived 
macrophages obtained from WT C57BL/6 mice, and as the ApoE-/- and LDLR-/- mice used for 
the atherosclerosis mouse models were also on a C57BL/6 background, the assays were 
also performed in BMDMs generated from bone marrow of WT C57BL/6 mice. 
As a first measure of CD effects on the NLRP3 inflammasome in macrophages, the basal 
and LPS-induced expression of NLRP3 inflammasome components was determined by WB 
analysis. Macrophages were pretreated with CD for 16 hours prior to LPS priming, which is 
characterized by induction of NLRP3 and pro-IL-1β expression. It was hypothesized that 
during this pretreatment period CD would augment the production of 27-HC to subsequently 
induce LXR-mediated gene expression. Pretreatment with the synthetic LXR agonist T09 
was used as a positive control for the effects of LXR transcription factor activation on NLRP3 
inflammasome priming and ABCA1 expression levels were assessed as control for LXR 
activation in response to T09. Indeed, an increase in ABCA1 expression was observed in 
T09-pretreated BALB/c iMOs (Fig. 4-18A) and BMDMs (Fig. 4-18B) regardless of the LPS 
treatment. In line with previous data presented in this thesis, CD treatment in the absence of  
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Figure 4-18: Priming of the NLRP3 inflammasome is not affected upon CD pretreatment in vitro. 
(A) BALB/c iMOs or (B) WT BMDMs were pretreated for 16 h with 10 mM CD, 10 µM T0901317 (T09) or 
medium control. Subsequently cells were primed for 3 h with 200 ng/ml LPS or left unprimed. ABCA1, 
NLRP3, pro-IL-1 β and ASC protein expression was analyzed by western blot. β-tubulin expression was 
used as loading control. Data are presented as representative blot and densitometry analyses for each 
protein graphed as mean + SD of four independent experiments. 
CC-loading did not increase ABCA1 protein expression, presumably due to simultaneous 
cholesterol depletion of the cells. Concerning NLRP3 priming, protein expression of the 
NLRP3 inflammasome components NLRP3, pro-IL-1β and ASC was determined. No major 
differences were observed between BALB/c iMOs (Fig. 4-18A) and BMDMs (Fig. 4-18B). 
LPS stimulation increased NLRP3 and pro-IL-1β expression, while ASC expression was 
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mainly unaffected. However, neither CD nor T09 pretreatment had an influence on basal 
expression of NLRP3 inflammasome components. Likewise, the LPS-induced upregulation of 
NLRP3 and pro-IL-1β expression was not influenced by macrophage pretreatment with CD 
or T09. These results indicated that neither basal expression of NLRP3 inflammasome 
components nor LPS-mediated NLRP3 inflammasome priming was affected by CD treatment 
and LXR activation in macrophages. 
In order to assess whether CD treatment nevertheless affects NLRP3 inflammasome 
activation with regard to the potential influence of CD-mediated production of endogenous 
LXR ligands, macrophages were pretreated with CD or T09 for 16 hours prior to  
 
 
Figure 4-19: NLRP3 inflammasome activation by crystalline stimuli is decreased following CD 
pretreatment of normocholesterolemic macrophages. 
(A) BALB/c iMOs or (B) WT BMDMs were pretreated for 16 h with 10 mM CD, 10 µM T0901317 (T09) or 
medium control. Subsequently cells were primed for 3 h with 200 ng/ml LPS prior to stimulation with various 
NLRP3 stimuli: 5 mM ATP or 10 µM nigericin for 1 h, 1 mM LeuLeu for 4 h, 0.5 mg/ml silica crystals or  
1.5 mg/ml CC for 6 h. Secretion of mIL-1β was determined by ELISA. Data are shown as mean + SEM of 
four independent experiments with duplicates. Significance was determined by paired one-way ANOVA 
comparing each sample with the unstimulated control (None) applying Dunnett's post test for multiple 
comparisons (** = p<0.01, * = p<0.05, ns = not significant). 
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LPS-induced NLRP3 inflammasome priming and subsequent stimulation with various 
NLRP3inflammasome ligands. Overall the results obtained from the two different cell types 
were pretty similar. The only major difference was observed with the LXR agonist T09, which 
showed no effects in BALB/c iMOs (Fig. 4-19A), whereas it did affect NLRP3 inflammasome 
activation by certain ligands in BMDMs (Fig. 4-19B). CD pretreatment significantly reduced 
IL-1β secretion in response to silica and cholesterol crystals. Additionally, the response to 
LeuLeu was also consistently diminished in CD-treated cells. However, due to great variation 
in the LeuLeu response of non-pretreated cells, this reduction in IL-1β secretion was not 
significant. In BMDMs, IL-1β secretion in response to LeuLeu and crystalline stimuli was 
additionally decreased upon pretreatment with T09. In contrast, responses to ATP and 
nigericin were mainly unaffected by both pretreatments. 
 
 
Figure 4-20: CD pretreatment has no effects on crystal uptake and subsequent lysosomal damage in 
normocholesterolemic macrophages. 
(A,C) BALB/c iMOs or (B,D) WT BMDMs were pretreated for 16 h with 10 mM CD or medium control and 
stained with 5 µg/ml acridine orange for 15 min. Cells were incubated for 6 h with indicated concentrations 
of H-Leu-Leu-Ome (LeuLeu), silica crystals (SC), CCs or medium control prior to analysis by flow 
cytometry. (A,B) Median of SSC signal as measure of cellular crystal uptake. (C,D) Loss of acridine orange 
fluorescence was determined as measure of lysosomal damage presented as percentage of the parent 
single cell population (see 3.2.20, Fig. 3-5). Data are shown as mean + SEM of six independent 
experiments with duplicates. 
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Significant inhibition of NLRP3 inflammasome activation by CD pretreatment was observed 
exclusively in response to crystalline stimuli. Therefore, it was speculated that CD might 
affect macrophage membranes by extraction of membrane cholesterol, which in turn might 
impair crystal uptake, a prerequisite for NLRP3 inflammasome activation. To test this 
hypothesis, macrophages were pretreated for 16 hours with CD or medium control and 
subsequently incubated with different amounts of cholesterol or silica crystals. Crystal uptake 
into the macrophages was quantified using flow cytometry by analyzing the side scatter 
(SSC) signal, which increases when cells become more granular. As such, the SSC signal 
increases upon uptake of crystalline material (see Fig 3-5C). Indeed, crystal uptake into 
BALB/c iMOs (Fig. 4-20A) and BMDMs (Fig. 4-20B) could be determined in a dose-
dependent manner, but was unaffected by CD pretreatment. 
Besides crystal uptake, cholesterol depletion from macrophage membranes could also 
impact intracellular membranes and therefore impair crystal-mediated lysosomal damage. 
According to current knowledge, lysosomal damage plays an important role in the activation 
of the NLRP3 inflammasome in response to crystalline stimuli31, but also in response to 
LeuLeu136. As CD pretreatment had an effect on both crystalline stimuli and LeuLeu, it was 
investigated whether CD might reduce NLRP3 inflammasome activation by affecting 
lysosomal damage. Lysosomal damage occurred in both BALB/c iMOs (Fig. 4-20C) and 
BMDMs (Fig. 4-20D) in response to the same ligand concentrations that activated the 
NLRP3 inflammasome (see Fig 4-19). However, no differences in lysosomal damage were 
observed upon CD pretreatment compared to medium control pretreatment. 
In summary, these data showed that NLRP3 inflammasome activation was reduced upon CD 
pretreatment (and in BMDMs also upon LXR agonist pretreatment) when macrophages were 
stimulated with LeuLeu or crystalline stimuli. However, LPS-induced NLRP3 priming, uptake 
of crystalline stimuli and lysosomal damage were not influenced by CD pretreatment of 
normocholesterolemic macrophages, suggesting that CD is mediating its inhibitory effects on 
NLRP3 inflammasome activation by an as yet undefined mechanism. 
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5 Discussion 
While elevated blood cholesterol levels have long been considered a risk factor for 
atherosclerosis, the pathogenic role of crystalline cholesterol, which accumulates in the 
arterial intima during atherogenesis, has only recently been identified. CCs potently induce 
innate inflammatory responses, and are considered responsible for the underlying vascular 
inflammation driving atherosclerosis development and progression. However, so far it has 
not been investigated whether decreasing the amount of CCs in atherosclerotic plaques is a 
valuable strategy for pharmaceutical intervention in atherosclerosis. Therefore, this study 
investigated the potential of the cholesterol solubilizing and mobilizing compound  
2-hydroxypropyl-β-cyclodextrin (CD) to remove vascular CCs and thereby prevent murine 
atherosclerosis development and progression. 
5.1 Cholesterol crystal deposition as therapeutic target in 
atherosclerosis 
This study aimed at evaluating the potential of CCs as primary treatment target, by means of 
removing the trigger of inflammation24,25 and plaque instability73,74, rather than directly 
manipulating CC-induced inflammation as is currently being investigated in several clinical 
trials42. Theoretically, therapeutically targeting CCs can be achieved by dissolving and 
thereby removing existing CCs from atherosclerotic plaques or by preventing the formation of 
CCs in the vessel wall. The first evidence that prevention of CC formation might reduce  
CC-mediated inflammation and be atheroprotective originated from the genetic deletion of 
the oxLDL uptake receptor CD36 in murine diet-induced atherosclerosis. This study 
demonstrated that intracellular cholesterol crystallization upon oxLDL uptake into 
macrophages is dependent on CD36118. In turn, mice lacking CD36 developed smaller 
atherosclerotic plaques with significantly less CC deposits, which was accompanied by 
reduced aortic and systemic inflammation (section 4.1.1)118. 
CD was then tested for its capacity to prevent CC formation and potentially mediate the 
dissolution and removal of CCs from atherosclerotic plaque tissue in vivo. Of note, CD 
treatment did not affect general parameters like body weight, arterial blood pressure and 
heart rate, excluding the possibility of unequal intake of the atherogenic diet or differences in 
the general health of the animals throughout the study. In the atherosclerosis prevention 
model (section 4.1.2), CD treatment was effective in impairing atherosclerosis development 
and the deposition of CCs during atherogenesis. This was accompanied by reduced local 
and systemic inflammation as determined by decreased numbers of inflammatory 
macrophages inside the plaque and lower levels of circulating cytokines. Moreover, CD 
treatment was also effective in mediating the regression of already established 
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atherosclerotic plaques (section 4.1.3). Simply switching from atherogenic to chow diet 
significantly reduced the amount of CCs in the plaques as compared to the pretreatment 
control. This diet-induced CC reduction could be directly correlated to a reduction of serum 
cholesterol levels upon diet change and indicates the reversibility of CC deposition in diet-
induced murine atherosclerotic plaques. However, the diet change did not reverse 
atherosclerotic plaque size. In contrast, CD treatment in both regression models (with or 
without diet change) reduced the amount of existing CCs in the plaques while also mediating 
a reduction in plaque size, even under continuous feeding of the atherogenic diet. 
Interestingly, although parenteral CD administration was previously described to transiently 
decrease serum cholesterol levels in animal models and humans93,101, in this study CD did 
not change overall serum cholesterol levels determined at the end of each atherosclerosis 
model. This indicates that CD does not reduce CC plaque loads by lowering blood 
cholesterol levels and thereby removing the trigger for vascular CC deposition. While the 
prevention model suggests that CC deposition is impaired upon CD treatment, the regression 
studies moreover indicate that CD also actively removes existing CCs from atherosclerotic 
plaques. This feature distinguishes CD from other pharmacological substances, which have 
been recently identified to also reduce CC formation, improve plaque stability and improve 
clinical outcomes in patients with CVD, such as statins76, ezetimibe137 and inhibitors of 
proprotein convertase subtilisin/kexin type 9 (PCSK9)138,139. All these substances lower 
serum cholesterol levels, in particular LDL cholesterol, thereby reducing cholesterol 
deposition in the vessel wall, resulting in a diminished pool of free cholesterol in the 
atherosclerotic plaque and thus preventing CC formation. 
Altogether these studies indicate that CCs represent a viable treatment target in 
atherosclerosis and that reducing the amount of CCs in atherosclerotic plaques by genetic or 
pharmacological means can indeed impede atherogenesis. CD in particular was able to both 
prevent vascular CC deposition and remove preexisting CCs from atherosclerotic plaque 
tissues, and was therefore effective in mediating atherosclerosis regression. 
Recently, the presence of CCs was also shown in nonalcoholic steatohepatitis (NASH), a 
chronic metabolic liver disease characterized by hepatic lipid accumulation (known as 
hepatic steatosis), inflammation and fibrosis, which can lead to cirrhosis, liver failure, and 
hepatocellular carcinoma. NASH shares several disease characteristics of atherosclerosis, 
such as dysregulated cholesterol homeostasis resulting in cholesterol accumulation, 
intracellular CC deposition and macrophage inflammation. In addition, a growing body of 
evidence suggests that NLRP3 inflammasome activation also contributes to NASH-related 
liver inflammation140,141. As in atherosclerosis, NASH can be induced by excess dietary 
cholesterol in animal models, and as such cholesterol-lowering therapies, such as statin 
treatment, were protective against steatosis, inflammation, and fibrosis in patients with 
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nonalcoholic fatty liver disease and NASH141. In this context, the dissolution of preexisting 
hepatic CCs was observed in mouse models of diet-induced NASH upon combinational 
treatment of statins and ezetimibe142. Furthermore, in a collaboration study, we have also 
demonstrated the potential of CD treatment to promote cholesterol transport from lysosomes 
to the cytoplasm and to prevent the accumulation of hepatic CCs in diet-induced NASH143. 
The livers of the mice from the atherosclerosis prevention model (section 4.1.2.) were also 
controlled for signs of hepatic toxicity, and CD treatment reduced common markers of liver 
damage and fibrosis which are commonly increased by HFHC feeding of ApoE-/- mice (data 
not shown, personal communication with Dr. Sebastian Zimmer). Consequently, 
pharmaceutical targeting of CCs might also represent a beneficial treatment approach for 
other cholesterol-related metabolic diseases in which CC deposition is observed. 
5.2 2-Hydroxypropyl-β-cyclodextrin and cholesterol crystals 
The ability of β-cyclodextrins to form inclusion complexes with cholesterol is well described in 
the literature89,99. CD, as a hydroxypropylated β-cyclodextrin derivative, has a slightly lower 
cholesterol affinity than its parent β-cyclodextrin, but due to its increased water solubility CD 
has a greater potential to bring cholesterol into aqueous solution89. While the solubilizing 
interaction between CD and cholesterol molecules is well described, this study demonstrated 
that CD also interacts with and binds to crystalline cholesterol. Moreover, CD dose-
dependently mediated the dissolution of CCs in an aqueous solution (Fig. 4-4). These 
findings indicate that CD can form inclusion complexes with the cholesterol molecules in 
CCs, thereby triggering the release of cholesterol molecules from the crystals, which are 
usually quite inert in aqueous environment. 
In atherosclerosis CCs accumulate within the atherosclerotic plaque tissue. They are 
abundantly present in the extracellular space, for example in the lipid-rich necrotic core 
region of advanced atherosclerotic plaques. However, intracellular CCs are also present, 
mainly inside plaque macrophages24,119, and the general consensus is that these intracellular 
CCs are either formed inside the cells in response to free cholesterol accumulation or 
acquired by phagocytosis of extracellular CCs144. Therefore, for CD to mediate the removal 
of existing CCs from atherosclerotic plaque tissue, which was observed in the 
atherosclerosis regression models (section 4.1.3), it must be able to enter the plaque tissue 
and possibly also intracellular compartments. Cyclodextrins generally have a poor ability to 
cross biological membranes91, however, this study found that CD was efficiently taken up into 
macrophages and the cellular distribution of the internalized CD (dotted perinuclear pattern) 
(Fig. 4-6A-C), indicated CD uptake via endocytotic pathways. Accordingly, a recent study 
showed the uptake of fluorescently labeled randomly methylated β-cyclodextrin into intestinal 
epithelial cells via macropinocytosis145. This suggests that CD might be taken up into the 
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macrophages by random pinocytosis. However, since macrophages express several surface 
receptors which recognize carbohydrates or glucose-modified proteins, such as CLRs and 
scavenger receptors, which mediate ligand uptake146,147, CD could also be taken up into 
macrophages via receptor-mediated phagocytosis. Regardless of which pathway CD utilizes 
to enter macrophages, the fact that CD is taken up into macrophages provides the basis for 
CD-mediated dissolution of intracellular CCs. It is also likely that CD, if it is taken up by one 
of these endocytic pathways, will end up in the same subcellular compartments as CCs, 
which are either taken up by phagocytosis or form in phagolysosomal compartments due to 
free cholesterol accumulation, for example upon phagocytic uptake of oxLDL or apoptotic 
bodies. Although colocalization of CD and phagocytozed CCs could not be examined in the 
presented experiments due to insufficient image resolution, CD did mediate the dissolution of 
phagocytozed, intracellular CCs (Fig. 4-6D-E) at concentrations that did not affect 
macrophage morphology (Fig. 4-6D) or viability (Fig. 4-5). Further evidence for the 
dissolution of intracellular CCs was obtained from studies using CCs prepared from stable 
isotope-labeled D6-cholesterol (section 4.2.2). These studies revealed increased efflux and 
enzymatic metabolism of crystal-derived D6-cholesterol upon CD treatment of D6-CC-loaded 
macrophages. Since CCs are quite inert, this is only possible after D6-cholesterol is released 
from the crystals. 
Consequently, this study demonstrates the potential of the cholesterol solubilizing substance 
CD to interact with and dissolve crystalline cholesterol. The dissolution is not restricted to 
extracellular CCs, but also applies to intracellular CCs that had been phagocytozed by 
macrophages. In addition, intracellular CC formation upon uptake of oxLDL via CD36 in 
macrophages was able to be reversed upon CD treatment118. In vivo, CD is known to 
accumulate in various tissues for a short time after administration prior to renal 
excretion91,106. This transient tissue accumulation might allow CD to mediate the dissolution 
and removal of preexisting CCs from atherosclerotic plaques. 
5.3 2-Hydroxypropyl-β-cyclodextrin-mediated modification of 
macrophage cholesterol homeostasis 
Excessive accumulation of intracellular free cholesterol is known to be toxic for cells57. The 
dissolution of intracellular CCs by CD would be expected to increase intracellular pool of free 
cholesterol to detrimental levels, but interestingly no considerable cytotoxic effect of CD 
incubation on CC-loaded macrophages was observed (Fig. 4-5B). This already indicated that 
the cells are able to eliminate and/or detoxify this crystal-derived cholesterol, which was 
confirmed by more detailed investigations into the metabolism and efflux of crystal-derived 
cholesterol. CD treatment resulted in the dissolution of stable isotope-labeled D6-CCs and 
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promoted the cellular efflux, storage and enzymatic metabolism to oxysterols of the crystal-
derived D6-cholesterol (section 4.2.2). 
The effects of CD on cholesterol efflux and metabolism have been extensively studied in 
NPC-/-cells and animal models. Here, it was demonstrated that CD overcomes the lysosomal 
cholesterol efflux defect of NPC-/-cells and thereby promotes cellular cholesterol metabolism, 
storage and efflux103-106. Liu et al. suggested that cholesterol, which is trapped in lysosomes 
of NPC-/- cells, becomes mobilized by CD for lysosomal escape and is thereby shifted into 
the cell’s metabolically active cholesterol pool. In turn, this liberated cholesterol is rapidly 
esterified for nontoxic cholesterol storage and eliminated from the cells and ultimately the 
whole body in NPC-/- mice105,106. This study suggests that CD mobilizes cholesterol in a 
similar manner in CC-loaded macrophages, where the sequestered pool of free cholesterol 
resulting from NPC-deficiency in NPC disease is instead represented by the naturally quite 
inert CCs. A summary of the hypothesized functions of CD on CC-loaded macrophages is 
given in Fig. 5-1 and will be discussed in detail in the following sections. 
5.3.1 CD-mediated cellular storage of crystal-derived cholesterol 
CD treatment of D6-CC-loaded macrophages induced the formation of lipid droplets and 
increased the amount of esterified D6-cholesterol, indicating the nontoxic intracellular storage 
of the liberated crystal-derived cholesterol in lipid droplets (Fig. 4-7). Similarly, a decrease in 
intracellular CCs along with increased cholesterol ester storage was also observed in the 
livers of CD-treated hyperlipidemic mice in a NASH model, which is similar to the 
atherosclerosis models presented in this study143. Furthermore, increased cholesterol ester 
storage was also observed upon CD treatment of hypercholesterolemic NPC-/- mice, in 
almost every organ except the lungs106. Together these data indicate that CD treatment also 
promotes nontoxic cholesterol storage in vivo. 
This CD-induced esterification is most likely to occur because CD liberates the crystal-
derived D6-cholesterol and promotes its intracellular movement to cellular compartments, 
such as the ER, where cholesterol can be enzymatically converted to its esters by ACAT for 
nontoxic storage in lipid droplets. CD treatment however also induced LXR target gene 
expression. One of these LXR target genes is Srebp-1c, which in turn activates the 
expression of Scd-1. Scd-1 catalyzes the production of oleoyl-CoA, which is the preferred 
substrate for ACAT-mediated cholesterol esterification63. Therefore, besides mobilizing 
crystal-derived D6-cholesterol to the metabolically active cholesterol pool, CD might also 
indirectly improve cholesterol ester storage by activating LXRs and subsequently promoting 
ACAT activity. 
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5.3.2 CD-mediated metabolism of crystal-derived cholesterol 
27-HC is a bioactive, oxygenated cholesterol metabolite and is a key regulator of cellular and 
systemic cholesterol homeostasis, for example by serving as an endogenous LXR ligand123 
and a substrate for bile acid synthesis in the liver66. Interestingly, some crystal-derived  
D5-27-HC was detected in D6-CC loaded macrophages alongside unlabeled 27-HC from 
endogenous cholesterol, even in the absence of CD (Fig. 4-9). This confirms earlier studies 
showing that macrophages themselves can at least partially degrade CCs, since crystal-
derived cholesterol is demonstrably integrated into macrophage cholesterol metabolism148. 
However, CD treatment significantly increased the production of 27-HC from both crystal-
derived and endogenous cellular cholesterol in macrophages (Fig. 4-9). No changes in 
mRNA and protein expression levels of cholesterol 27-hydroxylase (Cyp27a1), which is the 
enzyme catalyzing the hydroxylation of cholesterol at the 27-position were observed upon 
CD treatment of hypercholesterolemic macrophages. This observation is in line with earlier 
studies, which also found increased 27-HC production upon cholesterol loading of 
macrophages without changes in 27-hydroxylase expression149. Therefore, it is more likely 
that CD promotes 27-HC production in CC-loaded macrophages in two steps: Firstly,  
CD-mediated dissolution of CCs increases the intracellular pool of free cholesterol thereby 
providing more substrate for mitochondrial 27-hydroxylase. This hypothesis is supported by 
the strong increase in crystal-derived D5-27-HC following CD treatment. Secondly, similar to 
what is described for NPC disease106, CD treatment presumably increases the turnover of 
intracellular cholesterol pools, thereby promoting cholesterol trafficking to mitochondrial 
membranes where it can be enzymatically converted to 27-HC. The latter scenario could also 
explain the unexpected increase in 27-HC production upon CD treatment seen in 
normocholesterolemic macrophages, where CD also reduces the total amount of cellular 
cholesterol (Fig. 4-13). 
Intriguingly, the majority of the 27-HC was actually found in the cell culture supernatants. 
Since 27-hydroxylase is a mitochondrial enzyme122, 27-HC must be generated inside the 
macrophages and then subsequently effluxed from the cell. Rapid efflux of 27-HC from 
macrophages in the presence of a lipophilic cholesterol acceptor such as β-cyclodextrin or 
HDL has indeed been previously described150. Moreover, β-cyclodextrin was shown to 
desorb the more polar oxysterols from model membranes much faster than cholesterol151, 
indicating that CD might more efficiently deplete oxysterols from macrophages than 
cholesterol. This suggests that an increase in 27-HC production in CD-treated macrophages 
contributes to the depletion of cellular cholesterol pools. 
Furthermore, oxysterols themselves were also found to increase cholesterol solubility in vitro 
and even mediated the dissolution of subcutaneous cholesterol implants in rats, which are 
comparable to crystalline cholesterol in atherosclerotic plaques77,152. Therefore, the 
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production of 27-HC might also aid in dissolving intracellular CCs, which explains the 
capacity of macrophages to partially degrade CCs and suggests a positive feedback loop for 
CD-mediated macrophage cholesterol metabolism and efflux. 
The production of oxysterols upon CD treatment was also observed in NPC patients, and 
indeed plasma 24(S)-HC levels are often used as biomarkers for the effectiveness of 
intracerebroventricular and intrathecal CD treatment153. 24(S)-HC levels were also 
determined in this study and while 24(S)-HC showed a similar trend to 27-HC induction by 
CD, this was not significant. This is presumably because 24(S)-HC is mainly produced by 
neurons in the CNS67, while 27-HC is the major oxysterol produced in response to 
cholesterol loading in macrophages123, and therefore maybe the most relevant oxysterol in 
atherosclerosis. 
5.3.3 Transcriptional macrophage reprogramming by CD-mediated 
LXR activation 
A key finding of this study was that CD treatment significantly increased the production of 
27-HC in macrophages, which is known to activate LXR transcription factors123. LXR 
transcription factor activation is important for regulating cellular cholesterol homeostasis, 
mainly by regulating cholesterol efflux pathways130. In this context, the major LXR target 
genes include the cholesterol efflux transporters ABCA1 and ABCG1125-127. CC loading of 
macrophages increased gene and protein expression of both cholesterol efflux transporters, 
which was considerably increased upon CD treatment (Fig. 4-10). Both the CC-mediated and 
the CD-amplified increase in ABCA1 and ABCG1 expression was LXR-dependent  
(Fig. 4-11). Earlier studies demonstrated that cholesterol loading of macrophages induces 
ABCA1 and ABCG1 expression in a dose-dependent manner128,129, and that the cholesterol 
dose applied correlated with 27-HC production and LXR activation in these cells123. 
Therefore, by simply dissolving intracellular CCs and increasing the intracellular 
metabolically active pool of free cholesterol, CD most likely triggers increased 27-HC 
production, subsequent LXR activation and induction of cholesterol efflux pathways. In 
keeping with this model, LXR target gene expression was also observed upon CD treatment 
of NPC-/- mice105. 
Genome-wide gene expression analysis of CD-treated normocholesterolemic and CC-loaded 
macrophages revealed that CD treatment led to a significant enrichment of previously 
published LXR target gene sets114 compared to untreated macrophages. These data 
confirmed LXR activation upon CC loading and even stronger LXR activation upon CD 
treatment of CC loaded macrophages on a genome wide scale. Interestingly, this analysis 
also showed that LXR target gene expression was induced in CD-treated 
normocholesterolemic macrophages. This finding was unexpected as CD removed 
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cholesterol from normocholesterolemic macrophages and induced genes in the cholesterol 
biosynthesis pathway, which was also confirmed by an increase in cholesterol synthesis 
markers (Fig. 4-13), and, consistent with the idea of the cells restoring cholesterol 
homeostasis in response to depletion, a decrease in cholesterol efflux gene expression 
would have been expected. However, as observed with mass spec analysis, CD treatment of 
normocholesterolemic macrophages also increased 27-HC production, which might be 
sufficient to mediate the observed increase in LXR target gene expression. Furthermore, CD 
treatment of normocholesterolemic macrophages also increased intracellular levels of 
desmosterol, which is a cholesterol precursor that has also been described as a potent 
endogenous LXR agonist in macrophages154,155. In general, the data presented in this study 
indicate a direct link between increased 27-HC production and LXR activation in response to 
CD treatment. However, it cannot be excluded that CD treatment also induces the production 
of other endogenous LXR ligands, such as other naturally occurring oxysterols with proposed 
LXR agonistic function including 20(S)-HC, 22(R)-HC, 24(S)-HC, 25-HC and 24(S), 25-
epoxycholesterol154, which contribute to the LXR-mediated transcriptional macrophage 
reprogramming upon CD treatment. In macrophages, however, of the oxysterols that were 
measured, 27-HC was the only oxysterol that was significantly regulated by CD, therefore 
presumably it is mediating many of the effects observed in vitro in macrophages. 
5.3.4 CD-mediated efflux of crystal-derived cholesterol 
It is well described that CD promotes the efflux of cholesterol from macrophages and other 
cells99,102,131. This study demonstrated that CD also increases the efflux of crystal-derived  
D6-cholesterol from D6-CC-loaded macrophages, which can be significantly increased by the 
addition of a cholesterol acceptor (Fig. 4-8). 
CC-loaded macrophages appeared to readily efflux some of the crystal-derived  
D6-cholesterol in a time-dependent manner after replenishment of fresh medium, confirming 
that they have mechanisms for partially degrading crystalline cholesterol themselves, thus 
making it available for cellular cholesterol efflux mechanisms (and cholesterol metabolism, 
see section 5.3.2)25,148. Free cholesterol is usually eliminated from macrophages via the 
cholesterol efflux transporters ABCA1 and ABCG1, which transfer the free cholesterol to 
lipid-free ApoA1 and HDL particles, respectively156. Since ABCA1 and ABCG1 were both 
upregulated upon CC-loading of macrophages (Fig. 4-10) and the cell culture medium used 
for these experiments was supplemented with FCS containing lipoproteins including HDL, it 
is likely that the macrophages effluxed the liberated crystal-derived D6-cholesterol via these 
cholesterol efflux transporters. 
This basal macrophage efflux of crystal-derived D6-cholesterol was significantly increased 
after 24 hours of CD treatment, indicating a more rapid dissolution of the CCs followed by 
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increased elimination of free cholesterol from the cells. The greater elimination might be 
explained by the LXR-dependent upregulation of ABCA1 and ABCG1 expression following 
CD treatment of CC-loaded macrophages (Fig. 4-11, section 5.3.3.), which could therefore 
more efficiently remove the liberated crystal-derived cholesterol. Furthermore, at the 
concentration used in these experiments, CD is also expected to function as cholesterol 
acceptor100 and could therefore also increase the removal of crystal-derived cholesterol. CD 
has been proposed to mediate cellular cholesterol depletion by desorbing cholesterol from 
the plasma membrane and bringing it into aqueous solution by forming a 2:1 CD-cholesterol 
inclusion complex157,158. However, CD might also affect the overall distribution of intracellular 
cholesterol by promoting the movement of cholesterol from intracellular membranes to the 
plasma membrane99, similar to what has been suggested for NPC disease, where CD 
overcomes the cholesterol transport defect that prevents cholesterol transport from the 
endolysosomal compartment to other cellular membranes105. Therefore, a CD-mediated 
increase in intracellular cholesterol turnover might cause more rapid incorporation of the 
liberated crystal-derived cholesterol into the plasma membrane and therefore increase  
CD-mediated desorption of crystal-derived cholesterol from these membranes. 
Prolonged CD treatment (48 hours) did not result in a further decrease of intracellular  
D6-cholesterol, indicating that the maximum CD-mediated cholesterol efflux capacity was 
already reached after 24 hours. Given that cyclodextrin inclusion complexes are known to be 
in a dynamic equilibrium with the free cyclodextrin and guest molecules89, it is possible that 
after 24 hours there are not enough free cyclodextrin molecules left to form further inclusion 
complexes, impeding further CC dissolution and cholesterol desorption from the membranes. 
Moreover, since CD enhances the bidirectional cholesterol flux between cells and the 
extracellular environment100 and pre-formed cyclodextrin-cholesterol inclusion complexes can 
also be used to enrich cells with cholesterol99, the effluxed D6-cholesterol might even be 
returned to the cells again. Another possible explanation is that some of the crystal-derived 
D6-cholesterol, which was liberated by CD, might already be esterified at 48 hours (Fig. 4-7), 
and thus can’t be removed by ABCA1- and ABCG1-mediated cholesterol efflux without prior 
hydrolysis by CEH58,156. CD was shown to be effective in removing both free and esterified 
cholesterol from macrophage foam cells100,102, which most likely works by improving 
intracellular cholesterol turnover, thus increasing CEH-mediated hydrolysis of esterified 
cholesterol and its subsequent efflux or desorption. However, this only works in the presence 
free cyclodextrin molecules, which is a further indication that CD’s capacity to remove 
liberated crystal-derived cholesterol is reached after 24 hours at this concentration, 
promoting the esterification of liberated free D6-cholesterol for nontoxic intracellular 
cholesterol storage. Whether the addition or replenishment of fresh CD would induce further  
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Figure 5-1: Model of CD function on CC-loaded macrophages. 
CD promotes the dissolution of intracellular CCs, resulting in an increased cellular free cholesterol (FC) pool 
(1). Furthermore, CD increases the turnover of intracellular cholesterol pools, which leads to increases in 
cellular cholesterol storage, cholesterol metabolism, and “active” and “passive” cholesterol efflux. Liberated 
crystal-derived FC is esterified by ACAT in the ER resulting in subsequent nontoxic storage of cholesterol 
esters (CE) in cytoplasmic lipid droplets (2). Furthermore, FC is metabolized into oxysterols, e.g. 27-HC by 
mitochondrial 27-hydroxylase (3). 27-HC activates LXR-transcription factors resulting in transcriptional 
reprogramming of the macrophages (4). LXR activation mediates the repression of NF-κB-mediated 
inflammatory responses (5) and induction of cellular cholesterol efflux pathways, including the upregulation 
of cholesterol efflux transporters ABCA1 and ABCG1 (6). ABCA1 transfers cellular FC to lipid-poor ApoA1 
particles generating nascent HDL particles (7). Esterification of FC in HDL particles by LCAT generates 
mature HDL particles, which accept cellular FC from ABCG1 (7). Furthermore, CD can remove cellular FC 
and oxysterols by desorption from the plasma membrane, with subsequent formation of 2:1 inclusion 
complexes (CD as “cholesterol sink”) and transfer to cholesterol acceptors, such as HDL (CD as 
“cholesterol shuttle”) (8). 
removal of crystal-derived cholesterol as well as a reduction in cellular cholesterol ester 
pools has not yet been investigated. 
The addition of lipid-poor reconstituted HDL (rHDL) particles significantly improved the 
crystal-derived D6-cholesterol efflux mediated by CD (Fig. 4-8). rHDL itself was shown to 
mediate the depletion of cellular cholesterol121 and indeed significantly removed unlabeled 
endogenous cholesterol from D6-CC loaded macrophages. However, rHDL alone was not 
able to mediate the depletion of crystal-derived D6-cholesterol, demonstrating that the 
presence of CD was required for the improved removal of crystal-derived D6-cholesterol, 
potentially by dissolving the crystals and making the liberated free cholesterol available for 
subsequent cellular cholesterol efflux mechanisms. In this setting rHDL most likely functioned 
as an extracellular cholesterol acceptor for ABCA1- and ABCG1-mediated active cholesterol 
efflux, but also for cyclodextrin-mediated cholesterol depletion according to the “shuttle/sink 
model” proposed by Atger et al. (Fig. 2-7)100. In this model, CD supposedly transfers 
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cholesterol molecules desorbed from the plasma membranes to lipid-poor rHDL particles and 
therefore functions as shuttle between the cells and the cholesterol acceptors (where the 
lipid-poor rHDL is the “sink”). 
In summary, this study indicated that CD might improve the removal of crystal-derived 
cholesterol from macrophages by several mechanisms (Fig. 5-1). CD enhances CC 
dissolution and potentially mobilizes intracellular crystal-derived cholesterol for active cellular 
cholesterol efflux via ABCA1 and ABCG1, but also for direct CD-mediated desorption from 
the plasma membranes and potential shuttling of cellular cholesterol to lipoproteins 
(extracellular cholesterol acceptors/ “sinks”). Moreover, increased oxysterol production by 
CD, subsequent LXR transcription factor activation and transcriptional upregulation of 
cholesterol efflux transporters might indirectly contribute to the improved removal of crystal-
derived cholesterol from macrophages upon CD treatment. 
5.4 RCT and alternative cholesterol excretion by 2-
hydroxypropyl-β-cyclodextrin 
Besides promoting macrophage efflux of crystal-derived cholesterol in vitro, CD also enabled 
the RCT of crystal-derived D6-cholesterol from D6-CC-loaded macrophages in vivo in a 
partially LXR-dependent manner (section 4.3.4). Macrophage cholesterol efflux is the first 
step of RCT, and is therefore a crucial event for the elimination of cholesterol from the 
body60. Since CD is excreted from the body via the urine89, and co-secretion of cholesterol 
with CD was observed in in animal models101 and also upon intravenous CD treatment of 
NPC patients (Zimmer and Grebe et al., in press), the commonly used macrophage-to-feces 
approach for assessing RCT was extended to include a macrophage-to-urine analysis. 
Indeed, CD treatment of mice injected with D6-CC-loaded WT macrophages induced the 
rapid elimination of crystal-derived D6-cholesterol from the body via both biliary and renal 
excretion. 
CD treatment increases the efficiency of cholesterol elimination from the body by providing 
an alternative pathway for cholesterol excretion into the urine in addition to HDL-mediated 
RCT to the liver for subsequent fecal excretion. Therefore, according to the “shuttle/sink 
model” proposed for CD-mediated cholesterol efflux in vitro (Fig. 2-7)100, CD facilitates 
macrophage cholesterol efflux and serves as cholesterol “shuttle” between cells and serum 
lipoproteins for biliary cholesterol excretion, while also serving as “sink” for directly removing 
cholesterol complexed to CD by renal excretion. 
CD-mediated excretion of crystal-derived cholesterol into both the feces and the urine was 
delayed and compromised in the in vivo RCT experiment with LXR-deficient macrophages. 
This indicates that the rapid RCT and elimination of crystal-derived cholesterol by CD is 
dependent on LXR transcription factor activation, presumably by LXR-mediated regulation of 
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cholesterol efflux pathways, including the upregulation of ABCA1 and ABCG1 expression. 
However, since the excretion of crystal-derived cholesterol is so quick (within 6-9 hours after 
CD treatment), it is most likely mediated by the LXR-dependent upregulation of the 
cholesterol efflux transporters in response to CC loading of the macrophages, rather than the 
secondary LXR-dependent increase in ABCA1 and ABCG1 expression upon CD treatment of 
CC-loaded macrophages (Fig. 4-11). Therefore, the LXR-dependency of this process is most 
likely independent of CD treatment. Nevertheless, since no fecal or urinary D6-cholesterol 
was detected in vehicle treated animals, CD treatment is definitely required for the RCT and 
excretion of crystal-derived cholesterol, where it presumably mediates intracellular CC 
dissolution and thereby enabling the efflux of the liberated crystal-derived cholesterol. 
5.5 Atheroprotective effects of 2-hydroxypropyl-β-cyclodextrin 
Chronic subcutaneous CD treatment was found to be atheroprotective in two different 
models of murine diet-induced atherosclerosis (sections 4.1.2 and 4.4). Analysis of CD 
treatment of hypercholesterolemic, CC loaded macrophages indicated that CD treatment 
might be atheroprotective by dissolving CCs, thus increasing macrophage cholesterol 
metabolism and production of endogenous LXR agonists, such as 27-HC, and thereby 
promoting macrophage cholesterol efflux and subsequent RCT (sections 4.2 and 4.3). 
However, these mechanistic data only provide insight into the effects of CD on 
hypercholesterolemic macrophages, which represent an important cell type of atherosclerotic 
plaques, but do not reflect the in vivo situation, where CD affects the whole body, including 
various organs and tissues with mixed cell populations. Therefore, the bone marrow 
transplantation atherosclerosis model was performed to evaluate whether CD’s 
atheroprotective effects in vivo were primarily due to changes in the cholesterol metabolism 
of macrophage foam cells. This model revealed that the cholesterol efflux transporters 
ABCA1 and ABCG1 were dispensable for CD-mediated atheroprotectivity, while the 
presence of LXR transcription factors in hematopoietic-derived cells was essentially required. 
However, CD-mediated atheroprotection is most likely multifactorial and not solely dependent 
on either LXR activation or enhanced RCT alone. 
5.5.1 Importance of CC dissolution for CD-mediated atheroprotection 
As discussed in section 5.1, prevention of vascular CC deposition as well as the 
pharmacological reduction of already existing plaque CCs was found to impede 
atherogenesis. Since CD-mediated atheroprotection was always associated with a reduction 
in plaque CC loads throughout this study, it is likely that the dissolution and removal of 
plaque CCs is one of the mechanisms involved in CD-mediated atheroprotectivity. Moreover, 
CD treatment either had no effect or even increased CC quantities in atherosclerotic plaques 
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of LDLR-/- mice transplanted with LXRα-/-/LXRβ-/- bone marrow, and in these mice CD was 
also not atheroprotective. 
Since LXR transcription factors are involved in the regulation of cholesterol efflux pathways, 
including ABCA1 and ABCG1 cholesterol efflux transporters130, and given the defect in  
CD-mediated RCT from LXRα-/-/LXRβ-/- macrophages, a plausible explanation would be that 
the LXR transcription factor absence impairs ABCA1- and ABCG1-mediated macrophage 
cholesterol efflux and therefore cholesterol removal from the atherosclerotic plaque tissue. 
However, CD treatment efficiently reduced the amounts of CCs in LDLR-/- mice transplanted 
with bone marrow of MAC-ABCDKO mice, which supposedly have a defect in macrophage 
cholesterol efflux. This indicates that CD can dissolve plaque CCs and subsequently remove 
the crystal-derived cholesterol independently of the cholesterol efflux transporters ABCA1 
and ABCG1. It also indicates that other LXR-mediated processes, beyond ABCA1- and 
ABCG1-mediated cholesterol efflux, such as the suppression of cholesterol biosynthesis 
under conditions of high cellular cholesterol61, might be more important in this context, 
especially since CD treatment of LXRα-/-/LXRβ-/- bone marrow transplanted mice even 
slightly increased CC plaque loads. This increase could be explained by the following 
scenario: CD treatment results in the dissolution of plaque CCs, resulting in increased 
amounts of free cholesterol, which cannot be efficiently removed and detoxified due to the 
lack of LXR transcription factors. Moreover, without LXR-mediated repression of cellular 
cholesterol biosynthesis, CD treatment might even further increase the cellular pool of free 
cholesterol. Subsequent cell death and increased inflammation might also promote the build-
up of free cholesterol in the plaques and consequently favor cholesterol (re)crystallization. 
The findings of the bone marrow transplantation model suggested a direct link between the 
amount of plaque CCs and atherosclerosis progression, and indicated that the CD-mediated 
dissolution and removal of plaque CCs might contribute to its atheroprotectivity. Plaque CC 
dissolution in atherosclerosis might be important to mobilize this inert pool of free cholesterol 
for increased metabolism and efflux from plaque tissue, similar to the proposed effects of CD 
in NPC disease106. However, this study does not prove the requirement of CD-mediated CC 
dissolution for its atheroprotective effects. 
5.5.2 CD-mediated 27-HC production and atheroprotection 
The observation that CD treatment significantly induced 27-HC production in CC-loaded 
macrophages (Fig. 4-9), was the impetus to investigate whether LXR transcription factors 
were also activated in this system. That CD treatment might also promote the production of 
the endogenous LXR agonist 27-HC in murine atherosclerosis in vivo was inferred from the 
bone marrow transplantation atherosclerosis model (Fig. 4-16), where LXR transcription 
factor activation was required for CD-mediated atheroprotectivity, and increased serum 
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levels of 27-HC upon CD treatment were observed. Significantly increased serum 27-HC 
levels were only observed in LDLR-/- mice reconstituted with MAC-ABCDKO and 
LXRα-/-/LXRβ-/- bone marrow (almost significant), but not in LDLR-/- mice transplanted with 
WT bone marrow. This could be explained by impaired macrophage cholesterol efflux due to 
ABCA1/ABCG1- and LXRα/LXRβ-deficiency of the hematopoietic derived cells, which might 
cause increased cellular cholesterol levels compared to WT cells, which consequently 
provides more substrate for the enzymatic conversion to 27-HC. This could also explain the 
lack of increased 27-HC serum levels upon CD treatment in the first atherosclerosis mouse 
models. 
While increased amounts of 27-HC are suggested be atheroprotective by activating LXR 
transcription factors and subsequent anti-atherogenic gene expression programs, a recent 
study suggested pro-atherogenic activities of 27-HC. 27-HC was recently identified to be an 
endogenous selective estrogen receptor modulator159 and as such 27-HC was found to 
promote pro-inflammatory processes via estrogen receptor α and thus inhibiting estrogen-
related atheroprotection160. These results were obtained from Cyp7b1-/- mice, where 27-HC 
accumulates because it cannot be further metabolized to 7α-hydroxycholesterol, a precursor 
of bile acid synthesis. Conversely, in Cyp7b1 competent animals, such as those used in our 
study, increased amounts of 27-HC could theoretically be efficiently converted to  
7α-hydroxycholesterol, and therefore promote bile acid synthesis and cholesterol removal via 
biliary excretion. Consequently, it is likely that prolonged accumulation of 27-HC is  
pro-atherogenic by activating estrogen receptors, while moderately or transiently increased 
27-HC might be anti-atherogenic via the activation of atheroprotective LXR transcriptional 
programs and an increase in bile acid synthesis and excretion. To properly evaluate whether 
increased 27-HC production is integral to the mechanism of CD-induced LXR-mediated 
atheroprotection, the effectiveness of CD treatment would need to be assessed in an 
atherosclerosis model with Cyp27a1 knockout mice or bone marrow chimeras. However, 
Cyp27a1-/-/ApoE-/- mice, which do not produce any 27-HC, already show decreased 
atherosclerosis development, which is supposedly due to changes in lipoprotein profiles, with 
decreased LDL/VLDL cholesterol and increased HDL cholesterol, as well as compensatory 
mechanisms such as increased Cyp7a1-mediated conversion of cholesterol to  
7α-hydroxycholesterol161. In contrast, heterozygous Cyp27a1+/-/ApoE-/- mice develop more 
severe atherosclerotic lesions, which is assumed to be caused by decreased production of 
27-HC and missing compensatory mechanisms resulting in impaired cholesterol efflux from 
plaque macrophages161. Therefore, the role of Cyp27a1 in atherogenesis is not fully 
understood and seems to be quite complex due to different functions of Cyp27a1 in hepatic 
and extrahepatic cells. Maybe a bone marrow transplantation model with Cyp27a1-/- donor 
bone marrow might overcome this complexity, as only hematopoietic derived cells would 
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carry the Cyp27a1 deficiency. Therefore, if 27-HC is crucially involved in CD-mediated LXR 
activation in vivo, these mice should show the same CD treatment phenotype than 
LDLR-/- mice transplanted with LXRα-/-/LXRβ-/- bone marrow. Furthermore, as already 
discussed in section 5.3.3, 27-HC was the only significantly induced endogenous LXR 
agonist analyzed in this study, but it cannot be excluded that CD induces the production of 
other sterol-based endogenous LXR agonists in vivo. Therefore, it is possible that other  
CD-induced endogenous LXR agonists might compensate for a lack in 27-HC or might 
generally be more important than 27-HC, or alternatively, that several CD-induced 
endogenous LXR agonists act in concert to mediate the atheroprotective LXR transcription 
factor activation in response to CD treatment. 
5.5.3 Potential mechanisms of LXR-mediated atheroprotection 
Mice lacking LXR transcription factors develop enhanced atherosclerosis, suggesting a 
protective role for these transcription factors, and complementary to this, administration of 
synthetic LXR agonists was shown to be atheroprotective in mice116,124,162. The 
atheroprotective effects of LXR agonists have been attributed to the two main functions of 
LXR transcription factors: upregulation of genes involved in macrophage cholesterol efflux 
such as ABCA1 and ABCG1 and the subsequent regulation of RCT116,163 and suppression of 
inflammation via transrepression of NF-κB target genes164. 
CD activated LXR transcription factors in hypercholesterolemic macrophages in vitro  
(section 4.3), and promoted macrophage cholesterol efflux (Fig. 4-8) as well as RCT of 
crystal-derived cholesterol from macrophages in a partially LXR-dependent manner  
(Fig. 4-14). Moreover, CD treatment mediated the upregulation of cholesterol efflux 
transporter ABCA1 and ABCG1 expression in aortic tissue of CD-treated animals (Zimmer 
and Grebe et al., in press). Although, these results indicated that CD might be 
atheroprotective by LXR-mediated upregulation of the cholesterol efflux transporters ABCA1 
and ABCG1 in macrophages, which are important for macrophage cholesterol efflux and 
subsequent RCT165, CD was still atheroprotective in LDLR-/- mice transplanted with  
MAC-ABCDKO bone marrow. Nevertheless, LXR transcription factor activation in 
hematopoietic-derived cells was required for CD-mediated atheroprotection, indicating that 
LXR-mediated processes other than the upregulation of macrophage cholesterol efflux and 
RCT might be responsible for CD-mediated atheroprotection. This is in line with current 
literature demonstrating that synthetic LXR agonist treatment is atheroprotective in 
LDLR-/- mice transplanted with MAC-ABCDKO bone marrow, which suggests a key role for the 
LXR-mediated anti-inflammatory effects in atheroprotection166. However, this study with 
synthetic LXR agonists did not definitively prove that LXR activation induces anti-
inflammatory pathways in vivo, rather only reported a reduction of inflammatory cells 
Discussion 
 
 110 
(macrophages) in the atherosclerotic plaques of LXR agonist-treated mice. In addition to 
reducing macrophage plaque loads in the ApoE-/- mouse models CD treatment also 
decreased circulating pro-inflammatory cytokine levels (section 4.1.2, Zimmer and Grebe et 
al., in press). However, this decrease in macrophage plaque loads was not observed upon 
CD treatment of the LDLR-/- mice in the bone marrow transplantation atherosclerosis models 
(Fig. 4-15), probably because of the less advanced atherosclerotic plaques in the latter 
mouse model. Nevertheless, gene expression analysis of the aortic tissue of these mice 
revealed that CD treatment induced inhibitory gene expression changes of genes involved in 
NLRP3 inflammasome activation in vivo, which was dependent on LXR transcription factor 
activation in hematopoietic-derived cells (Fig. 4-17). In particular, CD treatment 
downregulated genes encoding for the NLRP3 inflammasome components NLRP3, ASC and 
caspase-1 as well as the pro-inflammatory inflammasome effector cytokines IL-1β and IL-18, 
while upregulating SGT1 and HSP90, which have been described as inhibitors of NLRP3 
inflammasome function. Similar, but even stronger inhibitory effects of CD treatment on 
genes involved in NLRP3 inflammasome activation were also observed in ex vivo cultures of 
human atherosclerotic plaque tissue (Zimmer and Grebe et al., in press). Indeed, NLRP3 and 
HSP90 have both been identified as LXR target genes by ChIP sequencing analysis of 
human macrophages treated with a synthetic LXR agonist135. Furthermore, NLRP3 
expression is upregulated in response to NF-κB transcription factor activation28, which is 
inhibited by transrepression mechanisms of activated LXRs164. This data indicated that CD 
might be atheroprotective by LXR-dependent inhibition of NLRP3 inflammasome activation in 
atherosclerotic plaque tissue, which would in turn decrease CC-mediated pro-atherogenic 
inflammatory responses. 
The effect of CD treatment and potential subsequent LXR activation on NLRP3 
inflammasome activation, in particular in response to CCs, was assessed in vitro in murine 
macrophages (section 4.5). In contrast to the genetic changes in in vivo-treated murine or  
ex vivo-treated human atherosclerotic plaque tissue, CD treatment of normocholesterolemic 
macrophages did not affect basal or LPS-induced protein expression of NLRP3 
inflammasome components, but neither did LXR agonist treatment (Fig. 4-18). However, 
NLRP3 was identified as an LXR target gene in human macrophages135, but currently there 
is no evidence in the literature that NLRP3 is an LXR target gene in murine macrophages. 
Nevertheless, NLRP3 inflammasome activation by LeuLeu or crystalline stimuli was reduced 
upon both CD pretreatment and LXR agonist pretreatment (Fig. 4-19), indicating that LXR 
activation might be important for this inhibition. Furthermore, this finding suggested that CD 
treatment and LXR activation might affect the uptake of crystalline material or subsequent 
lysosomal damage, which is hypothesized to be part of the NLRP3 inflammasome activation 
mechanism in response to these ligands (see section 2.1.3.2)28, but neither of these 
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mechanisms were influenced by CD treatment in this experimental setup (Fig. 4-20). 
Therefore, these data suggest that CD treatment can indeed inhibit CC-mediated NLRP3 
inflammasome activation in macrophages by an as yet undefined mechanism. This 
unidentified mechanism is possibly mediated by CD-induced LXR activation, since the same 
NLRP3 inflammasome inhibition was observed in response to LXR agonist treatment. In 
conclusion, the gene expression analysis of human and murine aortic plaque tissue as well 
as the in vitro data on macrophage NLRP3 inflammasome activation indicate that CD inhibits 
NLRP3 inflammasome activation in an LXR-dependent manner and that this might contribute 
to CD’s atheroprotective effects by decreasing CC-mediated pro-atherogenic inflammatory 
responses in atherosclerotic plaques. 
Another potential mechanism of LXR-mediated atheroprotection is the regulation of 
efferocytosis. Upon phagocytic uptake of apoptotic cells, LXR transcription factors become 
activated, presumably in response to intracellular cholesterol accumulation  
(section 2.2.5.4)61. While LXR activation upregulates the expression of the TAM receptor 
tyrosine kinase Mer, which has a crucial role in phagocytosis and therefore promotes 
apoptotic cell clearance, LXR activation can also simultaneously suppress inflammatory 
pathways that might be induced by phagocytozed apoptotic cells167. Consequently,  
LXR-deficient macrophages also have a defect in phagocytosis of apoptotic cells and induce 
abnormal pro-inflammatory responses. Effective phagocytic clearance of apoptotic cells by 
macrophages without activation of inflammatory responses is important for keeping immune 
homeostasis and defective efferocytosis is thought to promote atherosclerosis plaque 
development and formation of a lipid-rich necrotic core35. Therefore, activation of LXR 
transcription factors upon CD treatment might also be atheroprotective by promoting effective 
efferocytosis and thereby inhibiting atherosclerosis plaque development. 
Of note, CD treatment did not only prevent the development and progression of murine 
atherosclerosis, but was also effective in mediating the regression of already established 
atherosclerotic plaques (section 4.1.3). This might be the most important feature of  
CD-mediated atheroprotection for human disease, because atherosclerosis patients are 
usually only diagnosed in advanced disease stages with established atherosclerotic plaques. 
LXR activation was also implicated in mediating the regression of already established 
atherosclerotic plaques by inducing the expression of chemokine receptor CCR7, which 
promotes maximal egress of monocyte-derived cells from murine aortic plaques168,169. 
Although the gene expression data of the aortas from the bone marrow transplantation model 
did not show any significant upregulation of CCR7 by CD treatment, this may be because 
whole aortic tissue was analyzed, while the published studies analyzed monocyte-derived 
cell populations isolated from atherosclerotic plaques by laser capture microscopy. The 
slightly decreased amounts of plaque macrophages in the regression models however 
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indicate a potential involvement of LXR-mediated monocyte-derived cell egress. Moreover, 
CD treatment in vitro strongly increased the expression of CCR7 induction in bone marrow 
derived DCs and also slightly in BMDMs, which correlated with LXRα expression levels (data 
not shown, results from single preliminary experiment). These data indicate that  
LXR-dependent, CCR7-mediated egress of monocyte-derived cells might be important for 
atherosclerosis regression upon CD treatment and might therefore also contribute to the 
LXR-dependent atheroprotective effects of CD. 
5.5.4 Indications of atherogenic adaptive immune response inhibition 
by β-cyclodextrin derivatives 
The data presented in this thesis suggest that there is significant therapeutic potential in 
cholesterol solubilizing β-cyclodextrins, in particular CD, for the treatment of atherosclerosis. 
This was confirmed by a study published last year, which demonstrated the atheroprotective 
effects of KLEPTOSE® CRYSMEB (Roquette, France) treatment in diet-induced 
atherosclerosis in ApoE-/- mice170. Unlike CD (hydroxypropylated β-cyclodextrin), 
KLEPTOSE® CRYSMEB is a patented low methylated β-cyclodextrin developed for 
pharmaceutical formulations, which (similar to CD) possesses improved safety compared to 
highly methylated β-cyclodextrins*. 
Similar to CD, methyl β-cyclodextrin was found to decrease atherosclerotic plaque size 
without changing total serum cholesterol levels. However, Montecucco et al. observed that 
methyl β-cyclodextrin treatment increased HDL cholesterol levels in ApoE-/- mice, and 
suggested that improving the serum lipoprotein profile contributes to the atheroprotective 
effects of methyl β-cyclodextrin. In contrast, CD treatment did not induce any changes HDL 
cholesterol levels in LDLR-/- mice (Fig. 4-16). This discrepancy is most likely due to the 
different mouse models used, which possess different lipoprotein profiles. The lipoprotein 
profile of the LDLR-/- mouse model most closely resembles that of dyslipidemic humans36 and 
might therefore be more relevant with regard to human disease. Moreover, these 
discrepancies might be due the different types of modified β-cyclodextrin as well as 
differences in treatment time and dosage. However, as CD was protective in the  
LDLR-/-model without modulation of serum lipoprotein profiles, this suggests that the increase 
in HDL seen with methyl β-cyclodextrin might be negligible for its atheroprotectivity. 
Montecucco et al. observed reduced plaque T lymphocyte numbers and a reduction in 
genetic markers for type 1 T helper cell (Th1)-mediated immune responses. Their data 
indicated that methyl β-cyclodextrin reduced proliferation of CD4-positive Th1 cells and 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
* ROQUETTE website: http://www.roquette-pharma.com/crysmeb-beta-cyclodextrin-pharmaceutical-
excipient-injectable-dosage-forms/ - 19th March, 2016, 5:08 pm 
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subsequent IFNγ production. IFNγ exerts various pro-atherogenic effects, which promote 
plaque development and contribute to plaque destabilization171, and IFNγ-producing Th1 
cells are therefore considered main drivers of disease progression44. Consequently they 
concluded that methyl β-cyclodextrin is atheroprotective by reducing adaptive Th1-mediated 
immune responses170. 
The work presented in this thesis was focused on the effects of cholesterol solubilizing CD 
on plaque CCs and subsequent CC-mediated innate immune responses elicited by plaque 
macrophages. The detailed analysis of macrophage cholesterol metabolism indicated that 
LXR transcription factor activation was important for CD’s atheroprotective effects  
(section 4.2.2 and 4.3), and this was confirmed in vivo in the bone marrow transplantation 
atherosclerosis mouse models (section 4.4), which suggests that hematopoietic LXR 
transcription factor activation is required for CD’s atheroprotectivity. Interestingly, LXR 
activation was shown to inhibit Th1-type pro-inflammatory cytokine expression in human 
CD4-positive lymphocytes172, indicating that methyl β-cyclodextrin might reduce  
Th1-mediated immune responses by activating LXR-mediated transcriptional programs. 
Conversely, reduced adaptive Th1-mediated immune responses resulting from LXR 
activation might also contribute to CD’s atheroprotectivitiy. Moreover, the pro-atherogenic 
character of IL-18171, which is the major cytokine promoting Th1 differentiation and 
subsequent IFNγ production44, is a pro-inflammatory IL-1β family cytokine produced upon 
CC-mediated NLRP3 inflammasome activation24. This might represent another connection 
between the findings on the atheroprotective effects of CD in this study and methyl  
β-cyclodextrin in the study of Montecucco and colleagues respectively. Both the CD-
mediated reduction in plaque CCs (Fig. 4-2 and Fig. 4-15) and the LXR-dependent 
transcriptional deactivation of the NLRP3 inflammasome (Fig. 4-17) might decrease CC-
mediated inflammasome activation and subsequent IL-18 production, Th1 differentiation and 
adaptive Th1-mediated immune responses. 
Combining the findings of the presented study and the study of Montecucco and colleagues, 
β-cyclodextrin-mediated atheroprotective effects might be triggered by plaque CC 
dissolution, increased production of endogenous LXR agonists and subsequent activation of 
LXR-mediated transcriptional programs, which might improve aortic cholesterol homeostasis 
and suppress both innate and adaptive inflammatory responses. 
5.6 Potential clinical application of 2-hydroxypropyl-β-
cyclodextrin for treatment of atherosclerosis 
Atherosclerosis treatment currently relies on pharmacological lowering of blood LDL 
cholesterol levels to decelerate disease progression and surgical intervention to bypass 
narrowed arteries or remove atherosclerotic plaque tissue33. However, no appropriate 
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pharmacological treatment for mediating atherosclerotic plaque regression is currently 
available, although evidence for the possibility of atherosclerosis plaque regression in 
humans, for example by long-term high-dose statin treatment, has accumulated over the last 
years173. Current studies on human plaque regression suggest that regression requires large 
reductions in LDL cholesterol levels and concurrent great enhancements in HDL function in 
RCT173. The work in this thesis identified that CD treatment prevented the development and 
progression of murine atherosclerosis, but also effectively mediated the regression of already 
established murine atherosclerotic plaques (section 4.1.3). Although CD treatment in mice 
did not alter serum cholesterol levels and serum lipoprotein profiles, it was found to 
significantly increase RCT from macrophages and subsequent fecal and renal cholesterol 
excretion (section 4.3.4), thus providing an additional mechanism for cholesterol removal 
from the body. Moreover, CD promoted the production of endogenous LXR agonists and 
thereby mediated the activation of LXR transcription factors. Macrophage LXR transcription 
factor activation by synthetic LXR agonists, such as T0901317 and GW3965, was shown to 
inhibit murine atherosclerosis development and promote atherosclerotic plaque 
regression124,162. Based on these findings, there was great interest in developing synthetic 
LXR-activating molecules as anti-atherogenic drugs in humans. However, initial clinical trials 
uncovered unwanted side effects, such as fatty liver disease and liver toxicity in response to 
LXR-mediated hepatic lipogenesis174. In contrast, CD treatment potentially induces  
LXR-mediated transcriptional reprogramming via the production of endogenous LXR 
agonists, such as 27-HC, as was also observed in ex vivo cultures of human atherosclerotic 
plaque tissue (Zimmer and Grebe et al., in press). Moreover, CD treatment did not induce 
signs of hepatic toxicity in the presented ApoE-/-atherosclerosis mouse models, but it rather 
decreased common markers of liver damage and fibrosis (data not shown, personal 
communication with Dr. Sebastian Zimmer), and which was also shown in studies of CD 
treatment in murine NASH143. 
The following mechanism of action for CD efficacy in atherosclerosis is therefore proposed: 
CD mediates LXR activation by promoting CC dissolution, thereby increasing intracellular 
free cholesterol and providing more substrate for cholesterol metabolism to bioactive 
oxysterols, which can function as LXR agonists. A similar mechanism of action was proposed 
for CD treatment in NPC disease, where CD is thought to mobilize cholesterol sequestered in 
lysosomes and shift it into the cell’s metabolically active cholesterol pool and thereby 
improving cholesterol efflux, storage and metabolism105,106. These changes in cholesterol 
metabolism were absent in CD-treated non-NPC mice, indicating that CD treatment only 
induced these changes in the presence of a large sequestered pool of cholesterol105,106. 
While such sequestered cholesterol pools are present throughout the body in NPC patients, 
in atherosclerosis they are predominantly present in the arterial plaque tissue, including 
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hypercholesterolemic cells such as macrophage foam cells and inert cholesterol crystals. 
Hypothetically, the effects of CD in atherosclerosis might therefore be more or less restricted 
to atherosclerotic tissues. Such a directed and specific treatment might prevent undesired 
side effects. For example, LXR-mediated anti-inflammatory effects would be mainly exerted 
locally, therefore circumventing the detrimental risks of inhibiting systemic inflammation. 
The atheroprotective effects of CD have so far only been demonstrated in mice, but ex vivo 
cultures of human atherosclerotic plaque tissue incubated with CD showed that CD can also 
induce the proposed atheroprotective pathways in human disease, with cholesterol efflux, 
production of endogenous LXR agonists and LXR transcriptional reprogramming all being 
upregulated upon CD treatment (Zimmer and Grebe et al., in press). Collectively, these 
findings suggest that CD might be a promising compound for the treatment of human 
atherosclerosis. Moreover, the use of CD as an active drug in NPC disease with FDA IND 
approval and a first completed phase 1 clinical trial provides evidence for the safety of  
long-term intravenous (and intrathecal) CD administration in humans (section 2.3.3)95. 
However, there are several possible limitations to the pharmaceutical use of CD in the 
treatment of human atherosclerosis. The most substantial limitation might be the bad oral 
bioavailability of CD89,91, which would require the parenteral (most likely intravenous) 
administration of CD. While this might be suitable for short-term treatments, which could be 
effective in temporarily stabilizing rupture-prone plaques in patients at high risk for 
cardiovascular events, it is impractical for long-term treatment, which might be required for 
mediating atherosclerosis regression. Furthermore, the pharmacokinetics of intravenously 
administered CD in humans demonstrate the rapid tissue and plasma clearance of CD in 
individuals with normal kidney function (section 2.3.1.3)89. Even the highest doses of CD 
currently applied to humans intravenously in the context of high-dose itraconazole treatment 
(8 g CD twice a day) only yield plasma CD levels of up to approximately 700 µg/ml (equals 
about 0.5 mM) (Fig. 2-6), which is 20-fold less to the concentration used in the presented  
in vitro studies. The pharmacokinetics of CD are similar in mice106, where CD administration 
twice a week was sufficient for atheroprotection. However, it remains to be determined 
whether a subtoxic and well-tolerated CD dose is sufficient to prevent and or indeed reverse 
human atherosclerosis. 
Combinational therapies with CD and other pharmacological substances that simultaneously 
lower LDL cholesterol levels (e.g. statins, ezetimibe, PCSK9 inhibitors) or increase  
HDL-mediated reverse cholesterol transport (e.g. phosphatidylcholine liposomes, ApoA1 
mimetic peptides, rHDL)173, might augment the therapeutic efficacy of CD to impair 
atherosclerosis progression and mediate atherosclerotic plaque regression. A combinational 
therapy with CD and rHDL seems particularly promising, considering the improved crystal-
derived cholesterol efflux from macrophages upon combined treatment with CD and rHDL 
Discussion 
 
 116 
observed in this study (Fig. 4-8). Moreover, CSL112, a new formulation of the rHDL used in 
this study (CSL111), was recently evaluated in a phase 2a clinical trial, which revealed a 
rapid and strong increase in RCT while being well tolerated in patients with stable 
atherosclerosis175. Considering the “shuttle/sink” model proposed for CD-mediated cellular 
cholesterol efflux (Fig. 2-7)100, CD might act as a cholesterol shuttle for further improving the 
rHDL-mediated RCT. Moreover, CD might also facilitate macrophage cholesterol efflux by 
LXR-mediated transcriptional reprogramming. Vice versa, a complementation of CD 
treatment with rHDL might even be required for ensuring adequate RCT in humans, since 
mice have naturally much higher HDL cholesterol levels than humans36. Beyond these 
potential advantages, rHDL induces the expression of activating transcription factor 3 (ATF3) 
which mediates dramatic anti-inflammatory effects on macrophages121 and could therefore 
complement the LXR-mediated anti-inflammatory pathways induced by CD treatment. 
In summary, CD is a promising candidate for treating human atherosclerosis. However, the 
potential of CD mono- or combinational therapies for mediating atheroprotection or 
atherosclerosis regression in humans remains to be determined. Therefore, clinical studies 
are required to evaluate the safety and efficacy of CD treatment in atherosclerosis patients. 
5.7 Conclusion 
CC deposition in atherosclerotic plaques is well established as a histopathological feature of 
late stage disease but was for a long time regarded merely as a result of disease 
progression. However, CCs are already present in early atherosclerotic plaques, where they 
importantly contribute to the underlying vascular inflammation driving atherosclerosis 
development and progression. 
This study investigated whether decreasing the amount of CCs in the plaque represents a 
valuable strategy for pharmaceutical intervention in atherosclerosis and whether the 
cholesterol solubilizing substance CD (2-hydroxypropyl-β-cyclodextrin) has the potential to 
mediate vascular CC removal and impair murine atherosclerosis development and 
progression. The genetic and pharmacological reduction of vascular CC deposits was 
associated with decreased atherosclerosis and therefore this study identified that CCs 
represent a viable treatment target in atherosclerosis. CD treatment effectively decreased 
murine atherosclerosis development and progression, and was moreover even effective in 
mediating the regression of already established atherosclerotic plaques. CD treatment 
reduced the deposition of vascular CCs and mediated the removal of existing CCs from 
already established plaques. In vitro, CD treatment of CC-loaded macrophages mediated the 
dissolution of intracellular CCs and subsequently promoted crystal-derived cholesterol efflux, 
storage and metabolism to bioactive oxysterols, which can function as endogenous LXR 
agonists. Accordingly, CD treatment also resulted in the LXR-dependent transcriptional 
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reprogramming of macrophages towards increased cholesterol efflux, which promoted 
reverse cholesterol transport and cholesterol excretion in vivo. Moreover, LXR transcription 
factor activation was required for the atheroprotective and anti-inflammatory effects of CD in 
vivo in murine atherosclerosis. 
This study demonstrates that CD is atheroprotective in mice by dissolving and removing CCs 
from atherosclerotic plaques and by promoting the production of cholesterol-derived 
endogenous LXR agonists that activate anti-atherogenic transcriptional processes. Since CD 
treatment is already in clinical use as drug excipient and active drug for NPC disease, it 
could be directly tested in clinical trials for the prevention or treatment of human 
atherosclerosis.	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KEY FACTS
CVDs are the number 1 cause of death globally: more people die
annually from CVDs than from any other cause.
An estimated 17.5 million people died from CVDs in 2012,
representing 31% of all global deaths. Of these deaths, an estimated
7.4 million were due to coronary heart disease and 6.7 million were
due to stroke .
Over three quarters of CVD deaths take place in low- and middle-
income countries.
Out of the 16 million deaths under the age of 70 due to
noncommunicable diseases, 82% are in low and middle income
countries and 37% are caused by CVDs.
Most cardiovascular diseases can be prevented by addressing
behavioural risk factors such as tobacco use, unhealthy diet and
obesity, physical inactivity and harmful use of alcohol using
population-wide strategies.
People with cardiovascular disease or who are at high cardiovascular
risk (due to the presence of one or more risk factors such as
hypertension, diabetes, hyperlipidaemia or already established
disease) need early detection and management using counselling and
medicines, as appropriate.
What are cardiovascular diseases?
Cardiovascular diseases (CVDs) are a group of disorders of the heart
and blood vessels and they include:
coronary heart disease – disease of the blood vessels supplying the
heart muscle;
cerebrovascular disease – disease of the blood vessels supplying the
brain;
peripheral arterial disease – disease of blood vessels supplying the
arms and legs;
rheumatic heart disease – damage to the heart muscle and heart
valves from rheumatic fever, caused by streptococcal bacteria;
congenital heart disease – malformations of heart structure existing at
birth;
deep vein thrombosis and pulmonary embolism – blood clots in the
leg veins, which can dislodge and move to the heart and lungs.
Heart attacks and strokes are usually acute events and are mainly
caused by a blockage that prevents blood from flowing to the heart or
brain. The most common reason for this is a build-up of fatty deposits on
the inner walls of the blood vessels that supply the heart or brain.
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Strokes can also be caused by bleeding from a blood vessel in the brain
or from blood clots. The cause of heart attacks and strokes are usually
the presence of a combination of risk factors, such as tobacco use,
unhealthy diet and obesity, physical inactivity and harmful use of alcohol,
hypertension, diabetes and hyperlipidaemia.
What are the risk factors for cardiovascular disease?
The most important behavioural risk factors of heart disease and stroke
are unhealthy diet, physical inactivity, tobacco use and harmful use of
alcohol. The effects of behavioural risk factors may show up in
individuals as raised blood pressure, raised blood glucose, raised blood
lipids, and overweight and obesity. These “intermediate risks factors” can
be measured in primary care facilities and indicate an increased risk of
developing a heart attack, stroke, heart failure and other complications.
Cessation of tobacco use, reduction of salt in the diet, consuming fruits
and vegetables, regular physical activity and avoiding harmful use of
alcohol have been shown to reduce the risk of cardiovascular disease. In
addition, drug treatment of diabetes, hypertension and high blood lipids
may be necessary to reduce cardiovascular risk and prevent heart
attacks and strokes. Health policies that create conducive environments
for making healthy choices affordable and available are essential for
motivating people to adopt and sustain healthy behaviour.
There are also a number of underlying determinants of CVDs or "the
causes of the causes". These are a reflection of the major forces driving
social, economic and cultural change – globalization, urbanization and
population ageing. Other determinants of CVDs include poverty, stress
and hereditary factors.
What are common symptoms of cardiovascular diseases?
Symptoms of heart attacks and strokes
Often, there are no symptoms of the underlying disease of the blood
vessels. A heart attack or stroke may be the first warning of underlying
disease. Symptoms of a heart attack include:
pain or discomfort in the centre of the chest;
pain or discomfort in the arms, the left shoulder, elbows, jaw, or back.
In addition the person may experience difficulty in breathing or shortness
of breath; feeling sick or vomiting; feeling light-headed or faint; breaking
into a cold sweat; and becoming pale. Women are more likely to have
shortness of breath, nausea, vomiting, and back or jaw pain.
The most common symptom of a stroke is sudden weakness of the face,
arm, or leg, most often on one side of the body. Other symptoms include
sudden onset of:
numbness of the face, arm, or leg, especially on one side of the body;
confusion, difficulty speaking or understanding speech;
difficulty seeing with one or both eyes;
difficulty walking, dizziness, loss of balance or coordination;
severe headache with no known cause; and
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fainting or unconsciousness.
People experiencing these symptoms should seek medical care
immediately.
What is rheumatic heart disease?
Rheumatic heart disease is caused by damage to the heart valves and
heart muscle from the inflammation and scarring caused by rheumatic
fever. Rheumatic fever is caused by an abnormal response of the body to
infection with streptococcal bacteria, which usually begins as a sore
throat or tonsillitis in children.
Rheumatic fever mostly affects children in developing countries,
especially where poverty is widespread. Globally, about 2% of deaths
from cardiovascular diseases is related to rheumatic heart disease.
Symptoms of rheumatic heart disease
Symptoms of rheumatic heart disease include: shortness of breath,
fatigue, irregular heart beats, chest pain and fainting.
Symptoms of rheumatic fever include: fever, pain and swelling of the
joints, nausea, stomach cramps and vomiting.
Why are cardiovascular diseases a development issue in low-
and middle-income countries?
At least three quarters of the world's deaths from CVDs occur in low-
and middle-income countries.
People in low- and middle-income countries often do not have the
benefit of integrated primary health care programmes for early
detection and treatment of people with risk factors compared to
people in high-income countries.
People in low- and middle-income countries who suffer from CVDs
and other noncommunicable diseases have less access to effective
and equitable health care services which respond to their needs. As a
result, many people in low- and middle-income countries are detected
late in the course of the disease and die younger from CVDs and
other noncommunicable diseases, often in their most productive
years.
The poorest people in low- and middle-income countries are affected
most. At the household level, sufficient evidence is emerging to prove
that CVDs and other noncommunicable diseases contribute to poverty
due to catastrophic health spending and high out-of-pocket
expenditure.
At macro-economic level, CVDs place a heavy burden on the
economies of low- and middle-income countries.
How can the burden of cardiovascular diseases be reduced?
“Best buys” or very cost effective interventions that are feasible to be
implemented even in low-resource settings have been identified by WHO
for prevention and control of cardiovascular diseases. They include two
types of interventions: population-wide and individual, which are
recommended to be used in combination to reduce the greatest
cardiovascular disease burden.
Examples of population-wide interventions that can be implemented to
reduce CVDs include:
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comprehensive tobacco control policies
taxation to reduce the intake of foods that are high in fat, sugar and
salt
building walking and cycle paths to increase physical activity
strategies to reduce harmful use of alcohol
providing healthy school meals to children.
At the individual level, for prevention of first heart attacks and strokes,
individual health-care interventions need to be targeted to those at high
total cardiovascular risk or those with single risk factor levels above
traditional thresholds, such as hypertension and hypercholesterolemia.
The former approach is more cost-effective than the latter and has the
potential to substantially reduce cardiovascular events. This approach is
feasible in primary care in low-resource settings, including by
non-physician health workers.
For secondary prevention of cardiovascular disease in those with
established disease, including diabetes, treatment with the following
medications are necessary:
aspirin
beta-blockers
angiotensin-converting enzyme inhibitors
statins.
The benefits of these interventions are largely independent, but when
used together with smoking cessation, nearly 75% of recurrent vascular
events may be prevented. Currently there are major gaps in the
implementation of these interventions particularly at the primary health
care level.
In addition costly surgical operations are sometimes required to treat
CVDs. They include:
coronary artery bypass
balloon angioplasty (where a small balloon-like device is threaded
through an artery to open the blockage)
valve repair and replacement
heart transplantation
artificial heart operations
Medical devices are required to treat some CVDs. Such devices include
pacemakers, prosthetic valves, and patches for closing holes in the
heart.
WHO response
Under the leadership of the WHO, all Member States ( 194 countries)
agreed in 2013 on global mechanisms to reduce the avoidable NCD
burden including a "Global action plan for the prevention and control of
NCDs 2013-2020". This plan aims to reduce the number of premature
deaths from NCDs by 25% by 2025 through nine voluntary global targets.
Two of the global targets directly focus on preventing and controlling
CVDs.
Global action plan for the prevention and control of NCDs 2013-2020
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The sixth target in the Global NCD action plan calls for 25% reduction in
the global prevalence of raised blood pressure. Raised blood pressure is
one of the leading risk factors of cardiovascular disease. The global
prevalence of raised blood pressure (defined as systolic and/or diastolic
blood pressure ≥140/90 mmHg) in adults aged 18 years and over was
around 22% in 2014.
Reducing the incidence of hypertension by implementing population-wide
policies to reduce behavioural risk factors, including harmful use of
alcohol, physical inactivity, overweight, obesity and high salt intake, is
essential to attaining this target. A total-risk approach needs to be
adopted for early detection and cost-effective management of
hypertension in order to prevent heart attacks, strokes and other
complications.
The eighth target in the Global NCD action plan states at least 50% of
eligible people should receive drug therapy and counselling (including
glycaemic control) to prevent heart attacks and strokes. Prevention of
heart attacks and strokes through a total cardiovascular risk approach is
more cost-effective than treatment decisions based on individual risk
factor thresholds only and should be part of the basic benefits package
for pursuing universal health coverage. Achieving this target will require
strengthening key health system components, including health-care
financing to ensure access to basic health technologies and essential
NCD medicines.
In 2015, countries will begin to set national targets and measure
progress on the 2010 baselines reported in the "Global status report on
noncommunicable diseases 2014". The UN General Assembly will
convene a third high-level meeting on NCDs in 2018 to take stock of
national progress in attaining the voluntary global targets by 2025.
Global status report on noncommunicable diseases 2014
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